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Acute Myeloid Leukaemia (AML) is the most common acute white blood cell 
cancer in adults, with a U.K. incidence of  3,100 new cases/year approximately 30% of 
all leukaemia. Survival remains below 15% for patients over the age of 60 diagnosed 
with AML, who respond poorly to  standard non-specific chemotherapy treatment, 
therefore there is a need for new targeted therapies .    
Recently, expression of cytosolic isoform of Branched Chain Aminotransferase 
(BCAT1) has been correlated with shorter overall survival in AML. Current research has 
focussed on the BCAT1 metabolites α-ketoglutarate (α-KG) , glutamate and leucine, 
however BCAT1 contains a redox active CXXC motif, a feature of antioxidant enzymes 
such as Thioredoxin, suggesting BCAT1 may have a novel antioxidant role.   
Overproduction of Reactive Oxygen Species (ROS) in AML is extremely well 
characterised and contributes to the pathogenesis of the disease. Targeting leukaemia 
cells with pro-oxidants to overwhelm the antioxidant capacity of the cell is recognised 
as an attractive strategy, particularly in respect to leukemic stem cells which are a major 
cause of therapy resistance and relapse. Therefore, in this study, the potential 
antioxidant effect of the BCAT1 CXXC motif was investigated with respect to well 
documented redox mediated processes dysregulated in AML. These redox mediated 
processes included cellular proliferation, differentiation and apoptosis. To evaluate this 
a myeloid leukaemia cell line, U937 (ATCC CRL 1293.2) was engineered to stably 
overexpress wild-type BCAT1 protein and CXXC motif mutant BCAT1. 
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The key findings of the study showed that the BCAT1 CXXC motif provides a 
protective effect against ROS mediated apoptosis induced by serum starvation in U937 
cells. Moreover the CXXC motif reduced intracellular ROS and CD36+ cells, a marker of 
macrophage differentiation following addition of Phorbol 12-myristate 13-acetate 
(PMA) which has been demonstrated to induce differentiation of U937 cells using H202, 
a biologically relevant ROS species, as a secondary messenger. Finally, the feasibility of 
targeting BCAT1 with standard chemotherapy, metabolic inhibitors and pro-oxidants 
therapy has been explored with a view to developing a treatment strategy for patients 
with BCAT1high and BCAT1low levels of expression. For the first time this study 
demonstrated that the BCAT1 CXXC motif reduces intracellular ROS and provides 
protection against apoptosis in response to treatment with pro-oxidant Rotenone whilst 
BCAT1 increases sensitivity to standard chemotherapeutic Cytarabine (Ara-C).  
Overall, the findings in this study indicate that the BCAT1 CXXC motif  acts as a novel 
antioxidant in AML impacting redox mediated cellular differentiation and apoptosis 
through ROS modulation. Similarly, the BCAT1 and the antioxidant capacity of the CXXC 
motif can protect against  pro-oxidant therapy, an important finding that could inform 




Chapter 1: Introduction 
1.1 Leukaemia  
1.1.1 Haematopoiesis  
Haematopoiesis is the process by which pluripotent haematopoietic stem cells 
(HSCs) residing in the bone marrow differentiate along several well-defined pathways 
producing the full complement of differentiated blood tissue. In mammals, 
hematopoietic development occurs in two main stages throughout embryogenesis 
called primitive and definitive haematopoiesis(Ivanovs et al., 2017). These stages occur 
in several different locations in the early embryo as it develops and are sometimes 
referred to as waves, representing their overlapping nature. In murine models, primitive 
haematopoiesis takes place in a region called the Yolk sac at embryonic day 7. It is 
marked by a relatively simple model of cellular differentiation, producing endothelial 
cells and primitive red blood cells, with embryonic haemoglobin that supply blood to the 
developing embryo. This is followed by the emergence of HSCs, which develop in the 
aorta-gonad-mesonephros (AGM) region several days later (Ivanovs et al., 2017). HSCs 
are capable of self-renewal and functionally defined as being able to reconstitute the 
hematopoietic system following transplantation into irradiated bone marrow (Mikkola 
and Orkin, 2006; Boulais and Frenette, 2015). Following development of the vasculature 
around day 12, HSCs migrate to the liver where they proliferate and finally to the bone 
marrow by day 17-18 (Jagannathan-Bogdan and Zon, 2013). Population of the bone 
marrow marks the transition from primitive to definitive haematopoiesis, which is 
maintained throughout adult life. In the definitive hematopoietic model, the lineage 
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repertoire is expanded to include the full complement of blood tissue. This includes the 
leukocytes of the immune system, of which there are two primary branches, the 
‘lymphoid lineage’ and ‘the myeloid lineage’ (Figure 1.1). The lymphoid lineage produces 
the lymphocytes of the adaptive immune system, which consists of Natural Killer cells, 
T-cells and B-cells, whilst the myeloid lineage matures into cells of the innate immune 
system including, neutrophils, basophils, macrophages, dendritic cells, thrombocytes 
and erythrocytes  (Weiskopf et al., 2016).  
Self-renewing long-term HSCs sit at the top of this developmental hierarchy, existing 
in a stable quiescent state, which provides a lifelong pool of HSCs (Figure 1.1).  
Maintenance of the HSC pool and mechanisms that drive self-renewal are still poorly 
understood, given the structural complexity of the bone marrow niche and the difficulty 
of analysing cells in situ (Morrison and Scadden, 2014). Initial experiments pointed 
towards HSCs direct association with Osteoblasts that line the inner bone marrow or 
endosteal bone surface mediated by N-Cadherin (Zhang et al., 2003). However, this 
direct interaction through N-Cadherin has been subject to debate, as knockout of N-
Cadherin in HSCs and Osteoblasts did not change HSC numbers (Bromberg et al., 
2012).Other studies suggest that quiescence is maintained through thrombopoietin and 
angiopoietin-1 produced by activated Osteoblasts (Arai et al., 2004; Yoshihara et al., 
2007).  
Another pivotal study using cell surface markers CD150, CD48 and CD244 to 
differentiate between multipotent and pluripotent progenitors, located most HSCs next 
to the sinusoidal endothelium, a type of capillary within the bone marrow termed the 





Figure 1.1 Haematopoiesis. In myeloid development generation of self-renewing Long-
term Haematopoietic Stem Cells (LT-HSC) residing in the bone marrow requires 
expression of transcription factors Runx-1, Scl/tal-1 and Lmo-2. Short-term 
Haematopoietic Stem Cells (ST-HSC) differentiate into the common myeloid progenitor 
(CMP) which further differentiates the granulocyte/ macrophage progenitor (GMP). This 
is the last common precursor of the granulocytic and monocytic lineages of cells from 
which myeloid leukaemia arises development of which is directed by GATA-1 and PU.1 
respectively. In normal development these immature blasts cells mature into terminally 





the osteoblastic and vascular niches interact or migrate between the two remains 
uncertain. One major factor to be elucidated in HSC maintenance is the production of 
chemoattractant CXC chemokine ligand (CXCL) 12 by CXCL12-abundant reticular (CAR) 
cells, that are localised to the vascular niche. High CXCL12 expression by CAR cells 
resulted in contact with increased numbers of HSCs, whilst deletion of its corresponding 
receptor (CXCR4) in HSCs resulted in a severe reduction in HSC numbers, suggesting 
CXCL12 may modulate movement to the vasculature (Sugiyama et al., 2006). 
Subsequently CXCL12 was shown to be expressed primarily by perivascular stromal cells 
and at lower levels by endothelial cells, osteoblasts and HSCs. Deletion of CXCL12 from 
vascular niche cells including endothelial and stromal cells depleted HSCs whilst deletion 
of CXCL12 from osteoblasts did not deplete HSCs, highlighting the importance of the 
vascular niche in HSC(Ding and Morrison, 2013; Greenbaum et al., 2013; Morrison and 
Scadden, 2014). 
It was believed that HSCs regulate quiescence vs proliferation in the bone marrow 
microenvironment because the Osteoblastic niche provides a hypoxic environment for 
maintaining quiescence, whilst the vascular niche is more oxygenated allowing HSCs to 
proliferate and differentiate (Suda, Takubo and Semenza, 2011). This view is supported 
by data demonstrating areas of regional hypoxia  associated with the endosteum 
(Spencer et al., 2014), and the HSCs within this niche stabilise hypoxia inducible factor-
1 alpha (HIF-1α), allowing cells to shift to anaerobic metabolism and survive in low 
oxygen conditions (Suda, Takubo and Semenza, 2011). However more recent reports 
conflict with this interpretation by demonstrating that oxygen tension was lowest 
around vascular sinusoids and highest near the endosteum, moreover the bone marrow 
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hypoxic niche was lost when haematopoiesis was nullified by cytotoxic drugs, indicating 
that oxygen consumption during haematopoiesis renders the marrow hypoxic (Morrison 
and Scadden, 2014; Spencer et al., 2014). 
Perhaps better understood is how HSCs direct differentiation by expression of 
lineage specific transcription factors. One of the best studied examples are PU.1 and 
GATA-1 which are essential for the development of myeloid and erythroid lineages 
respectively (Burda, Laslo and Stopka, 2010). PU.1 has been shown to direct macrophage 
differentiation where continuous overexpression of PU.1 in multipotent progenitors 
directed a strong bias toward macrophage differentiation over granulocytes and 
eliminated erythroid differentiation(McIvor et al., 2003). Supporting this, PU.1 knockout 
mice displaying an 80% reduction in PU.1 expression developed AML whilst viral 
overexpression rescued myeloid differentiation (Rosenbauer et al., 2004). Importantly 
PU.1 and GATA-1 have been demonstrated to act antagonistically, where inhibition 
occurs in a dose dependent manner and is mediated by direct physical interaction  
(Nerlov et al., 2000). PU.1 binds to GATA-1 on DNA where PU.1 recruits transcriptional 
corepressor pRB and histone H3K9 methyltransferases that creates a repressed 
chromatin structure and silencing GATA-1 directed gene expression (Rekhtman et al., 
2003; Burda, Laslo and Stopka, 2010). Conversely, GATA inhibits binding of PU.1 to c-
Jun, a critical coactivator of PU.1(Zhang et al., 1999). Further evidence to support this 
antagonistic mechanism has been demonstrated in an in vivo Zebrafish model, where 
loss of GATA-1 directs to a monocytic fate whilst the converse is true of PU.1 (Orkin and 
Zon, 2008; Galloway et al., 2005; Rhodes et al., 2005).   
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The relationship between hematopoietic transcription factor dysregulation and 
leukemic malignancy has been extensively studied. Several transcription factors found 
to be essential to the production of HSCs by gene knockout experiments in mouse 
models include RUNX-1, SCL1/TAL1 and LMO-2. These were first discovered through the 
analysis of chromosomal translocations in human leukaemia underlining, the 
importance of genetic control of differentiation the pathogenesis of blood cancers 
(Shivdasanl, Mayer and Orkin, 1995; Rabbitts, 1998; Lacaud et al., 2002).  
 
1.1.2 Subtypes of Leukaemia   
Leukaemia is a cancer of the blood, which is characterised by proliferation of 
abnormal immature white blood cells or leukocytes, known as blast cells (Hoffbrand, 
Moss and Pettit, 2016). Leukaemias have an incidence of approximately 10 100 cases 
per year in the UK, which accounts for 3% of all new cancer cases(Leukaemia | Cancer 
Research UK, 2017). Incidence rates for leukaemia have risen by 16% in the UK over the 
last ten years, reflecting an aging population where leukaemia incidence and mortality 
rates remains the highest amongst people aged 85-89. Incidence rates are expected to 
rise a further 5% to 19 cases per 100 000 by 2035. Despite this, mortality rates have 
fallen in the last ten years by 7% and are projected to fall by a further 18% to 8 deaths 
per 100 000 people by 2035. This increased survival reflects decades of research and 
advances in leukaemia treatment since the 1970s, which has increased the 10 year 
survival rate nearly 10-fold from approximately 5% to 46% (2010-11) (Leukaemia (all 
subtypes combined) statistics | Cancer Research UK, 2017).For Acute Myeloid Leukaemia 
specifically, data from the Medical Research Council trials collected between 1988– 
21 
 
2012, shows an increased overall survival rate from just 4% to 22% for patients ages >60 
years old only, highlighting the challenge in treating older patients (Burnett A.K., 2012). 
Despite an overall progress in treatment outcome, leukaemia remains a 
heterogeneous disease, with large variations in incidence and prognostic outlook, 
depending on the subtype and age. Broadly leukaemia is categorised based on four 
criteria; whether a leukaemia is chronic or acute and whether it originates from the 
myeloid or lymphoid lineage of white blood cells (Leukaemia | Cancer Research UK, 
2020). This gives rise to 4 main types of leukaemia: Acute Myeloid Leukaemia (AML), 
Chronic Myeloid Leukaemia (CML), Acute Lymphocytic Leukaemia (ALL) and Chronic 
Lymphocytic Leukaemia (CLL). Chronic leukaemias proliferate more slowly and are 
generally made up of more mature leukocytes meaning symptoms can take years to 
manifest, whilst acute forms can progress extremely quickly and without immediate 
treatment survival can be measured in months (Hoffbrand, Moss and Pettit, 2016). This 
is reflected in overall survival rates in the USA from 2007-2013 for CML (68.7%), CLL 
(86.8%), ALL (71.6%) and AML (28.1%) (Leukemia and Lymphoma Society, 2020). 
 
1.2 Acute Myeloid Leukaemia  
AML is blood cell cancer of the myeloid lineage of white blood cells (leukocytes) and 
it is the most common acute white blood cell cancer in adults, with a U.K. incidence of 
around 3,100 new cases/year approximately 30% of all leukaemia (Leukaemia | Cancer 
Research UK, 2020). AML is characterised by a block in cellular differentiation and rapid 
proliferation of immature leukocytes, the block in differentiation and clonal expansion 
of these immature progenitors or ‘myeloblasts’ causes an abnormal accumulation in the 
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bone compromising normal haematopoiesis, consequently patients suffer from a range 
of cytopenias (a reduction in the number of mature blood cells), including red blood cells 
(anaemia), neutrophils (neutropenia) and platelets (thrombocytopenia). These 
cytopenias manifest as a range of symptoms, including, bone and joint pain, lethargy, 
increased susceptibility to infection and bleeding (Döhner, Weisdorf and Bloomfield, 
2015). As blast-crisis progresses, myeloblast cells can infiltrate peripheral blood and 
migrate to the spleen and liver enlarging these organs, eventually the disease may 
progress and metastasise to the central nervous. If left untreated, death can typically 
occur within 3-6 months due to bone marrow failure. (Oran and Weisdorf, 2012). 
Traditional treatment of AML involves an initial course of chemotherapy known as 
the induction stage. At this stage patients are assessed to determine their fitness for 
high dose or low dose chemotherapy as non-specific chemotherapeutic agents target 
both healthy and malignant cells and the presence pre-existing health conditions results 
in poorer treatment outcomes(Østgård et al., 2015). For example, the 
chemotherapeutic agent Cytarabine (1β-arabinofuranosylcytosine) is a nucleoside 
analogue of the nucleic acid cytosine where the ribose sugar of the sugar phosphate 
backbone for arabinose is substituted producing cytosine arabinose. Cytarabine is 
randomly incorporated into DNA during semiconservative replication in S-phase 
interrupting daughter strand synthesis, thus inhibiting all cell growth (Momparler, 
2013).  
Following induction therapy, patients that are in remission are progressed to the 
consolidation phase, where additional rounds of chemotherapy aim to eliminate any 
residual malignant cells. Patients that do not respond to induction therapy may undergo 
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radiotherapy which is used to irradiate the bone marrow before haematopoietic stem 
cell transplantation that may reconstitute the bone marrow and restore normal 
haematopoiesis (Acute myeloid leukaemia - NHS, 2020). The physical demands of non-
specific therapies contribute to the relatively poor survival data for AML compared to 
other leukaemia subtypes, where older patients are placed on lower dose 
chemotherapy regimens that result in more refractory outcomes i.e. residual blast cells 
remaining following the first round of intensive treatment (Löwenberg et al., 2011). For 
these reasons AML survival in patients younger than 15 years is 68.8%  (Leukemia and 
Lymphoma Society, 2020) whilst survival remains around 22% for patients over the age 
of 60(Burnett, 2013).Therefore, there has been a drive over the last 20 years to 
understand the underlying cytogenetic and biochemical characteristics of AML, so that 
new-targeted therapies may be established.  
1.2.1 AML Classification 
AML was first comprehensively classified by a French-American-British co-operative 
group of haematologists in 1976 (Bennett et al., 1976). Commonly known as the FAB 
system, AML subtypes were based on morphological differences of peripheral blood and 
bone marrow when Romanowsky stained (a precursor of the modern Giemsa stain) and 
examined under a light microscope. Cells were separated based on two criteria, 1) the 
direction of differentiation along cell lineages and 2) the degree of maturation. This 
defined 8 sub-groups M0-M7, beginning with M0 which represents the most 
undifferentiated i.e. most ‘stem-cell like’ acute myeloblastic leukaemia. Types M1-M3 
are predominantly granulocytic in nature, but differ in terms of their level of maturation 
and therefore were termed ‘Myeloblastic leukaemia without maturation’ (M1), 
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‘Myeloblastic leukaemia with maturation’ (M2), and ‘Hypergranular promyelocytic 
leukaemia’ (M3) now called Acute promyelocytic leukaemia (APL) accordingly. M4 
displays both monocytic and granulocytic differentiation and was therefore was labelled 
‘Myelomonocytic leukaemia’ with a later further division of ‘Acute myelomonocytic 
leukaemia with eosinophilia’ (M4 eos). M5, M6 and M7 are predominantly monocytic, 
erythroid and megakaryoblastic differentiation and were termed ‘Acute monocytic 
leukaemia’, ‘Acute erythroid’ and ‘Acute megakaryoblastic leukaemia’ respectively 
(Table 1.1) (Bennett et al., 1976). Although the FAB system proved a useful initial 
framework, it failed to take into account many of the underlying genetic factors that 
affected patient survival called prognosis. This informed a new classification system 
implemented by the World Health Organisation (WHO), that organised leukaemia by a 
combination of immunophenotypic, morphologic, genetic and prognostic factors (Table 
1.2). Since it’s inauguration in 2001 it has been updated in 2008 and most recently in 
2016, chiefly to incorporate the increased understanding of AML pathogenesis provided 
by advances in sequencing technology (Arber et al., 2016). 
There are currently over 25 clinically distinct classifications of AML, which are 
primarily divided by gross cytogenetic alterations such as chromosomal translocations, 
inversions and deletions that the WHO classifies as ‘AML with recurrent genetic 
abnormalities. Other categories include ‘AML with myelodysplasia related changes’, 
‘Therapy related myeloid neoplasms’, ‘Myeloid sarcoma’ and ‘AML not otherwise 
specified (NOS)’. Chromosomal abnormalities have been particularly useful for 
clinicians, as they can be identified by karyotype analysis under a light microscope 
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allowing prognostic stratification and targeted treatment of certain AML subtypes 
(Degos et al., 1995; Mrózek, Heerema and Bloomfield, 2004). 
 
Table 1.1 FAB classification of Acute Myeloid Leukaemia (adapted 












1.2.2 AML Cytogenetics  
There are currently six recognised recurrent gross cytogenetic alterations that 
are associated with prognostic outlook, broadly separated into favourable and 
unfavourable abnormalities, however 10 year survival rates vary significantly between 
these abnormalities (Figure 1.2) (Grimwade et al., 2010).  
For example, the chromosomal translocation t(15;17) (PML-RARα), which fuses 
the tumour suppressor Promyelocytic Leukaemia Protein (PML) gene to the Retinoic 
acid receptor alpha(RARα) gene, results in loss of function of PML, culminating in a block 
in myeloid cell differentiation and the development of APL mediated by the PML-RARα 
fusion protein (Olsson et al., 2009). Patients with the PML-RARα fusion protein have a 
complete remission rate of >80%, due to the treatment with all-trans retinoic acid 
(ATRA), which targets PML-RARα an lifts the block in myeloid differentiation  (Figure 1.3) 
(Coombs, Tavakkoli and Tallman, 2015).  
Similarly, chromosomal translocation t(8;21) (RUNX1-RUNX1T1), which fuses the 
Runt-related transcription factor 1 (RUNX1) with the zinc finger protein ‘ETO’, resulting 
in transcriptional repression and a block in differentiation, has a ten year survival rate 
of >60% (Figure 1.3) (Mrozek and Bloomfield, 2008). Conversely, the t6;9 chromosomal 
translocation and inversions of chromosome 3 inv(3)/ t(3;3) result in subtypes that are 
highly therapy resistant, and survival rates remain extremely poor at 11% and 3% 
respectively (Grimwade et al., 2010). These various chromosomal translocations 









Figure 1.2  Ten year survival rates for cytogenetic abnormalities recognised in 














Figure 1.3 Common myeloid leukaemia cytogenetic lesions.  Translocations t(15;17) 
(PML-RAR) and t(8;21) (RUNX1-RUNX1T1) both produce transcription factor fusion 
proteins that result in transcriptional repression and blocks in differentiation. 
Categorised as prognostically favourable treatment with Retinoic acid initiates 








Diagnosis by karyotype analysis has proved a powerful prognostic indicator in AML, 
providing an invaluable tool that informs treatment strategies. However it is estimated 
that 40-50 % of patients are cytogenetically normal i.e. have no gross chromosomal 
translocations / inversions (Schlenk et al., 2008). Advances in gene expression analysis 
coupled with survival data, has identified several somatic gene mutations e.g. nucleolar 
phosphoprotein B23 (NPM1) and CCAAT/enhancer binding protein α (CEBPA) that are 
associated with altered outcomes (Suzuki, 2014). In last 10 years mutations in NPM1, 
CEPBA and RUNX1 have been incorporated into the latest WHO classification of 
haematological malignancies (Arber et al., 2016). RUNX1 and CEPBA are transcription 
factors involved in hematopoietic development, whilst NPM1 is a multifunctional 
protein involved in ribosome biogenesis and modulation of the p53 stress 
response.(Verhaak et al., 2005) 
There are additional gene mutations not currently recognised as clinically distinct 
but contribute to prognostic outlook. Typically, these mutations have resulted in 
changes to key proliferative signalling cascades that result in a change of gene 
expression. For example, transmembrane receptor tyrosine kinases; FMS-Like Tyrosine 
Kinase-3 (FLT3) and c-KIT are two of the most common accompanying mutations, 
occurring in approximately 25% and 8% of AMLs, resulting in the activation the PI3K-
AKT-mTOR, RAS-RAF-MEK-ERK and JAK-STAT signalling cascades that mediate growth 
and survival(Gilliland and Griffin, 2002; Cairoli et al., 2006). Both kinases are central to 
normal haematopoiesis and promote blood progenitor cell proliferation, however 
mutations in AML promote leukemic cell division (Escribano et al., 1998; Gilliland and 
Griffin, 2002)  
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1.2.3 Metabolic mutations  
Recently mutations in metabolic genes that alter or reprogram metabolic 
pathways have become a focus of research, highlighting the leukaemogenic importance 
of cellular processes outside of the typical growth and survival signalling pathways.(Feng 
et al., 2012)  
Proliferating cells have markedly different metabolic requirements to quiescent 
cells, which express basal levels of metabolic enzymes for repair and maintenance, since 
transformed cells e.g. AML cells, must accumulate sufficient pools of macromolecules 
such as lipids and nucleotides for cell division (Ward and Thompson, 2012).  Additionally, 
they exist in highly variable microenvironments that are generally characterised by poor 
nutrient availability and hypoxias such transformed cells display a reprogrammed 
metabolism that allows them to adapt to these conditions (Vander Heiden, Cantley and 
Thompson, 2009). Altered cancer metabolism was first observed by Otto Warburg who 
noted cancer cells favour relatively inefficient glycolysis to oxidative phosphorylation,  
even in aerobic conditions, hence it was termed aerobic glycolysis or the Warburg effect 
(Potter, Newport and Morten, 2016). As glycolysis is much less efficient at producing 
Adenosine triphosphate (ATP) than oxidative phosphorylation Warburg, assumed 
cancer cells had defective mitochondria, however we now understand cells redirect 
glucose carbon for nucleotide, lipid and protein synthesis (Liberti and Locasale, 2016). 
The emerging importance of metabolic reprogramming is reflected by the addition of 
deregulation of cellular energetics to Hanahan and Weinberg’s ‘Hallmarks of Cancer’ in 
2011 (Hanahan and Weinberg, 2011). 
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Important metabolic genes mutated / deregulated in AML are Isocitrate 
Dehydrogenases 1 and 2 (IDH1/IDH2). Both isoforms of this metabolic enzyme have 
been extensively studied in AML (Medeiros et al., 2017). The IDH isoenzymes are 
mutated in ~20% AML cases, these mutations are associated with worse patient 
outcomes (Feng et al., 2012). The IDH1/2 isoenzymes are the cytosolic and 
mitochondrial isoforms respectively, that catalyse the oxidative decarboxylation of 
isocitrate, to alpha-keto glutarate (α-KG) in the Citric Acid Cycle. (Medeiros et al., 2017).  
The Citric Acid Cycle (TCA) is a central metabolic nexus linking key processes 
including ATP generation through oxidative phosphorylation, lipid biosynthesis and 
regeneration of reducing equivalents for cellular redox reactions. IDH1/2 mutations 
result in a loss of normal catalytic activity, rendering the proteins unable to produce α-
KG. Instead mutant IDH enzymes have neomorphic activity catalysing the reduction of 
α-KG to a structurally similar oncometabolite 2-hyroxyglutarate, which competitively 
inhibits α-KG-dependant enzymes, leading to enhanced proliferation and blocked 
differentiation of HSCs. (Xu et al., 2011) IDH1 targeted therapies are currently under 
clinical investigation (Medeiros et al., 2017). However, 80% of AML patients have 
functional copies of IDH1, therefore identifying potential gene targets in this population 
is therefore of great importance. In recent years interest has increased in other 
metabolic enzymes that feed into the same pathway as IDH1 (Altman, Stine and Dang, 
2016).  
In the last 5 years, cytosolic Branched Chain Aminotransferase (BCAT1) 
overexpression has been associated with metastasis, cell proliferation and altered 
metabolism in various types of cancer(Zheng et al., 2016; Hattori et al., 2017; Zhang and 
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Han, 2017; Wang et al., 2019). The BCAT1 metabolite α-KG feeds into the same 
metabolic pathways mediated by IDH1, albeit at a different entry level (Figure 1.4). 
Interestingly, in AML BCAT1 over-expression has been shown to decrease intracellular 
levels of α-KG in a similar manner to mutant IDH1 and is linked with shorter patient 
survival (Raffel et al., 2017). Furthermore, a recent study in a glioma model 
demonstrated expression of BCAT1 was dependant on IDH1 mutational status, where 
knockdown of BCAT1 in cells with ‘wild-type’ IDH1 (IDH1wt) was sufficient to reduce the 
growth of the cancer, making BCAT1  an attractive potential target for patients with 
IDHwt status (Tönjes et al., 2013).  
Beyond IDH more recent research has highlighted the metabolic role of BCAT1 
in macrophage differentiation by modulation of the TCA. These studies demonstrated 
that, following lipopolysaccharide stimulation, inhibition of BCAT1 supresses 
production of itaconate, an anti-inflammatory metabolite has been that has been 
implicated in the switching of macrophages from a pro to an anti-inflammatory 
state(Papathanassiu et al., 2017; Yu et al., 2018). Moreover, this was subsequently 
shown to activate Nrf2 and antioxidant responses suggesting BCAT1 has a role 
modulating the antioxidant response in activated macrophages by altering TCA 
metabolites(Ko et al., 2020).  
1.3 BCAT1 
1.3.1 Enzyme kinetics   
BCAT1 belongs to the fold-type IV class of pyridoxal 5′-phosphate (PLP)-dependent 
enzymes and catalyses the transamination of branched chain amino acids (BCAA) 
Leucine, Isoleucine and Valine (Figure 1.4, Panel A). In this reversible reaction an α-
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amino group is transferred from the BCAAs to α-KG producing glutamate a branched 
chain-keto acid (BCKA); α-ketoisocaproate (KIC), α -ketomethylvalerate (KMV) and α -
ketoisovalerate (KIV) respectively (Figure 1.4, Panel B) (Davoodi et al. 1998).  
Like IDH, BCAT has two isoforms, the cytosolic isoform - BCAT1 and mitochondrial 
isoform - BCAT2. In vitro characterisation of both isoforms demonstrates that of the 
three BCKA substrates, KIC displays the lowest Km value, the substrate concentration at 
which half maximal enzyme reaction rate is achieved (Davoodi et al. 1998, Conwy at al 
2008). Moreover, the Km values of BCAT1 and BCAT2 for KIC and glutamate are 
approximately an order of magnitude lower than for leucine and α-KG, concurrently the 
enzymatic turnover (Kcat) is also 2-3 times faster in the direction of alpha-KG formation 
for both isoforms. This demonstrates both BCAT1 and BCAT2 strongly favour glutamate 
and KIC as substrates, whilst the primary products are leucine and α-KG. (Table 1.3). 
Despite favouring the same enzymatic direction, BCAT1 and BCAT2 differ with respect 
to their kinetics. BCAT1 has an increased Kcat and lower Km when metabolising KIC and 
Glutamate compared to BCAT2. This equates to an increased catalytic efficiency of 4905 
x103 M-1 S-1 for BCAT1 compared to 1525 x103 M-1 S-1 for BCAT2, which is perhaps a 
reflection of the substrate concentrations in their respective subcellular locations 
(Davoodi et al. 1998) 




Figure 1.4 Branched Chain Amino Acid Metabolism. A) BCAT1 catalyses transamination 
between branched-chain amino acids (BCAA) Leucine (Leu), Iso-Leucine (Ile) and Valine 
(Val) and their ketoacid counterparts ; α-ketoisocaproate (KIC), ), α -ketomethylvalerate 
(KMV) and α-ketoisovalerate (KIV). B)  IDH1 regenerates α-KG from isocitrate 
whereupon BCAT1 catalyses the transfer of NH3 from the BCAA to α-ketoglutarate (α-
KG) forming the respective branched-chain alpha-keto acid (BCKA) and glutamate. 
BCAT1 metabolites feed into the citric acid cycle and yield ATP. Where there is a build-
up of BCKA, BCAT1 will favour the reverse reaction, generating BCAA. (Adapted from 






Despite the in vitro enzyme kinetics favouring BCAA anabolism, BCAT1 is commonly 
seen as the first step in BCAA catabolism (Tönjes et al., 2013; Thewes et al., 2017). In the 
canonical forward reaction, BCAT1 catalyses the transfer of NH3 from the BCAA to α-KG 
forming the respective BCKA and glutamate. After transamination, BCKAs are further 
catabolised to Citric Acid Cycle intermediates acetyl coenzyme A (acetyl-CoA) and 
succinyl-CoA, providing macromolecule precursors and energy for mitochondrial ATP 
synthesis (Tönjes et al., 2013).  
Supporting this model, it was reported in glioblastoma cell lines that BCAT1 
expression was upregulated by the addition of cell-permeable dimethyl α-KG and could 
be suppressed by mutant IDH1 overexpression, a primary source of α-KG, in 
immortalized human astrocytes (Tönjes et al., 2013). Additionally, treatment with 
Gabapentin, a BCAT1 enzymatic inhibitor, resulted in an intracellular accumulation of 
BCAA and reduction in release of glutamate. These findings were replicated in AML cell 
lines, where normal expression of BCAT1 lead to a decrease in α-KG, whilst BCAT1 
knockdown caused an accumulation of α-KG (Raffel et al., 2017). Conversely BCAT1 
expression was shown to increase BCAA in a mouse model of CML (Hattori et al., 2017). 
In the Hattori study, BCAT1 expression in peripheral blood of patients was found to 
increase with disease progression from a chronic to acute phase and was associated with 
poorer survival. Interestingly, blocking BCAT1 metabolic activity with Gabapentin in the 
CML mouse model reduced intracellular BCAA concentrations and extended survival 
(Hattori 2017). Taken together, these studies indicate that the direction of BCAT1 
catalysis in disease states is dynamic and may be context dependant on substrate 
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concentrations providing the cancer cell with the ability to respond to fluctuating 
nutrient concentrations.  
1.3.2 Expression and survival 
Recently BCAT1 expression has been associated with a poor prognostic outlook in 
numerous cancers. For example, BCAT1 expression correlated with significantly poorer 
prognosis in breast cancer, gastric cancer, hepatocellular and urothelial 
carcinoma(Chang et al., 2016; Zheng et al., 2016; Xu et al., 2018a; Zou et al., 2019; Song 
et al., 2020).  In AML studies examining BCAT1 expression converge on the importance 
of BCAT1 in HSCs. For example, it was reported that BCAT1 expression was significantly 
higher in CD34+ CD38- leukemic stem cell populations and was significantly increased in 
relapsed AML samples (Raffel et al., 2017). Additionally an another recent study 
demonstrated that blocking BCAT1 induced cellular differentiation (Hattori et al., 2017), 
taken together these studies indicate a possible role for BCAT1 in cellular differentiation. 
To support this notion, analysis of open source Affymetrix by the Coles Lab at the 
University of Worcester shows that BCAT1 expression levels are high in HSCs and low in 
differentiated healthy white blood cells. Moreover, in disease context, examination of 
158 AML and 107 CLL patients at diagnosis for the expression level of BCAT1 revealed 
BCAT1 expression is highly dysregulated in AML and CLL blasts compared to healthy 
donor ‘normal’ bone marrow (Figure 1.5 Panel A). In contrast to BCAT1, BCAT2 
expression is relatively stable, indicating it is not significant in leukaemia development 
(Figure 1.5 Panel B). Expression of BCAT1 in these patients with CLL was also associated 
with poorer patient survival which is consistent with previous findings (Figure 1.6) (Coles 







Figure 1.5 Expression of BCAT1 and BCAT2. A) Affymetrix (U133a_Plus_2.0) gene 
expression data of BCAT1 expression in haematopoietic stem cells (HSC), acute myeloid 
leukaemia (AML; 157 patients), chronic lymphocytic leukaemia (CLL; 107 patients) and 
normal bone marrow tissue. B) Data compared with expression of BCAT2, a ubiquitously 









Figure 1.6 Five-year survival of patients displaying differential expression of BCAT1 and 
BCAT2. Kaplan Meier analysis displaying 5-year survival stratified for BCAT1 expression 
above (red line) or below (black line) the median for Acute Myeloid Leukaemia A)(AML; 
157 patients) and chronic lymphocytic leukaemia. B) (CLL; 107 patients). Figure adapted 








1.3.3 BCAT1 metabolic role in Cancer  
Leucine and α-KG both play important roles in cellular metabolism and their 
dysregulation is part of the metabolic rewiring of the cancer cell. For example, AML 
displays increased aerobic glycolysis resulting in a decreased flux of metabolites to the 
TCA through the glycolytic pathway (Emadi, 2015). Transformed cells compensate for 
this by an increased dependency on glutamine metabolism, which is converted to α-KG 
to replenish the TCA - a process called anaplerosis. In this pathway glutamine is 
converted to glutamate by Glutaminase (GLS) and subsequently to α-KG by Glutamate 
Dehydrogenase (GDH) or aminotransferases i.e. BCAT1. (Figure 1.7). Whilst the by-
product of GDH is the cytotoxic NH4+, the by-product of BCAT1 is leucine, which 
interestingly is required for GDH activation (Oppliger et al., 2012; Altman, Stine and 
Dang, 2016). Inhibition of the GLS isoform Glutaminase C (GAC), expressed in AML cell 
lines, negatively influences mitochondrial respiration, proliferation and survival, 
demonstrating the importance of glutamine and α-KG in AML cell metabolism (Jacque 
et al., 2015). 
 α-KG is not only a BCAT1 metabolite, but is also a cofactor for more than 60 α-
KG dependant dioxygenases enzymes, which have diverse roles including epigenetic 
regulation and the hypoxia response, both roles of which are dysregulated in AML 
(Drolle et al., 2015; Wouters and Delwel, 2016).  Raffel et al. reported that high 
expression levels of BCAT1 reduced intracellular α-KG and displayed a DNA 
hypermethylation phenotype similar to cases carrying a mutant IDH, in which epigenetic 







Figure 1.7 Metabolic Reprogramming in AML. Transformed cells displayed altered 
metabolism. An increase in aerobic glycolysis also known as the Warburg effect results 
increased lactate production and a decrease in mitochondrial Acetyl CoA shuttling. 
Glucose-6-P and Acetyl CoA are redirected for nucleotide and lipid biosynthesis 
respectively to fuel cell division. Concurrently an increase in glutamine results in 
increased α-KG levels that can anaplerotically replenish the depleted Citric Acid cycle 
(TCA) providing ATP and reducing equivalents. An increase in succinate derived 
mitochondrial ROS are metabolised by cellular antioxidants. Additionally, α-KG acts as a 
cofactor for histone demethylases that perform epigenetic alterations to the genome. 






Furthermore, Hypoxia Inducible Factor (HIF) transcription factors, which mediate 
primary transcriptional response to hypoxic stress, are regulated by α-KG dependant 
dioxygenases enzymes. Under normoxic conditions, HIF-α subunits are marked for 
the ubiquitin-proteasome degradation pathway through hydroxylation of proline by 
prolyl hydroxylase domain-containing protein 2 (PHD2), which is α-KG dependant 
(Deynoux et al., 2016). Knockdown of BCAT1 in leukaemia cells caused accumulation of 
α-KG leading to PHD2 mediated HIF1α protein degradation, conversely BCAT1 
expression stabilised HIF1α through a reduction in α -KG. Interestingly stabilisation of 
HIF-α has been shown to maintain HSC quiescence(Takubo et al., 2010). Given most 
standard chemotherapy relies on targeting dividing cells, induction of the hypoxia 
response through α-KG regulated HIFs provides a mechanism for therapy resistance in 
AML by promotion of quiescence (Matsunaga et al., 2012; Drolle et al., 2015).  
The other canonical forward reaction BCAT1 metabolic product, leucine, is an 
essential amino acid that cannot be manufactured de novo by the cell and plays an 
important role in nutrient sensing. Uptake of leucine is linked to glutamine through the 
LAT family of antiporters, which export glutamine in exchange for leucine(Altman, Stine 
and Dang, 2016). Additionally cells can scavenge intracellular or extracellular leucine 
through autophagy or macropinocytosis respectively, though these pathways are 
reported to be reduced in malignant hematopoietic progenitors (Sheen et al., 2011).   
Leucine is also obligatory for the activation of mammalian target of rapamycin 
complex 1 (mTORC1), a serine-threonine kinase multi-protein complex that has 
emerged as a signalling nexus that integrates upstream energy/nutrient availability, 
stress, oxygen sensing and exogenous signals from growth factors to effect downstream 
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changes in cell growth, metabolism and survival (Oppliger et al., 2012; Jewell, Russell 
and Guan, 2013). Whilst the precise amino acid sensing mechanism is not known, 
leucine  accumulates in the lysosome where it is required for the v-ATPase/Ragulator 
dependant guanine exchange of the Rag A/B and Rag C/D heterodimers. Activation of 
the pathway occurs with the guanosine diphosphate (GDP) to guanosine triphosphate 
(GTP) exchange of Rag A/B, which causes relocation of mTORC1 relocation from an 
undefined cytoplasmic location to the lysosomal surface where it is activated by Rheb. 
Once activated, mTORC1 positively regulates protein biosynthesis through p70 
ribosomal S6 kinase 1 (S6K1) which increases in mRNA biogenesis and translation of 
ribosomal protein S6 a component of the 40S ribosomal subunit (Oppliger et al., 2012). 
As well as upregulating anabolic processes mTORC1 activation downregulates catabolic 
processes, such as autophagy, through the regulation of a protein complex composed 
of unc-51-like kinase 1 (Chan, 2009). Therefore, leucine availability is important for 
protein biosynthesis and cell survival. 
Leucine is also obligatory for the allosteric activation of GDH, which as previously 
mentioned produces α-KG from glutamate, a vital step in the metabolism of glutamine. 
This pathway is upregulated in AML (Oppliger et al., 2012; Jewell, Russell and Guan, 
2013), the transamination of glutamate by BCAT1 provides a route to leucine production 
that does not require intracellular scavenging or export of glutamine, an important 
cellular resource. This may have important implications for mTORC1 activation which 
requires sufficient energy for activation as well as leucine availability.  
Monitoring of cellular energetics occurs upstream of mTORC1 via the 
serine/threonine kinase AMP-activated protein kinase (AMPK) complex (Xu, Ji and Yan, 
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2012). Increases in the cellular ADP/ATP ratio through mitochondrial respiration activate 
AMPK which negatively regulates mTORC1 through tuberous sclerosis complex (TSC) 1/2 
heterodimer. AMPK phosphorylates TSC2, which increases the GTPase activity of TSC2 
catalysing the hydrolysis of active GTP bound Rheb to inactive GDP form (Inoki, 
Corradetti and Guan, 2005). Consequently, mTORC1 may remain inactive after leucine 
activated localisation to the lysosomal surface if there is insufficient generation of ATP. 
Thus, the BCAT1 metabolic pathway may provide both the energetic and nutrient 
sensing requirements for mTORC1 activation through the generation of leucine and α-
KG respectively. Taken together, these studies highlight a central role for BCAT1 in AML 
metabolism, where the generation of leucine and α-KG by BCAT1 feed into multiple 
cellular processes that impact on AML cell survival, stemness and biosynthesis. 
 
1.3.4 The CXXC motif  
An important aspect of the BCAT isoenzymes is the presence of a surface CXXC 
motif, that is two cysteine amino acids (C) separated by two other amino acids (X), 
located 10 angstroms from the active site. In BCAT2 the CXXC motif (C315-X-X-C318) 
functions as a redox sensitive molecular switch modulating the catalytic activity of the 
enzyme(Myra E. Conway, Poole and Hutson, 2004). Mechanistically this is achieved 
through oxidation of the thiol (-SH) groups of the CXXC motif cysteines. Examination of 
the crystal structure revealed the N-terminal C315 exists as a thiolate anion (Cys-S-) at 
physiological pH, exposure to ROS intermediate hydrogen peroxide (H2O2) can oxidize 
the thiolate anion to sulfenic form (Cys-SOH) which can react with another Cys-SH 
forming a disulphide (Cys-S-S-Cys) and H2O (Figure 1.8). Disulphide bond formation 
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elicits a conformational change that inactivates the enzymatic capacity, this process can 
be reversed by the addition of antioxidant dithiothreitol (DTT) which restores the active 
from of the enzyme (Conway 2002). Site directed mutagenesis of the BCAT2 CXXC motif 
substituting the C-terminal cysteine to alanine (C318A) demonstrated the N-terminal 
C315 becomes irreversibly oxidised to a sulfonic acid when exposed to H2O2, resulting in 
complete loss of catalytic activity. Substitution of C315 to alanine (C315A) on BCAT2 
largely retained its enzymatic capacity whilst the ability to be regulated by H2O2 was lost, 
revealing that that C315 acts as a redox sensor whilst C318 is the ‘resolving’ cysteine 
that forms a disulphide bond with C315, protecting it from irreversible oxidation. 
(Conway 2004).  
Amino acid sequence alignment analysis between the BCAT1 and BCAT2 shows 
58% sequence homology, where the CXXC motif is conserved between the two isoforms, 
however the biochemical properties vary between the two (Goto et al. 2005). The 
midpoint redox potential, that is the electron potential at which the ratio of 
oxidised/reduced thiols,  is -225mV for BCAT2 CXXC motif and -310Mv for BCAT1. This 
demonstrates BCAT1 is more readily oxidised than BCAT2, otherwise stated it is a more 
powerful antioxidant i.e. more reducing in nature (Coles, Hancock and Conway, 2012). 
Whilst upon oxidation BCAT2 forms a disulphide bond that inactivates the protein, it has 
been demonstrated that the BCAT1 N-terminal cysteine (C335) is glutathionylated 
protecting its catalytic activity (Figure 1.8) (Conway et al., 2008). Conway et al 






Figure 1.8 Redox activity of the BCAT1 and BCAT2 CXXC motifs.  A) BCAT1 N-terminal 
Cys residue exists as a thiolate/thiol under reducing conditions cycling between the two 
using GSH as an electron donor. As the redox environment becomes more oxidised (2:1 
GSH/GSSG ratio) the N-terminal cysteine becomes S-glutathionylated restoring GSH 
with a modest loss in enzymatic activity. Glutathionylation of the C-terminal cysteine 
occurs upon further oxidation (1:2.5 GSH/GSSG ratio) A similar reaction occurs upon 
H2O2 mediated oxidative stress perhaps through sulphenic or sulphinic acid 
intermediates. B) BCAT2 N-terminal cysteine residue is active at a redox potential of >-
225 mV. Upon oxidation by mitochondrial free radicals it forms an inter subunit 







environment became more oxidised,  which could be induced by the addition of H2O2. 
Importantly, this S-glutathionylation could be reversed by the GSH/glutaredoxin 
antioxidant couple, thus linking BCAT1 it to a wider antioxidant network, a feature the 
BCAT2 isoform does not display.  
In fact CXXC motifs, or at least the presence of a single surface cysteine, are a 
common feature of many anti-oxidant enzymes e.g. thioredoxin (Trx1) and 
peroxiredoxin (Prdx1), which utilise cysteine thiol groups as reducing agents to perform 
their oxidoreductase activities (E. S. Arnér and Holmgren, 2000; Rhee, 2016). This 
suggests that BCAT1 may function as a novel antioxidant given the highly reducing 
nature of the BCAT1 CXXC motif (Coles, Hancock and Conway, 2012). In support of this 
theory, the redox midpoint potential of BCAT1 (-260mV) is lower than Trx1 (-230mV) 
suggesting that BCAT1 is a more powerful antioxidant by comparison (Pohl, 2003) 
(Figure 1.9). However, BCAT1’s role as an antioxidant is unknown. 
Antioxidant proteins produce an equilibrium of reduced/ oxidised forms called a 
redox couple that buffer against cellular redox changes.(Fomenko and Gladyshev, 2003) 
Physiologically normative changes in cellular reduction potential are produced as a cell 
moves from a proliferative state through to differentiation. Although there is variation 
between cell types, in general proliferation occurs between a reduction potential of -
260 to -210mV, differentiation -210 to -180mV and apoptosis -180 to -160 mV (F Q 
Schafer and Buettner, 2001). Interestingly, the AML cell line HL60 is in a proliferative 
state at -239 mV and apoptotic at -167mV a change of -72 mV (Figure 1.9) (F Q Schafer 
and Buettner, 2001). Therefore, it may be hypothesised that overexpression of 
antioxidant proteins may shift a cancer cell away from differentiation or cell death to a 
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more proliferative state. Indeed, leukaemia cells are known to upregulate antioxidant 
proteins in response to higher reactive oxygen species (ROS) production. For example, 
Trx1 is upregulated in relapsed AML patients and is correlated with higher ROS 
production and poorer patient prognosis (Chen et al 2010). Moreover, inhibition of Trx1 
increases sensitivity to the pro-oxidant Arsenic Trioxide, suggesting Trx1 is protecting 
AML cells from ROS induced cell death. (Jiang et al 2014).  
The relative contribution of the enzymatic and antioxidant activity of BCAT1 to 
the pathophysiology of AML has yet to be elucidated. The effect of BCAT1 expression on 
the metabolic and epigenetic mechanisms of oncogenesis remains the current research 
focus in the field. However, overproduction of ROS in AML is extremely well 
characterised and contributes to the pathogenesis of the disease. (Hole et al., 2013; 
Testa et al., 2016; Moloney et al., 2017) Preliminary data demonstrates that BCAT1 can 
directly metabolise H2O2 in vitro (Unpublished Coles et al). Moreover, analysis of the 
redox potential BCAT1 CXXC motif suggests it has an antioxidant capacity that is 
comparable to major cellular antioxidant Trx1.  Importantly BCAT1 CXXC motif S-
glutathionylation demonstrates an ability to interact directly with the most abundant 
cellular redox couple reduced/oxidised glutathione (GSH/GSSG), suggesting BCAT1 
could buffer these systems during periods of oxidative stress. This provides the rationale 
that overexpression of BCAT1 may be able to influence processes dysregulated in cancer 
including proliferation, differentiation and apoptosis by an antioxidant mechanism, 
namely the elimination of ROS and buffering the cellular antioxidant systems which are 






Figure 1.9 Redox control of cellular processes. Key cellular processes dysregulated in 
cancer including proliferation, differentiation and apoptosis are executed at different 
redox potentials. More negative/reductive environments favour quiescence and 
proliferation whilst a more positive/oxidative shift see cells arrest growth and 
differentiate, further oxidation may result in oxidative stress and apoptosis. Analysis of 
the CXXC motifs of BCAT1, BCAT2 and Thioredoxin reveal that BCAT1 is oxidised at a 
redox potential ~80-85mV lower than either Trx or BCAT2. S-glutathionylation of the 
BCAT1 CXXC motif at a ‘quiescent’ redox potential (-280- -310mV) often associated with 




1.4.  ROS 
1.4.1 Sources of ROS  
Reactive Oxygen Species (ROS) are a number of chemically reactive species 
including the oxygen radicals such as the superoxide anion (O2•−), the perhydroxyl radical 
(•OOH) the hydroxyl radical (OH•) and non-radicals oxidising agents such as 
hypochlorous acid (HOCl) and hydrogen peroxide (H2O2) that play an important role in 
cellular health and disease (Lushchak, 2014).  
The majority of cellular ROS is generated endogenously by partial reduction of 
oxygen in the final stages of mitochondrial oxidative phosphorylation. Initially succinate 
and nicotinamide adenine dinucleotide + hydrogen (NADH) generated from the TCA are 
oxidised passing their electrons to a series of adjacent protein complexes embedded in 
the inner mitochondrial membrane space known as the electron transport chain 
(Murphy, 2009).  The electrons are passed from one electron carrier to another from 
complex I to complex IV in a series of redox reactions that releases Gibbs free energy 
(ΔG) to power the transport of NADH derived H+ ions from the mitochondrial matrix 
across the inner membrane to the intermembrane space. This creates an 
electrochemical proton gradient that is utilised by ATP synthase which acts as an ion 
channel allowing protons to re-enter the mitochondrial matrix catalysing the formation 
of ATP from ADP and Pi. In the final step electrons held by Cytochrome C are passed to 
molecular oxygen which functions as the final electron acceptor creating the superoxide 
anion O2•−, which is reduced to H2O2 and finally H2O by the action of superoxide 
dismutase. However, leakage of electrons from the electron transport chain (ETC) or an 
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insufficient pool of H+ due to proton leakage leads to single electron reduction of O2 and 
over-generation of O2•-. (Brand et al 2011) 
Another major source of cellular ROS comes from the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase (NOX) family of proteins, which produce ROS 
not as a by-product as is the case with mitochondrial respiration, but as a primary 
function of the enzyme (Bedard and Krause, 2007). The NOX family of proteins, which 
consist of NOX1-5 as well as DUOX1/2, function as a membrane bound complexes that 
facilitate the import of electrons across the plasma membrane to molecular oxygen 
producing O2•-. Although functionally similar, they vary significantly in their subcellular 
localisation, tissue distribution and physiological effects.  
Perhaps the best understood remains NOX2, which was originally discovered as 
the source of neutrophilic respiratory bursts and has been extensively studied. It is from 
NOX2 that the model of NOX function is broadly derived(Panday et al., 2015). NOX2 
contains 2 transmembrane subunits gp91-phox (NOX2) and p22-phox, three cytosolic 
subunits (p47-phox, p67-phox, p40-phox), and the G-protein Rac. During NOX 
activation, stimuli induce Protein Kinase C (PKC) activation, which phosphorylates 
cytosolic p47/p67-phox dimer, eliciting a conformational change that exposes the p47-
phox SH3 domain. This is followed by translocation of p47/p67-phox and p40-phox to 
the membrane, where the SH3 domains of p47-phox interacts with the proline rich 
region of p22-phox, whereupon Rac translocates to the complex to activate NOX2. NOX2 
itself contains 6 transmembrane domains which contain 4 highly conserved heme 
binding histadines and a –COOH terminal cytosolic domain which contains FAD and 
NADPH binding domains. Electrons derived from NADPH are transferred to FAD then to 
52 
 
the transmembrane heme and finally to oxygen in the luminal or extracellular space 
generating superoxide(Brandes, Weissmann and Schröder, 2014).  
The significance of p47-phox and p22-phox interaction has been demonstrated 
clinically in a patient with Chronic granulomatous disease (CGD), an immune disorder 
characterised by the inability of phagocytes to generate superoxide through NOX 
resulting in the eponymous granulomas, a collection of macrophages that are unable to 
eliminate the infection. A single proline to glutamine substitution at residue 156 in the 
proline region of p22-phox results in impaired p47-phox translocation in cells stimulated 
with PMA which activates PKC  (Leussen et al. 1994). 
Whether it is generated through mitochondrial respiration or NOX, the 
superoxide anion (O2•−) is highly reactive and if left unchecked can cause damage to 
DNA, lipids and proteins. Therefore it is normally rapidly eliminated by enzymatic 
dismutation to H2O2 via cytosolic superoxide dismutase (SOD1) (rate constant = 2 × 
109 M−1s−1) (Fridovich, 1983). However, at this stage yet more ROS can be formed from 
H2O2  which can be broken down into the highly reactive hydroxyl (OH•) and perhydroxyl 
(•OOH) radicals via the iron catalysed Haber–Weiss and Fenton reactions or photolysis 
by UV light (Winterbourn, 1995): 
1) Fe2+ + H2O2 → Fe3+ + HO• + OH− 
2) Fe3+ + H2O2 → Fe2+ + HOO• + H+ 
3) H2O2 → HO• + HOO• + H2O 
Finally, O2•− may interact with nitric oxide (NO•) leading to formation of a distinct 
family of pro-oxidant molecules collectively known as reactive nitrogen species (RNS), 
the primary species being peroxynitrite (ONO−2) (Martínez and Andriantsitohaina, 2009). 
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Like O2•− the majority these ROS and RNS radicals are short-lived before being 
neutralised by a network of enzymatic and non-enzymatic antioxidant defences which 
maintain redox homeostasis(Baran et al., 2004). 
 
1.4.2 Antioxidant networks  
Cellular defences against ROS are orchestrated by a network of antioxidant 
enzymes that actively remove ROS including, Catalase and Glutathione peroxidase (GPx) 
and Peroxiredoxins (Prx), as well a oxidoreductases such as Thioredoxin (TRx) and 
Glutaredoxin (Grx), and  low molecular weight thiols, such as Glutathione (GSH). 
Collectively, these  act as redox couples that eliminate ROS through a series of reduction-
oxidation (Redox) reactions (Figure 1.10) (Li et al., 2000; Forman, Zhang and Rinna, 2009; 
Marengo et al., 2016).  In this system, H2O2 generated from the dismutation of 
mitochondrial or NOX derived O2•- is metabolised by peroxidase enzymes which include 
Catalase, GPx and Prxs. Whilst functionally analogous mechanistically, Catalase is able 
to achieve reduction of H2O2, independently whilst GPx and Prx require GSH and Trx 
respectively to act as electron donors and regenerate the enzymes to their reduced 
active form via oxidoreductase activity (Hanschmann et al., 2013).  
Catalase contains four identical subunits of 62 kDa, each subunit containing a 
prosthetic heme group, which is central to its enzymatic function. Reduction of H2O2 is 
a two-step process, initial oxidation of the iron containing heme complex by H2O2 leads 
to formation of an oxyferryl porphyrin cation radical represented in step one of the 
schematics as O=Fe(IV). A second H2O2 then reacts with O=Fe(IV)  to reform Fe(III) 
creating water and oxygen(Alfonso-Prieto et al., 2009):  
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1) H2O2 + Fe(III) → H2O + O=Fe(IV) (.+) 
2) H2O2 + O=Fe(IV)(.+) → H2O + Fe(III) + O2 
Like Catalase, GPx structure is tetrameric, however the catalytic redox 
mechanism relies on cysteine analogue selenocysteine that substitutes the thiol group 
(R-SH) with a selenium-containing selenol group (GPx-SeH) rather than iron-complexed 
haem (Battin and Brumaghim, 2009).  In the first step, oxidation of the selenol group 
with H2O2 yields selenic acid (GPx-SeOH) and H2O. Selenic acid reacts with GSH to form 
GPx-SeSG and an additional H2O before finally GPx is reduced back to GPx-SeH by GSH 
forming Glutathione disulfide (GSSG): 
1) GPx-SeH + H2O2 → GPx-SeOH + H2O 
2) GPx-SeOH + GSH → GPx-SeSG + H2O 
3) GPx-SeSG+ GSH → GPx-she + GS-SG 
4) GS–SG + NADPH + H+ → 2 GSH + NADP+ 
GSSG is regenerated to GSH by glutathione reductase using NADPH as a reducing 
equivalent creating NADP+, which in turn is restored by various oxidoreductase reactions 
of the TCA and pentose phosphate pathway (Jin and Zhou, 2019).  
 Peroxiredoxin utilises the cyclical oxidation-reduction of cysteine thiols in a 
manner mechanistically analogous to the BCAT1 CXXC motif, however the catalytic 
cysteine residues of Prx are located on different peptide chains forming inter-subunit 
disulphide bonds, this is in contrast to the contiguous arrangement of the CXXC motif 
which forms an intra-subunit bond. Typical 2-Cys Prx’s including Prx1-4, contain a highly 
conserved redox active N-terminal peroxidatic cysteine (CP) and a semi conserved 
resolving cysteine (CR) the location of which varies amongst the Prx family (Rhee, 2016). 
During catalysis CP is oxidised to a sulphenic acid (Prx-S-OH) intermediate by the 
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peroxide substrate releasing H2O. The hydroxyl group of the sulphenic acid is liberated 
by the formation of the inter-subunit disulphide bond between the peroxidatic cysteine 
and the resolving cysteine releasing a second H2O molecule (Woo et al., 2010). Oxidised 
Prx disulphide bonds are reduced back to cysteine thiols by Trx, a 12kDa oxidoreductase 
that facilitates the reduction of oxidised proteins (E. S. J. Arnér and Holmgren, 2000). 
Thioredoxin is characterised by a tertiary structural motif, the thioredoxin fold 
which consists of three α-helices surrounding a central core of a four-stranded β-sheet 
and a highly conserved CXXC motif active site. Like BCAT1, the CXXC motif consists of 
two vicinal cysteine residues separated by two variable amino acids, the N-terminal 
cysteine thiol has a low pKa value and is deprotonated at physiological pH forming the 
thiolate anion (R-S-) ( Arnér and Holmgren, 2000). Thiolate nucleophilic attack of a  
disulphide bond on another protein (substrate) results in Thx-substrate mixed 
disulphide linkage, that is resolved by the C-terminal cysteine thiol that breaks the mixed 
disulphide, yielding the reduced protein substrate and an oxidized Trx.  Reduced Trx is 
regenerated by thioredoxin reductase (TrxR), which like glutathione reductase utilises 











Figure 1.10 The glutaredoxin and thioredoxin redox cycle. Cysteine S-glutathionylation 
as seen in BCAT1 is removed by reduced GrX which is regenerated by GSH or NADPH, 
ultimately the electron source is NADPH regenerated by the pentose phosphate 
pathway (Panel A). H2O2 induced cysteine disulphide bond formation is reversed by Trx 
causing the CXXC motif of TrX to form an intramolecular disulphide bond.  This is reduced 
again by the action of TrxR utilising reducing equivalents from a TrxR FADH domain and 
















Cys-S – S-Cys 











1.5 Oxidative Stress in cancer  
1.5.1 Genomic integrity  
Excessive ROS production through endogenous or exogenous mechanisms or a 
decrease in cellular antioxidant defences, can cause cells to enter a state of biochemical 
imbalance known as oxidative stress. Unchecked ROS can cause oxidative damage DNA, 
lipids and proteins and alter redox signalling cascades (Ray, Huang and Tsuji, 2012).  
Genomic insults to oncogenes or tumour suppressors mediated by ROS, can lead 
to malignant transformation, for example hydroxyl radicals cause double-strand breaks 
or oxidative base pair damage, that results in a range of derivatives (Cadet and Richard 
Wagner, 2013). Due to a high reduction potential, guanine is most frequently attacked 
by ROS, commonly resulting in the 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) DNA 
lesion (Radak and Boldogh, 2010). This represents approximately 1 in 20 of all DNA 
lesions and left unrepaired results in mutagenic mismatched pairing with adenine and 
the G:C to T:A transversion event. Base excision repair initiated by DNA glycosylase 
enzymes that cleave the N-glycosidic bond connecting nucleobases to the sugar 
phosphate backbone, results in the excision of 8-oxodG. Due to oxidised bases acting as 
poor substrates for enzymes involved in DNA synthesis, 8-oxodG is conveniently 
excreted in urine and therefore has frequently been used as a biomarker to assess 
oxidative DNA damage (Loft and Poulsen, 1996; Roszkowski et al., 2011). Based on this 
method alone, even under steady state or normal physiological ROS production, DNA is 
oxidatively damaged at a rate of 105 residues per cell per day in rats and 104 in humans, 
perhaps reflecting the lower basal metabolic rate of human cells (Loft and Poulsen, 
1998). Urinary excretion and leukocyte DNA levels of 8-oxodG were reported to increase 
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up to 50% in response to smoking tobacco, a source of exogenous ROS(Loft and Poulsen, 
1998). Furthermore, similar increases in 8-oxodG have been observed in cancer patients 
exhibiting various malignant tumours compared to healthy individuals, underlining the 
role ROS plays in carcinogenesis (Loft and Poulsen, 1996; Roszkowski et al., 2011). In 
healthy cells DNA damage initiates the ATM-p53 DNA damage response pathway, where 
in the cell cycle is arrested and the damage is either repaired or the damaged cell is 
eliminated through induction of apoptosis. Archetypal DNA damage response  protein 
TP53 is mutated in approximately half of human cancers making, it the most frequently 
mutated cancer gene further underlining the importance of maintaining genomic 
integrity (Reinhardt and Schumacher, 2012).   
 
1.5.2 Redox signalling  
As well as driving  genomic mutation, defective control of ROS homeostasis can 
alter redox sensitive signalling cascades that impact cellular proliferation, differentiation 
and apoptosis (Ray, Huang and Tsuji, 2012).  As with the BCAT CXXC motif, redox 
signalling is mediated, in part, by cysteine thiols that can undergo reversible H2O2 
oxidation altering the activity of redox sensitive proteins. This oxidation may result in 
several oxidised thiol derivatives, including sulphenic acids (-SOH), which can undergo 
further oxidation to sulphinic (Cys- SO3) and finally sulphonic acids (Cys- SO3)( Miki and 
Funato, 2012). Sulphenic acids can be reduced by disulphide reductases, such as Trx and 
glutaredoxin (Grx), restoring protein function. In this way ROS can act as a secondary 
messenger relaying the redox status of the cell and modulating a cellular response 












Figure 1.11 Protein thiol oxidation/ reduction reaction inducing conformational 
change and homeostatic regeneration via glutathione/ NADPH redox couple. Protein 
thiols are oxidised to form intramolecular disulphide bridges that form part of the 
secondary structure of the protein. Formation or dissolution of disulphide bridges 
induce a conformational change that acts as a molecular nano switch modulating 
enzymatic activity. Proteins can regenerate by antioxidants such as glutathione which in 






is largely irreversible and a manifestation of oxidative stress that can result in impaired 
redox signalling. 
For example, receptor tyrosine kinases (RTK) such as epidermal growth factor 
(EGF) and platelet derived growth factor (PDGF), result in the activation of signal 
transduction pathways PI3-K-AKT. The activity of these RTKS are negatively regulated by 
protein-tyrosine phosphatases (PTP) such as PTEN, a gene frequently mutated in human 
cancer, which dephosphorylates PI3-K (Morotti et al., 2015). PTPs are redox active and 
can be deactivated by ROS through the oxidation of cysteine residues to sulphenic acid 
intermediates, resulting in the activation of the PI3-K-AKT (Figure 1.12) (Leslie et al., 
2003). In fact, EGF and PDGF stimulation results in a transient oxidative burst generated 
from NOX proteins that are required for growth factor induced RTK phosphorylation. 
NOX derived H2O2 mediated oxidation and subsequent disulphide bond formation of 
between Cys121 and Cys71 inactivates PTEN, whilst reduction by Trx restores PTEN activity 
(Schieber and Chandel, 2014). Given NOX derived oxidative bursts could cause cellular 
damage or alter thiol signalling away from the site of generation, the cell exerts localised 
control via membrane associated antioxidant Prdx1. Prdx1 is inactivated upon growth 
factor stimulation causing localised accumulation of H2O2 and inhibition of PTP activity 
(Woo et al., 2010).  
High ROS levels are also a feature of AML, which displays defective control over 
RTK- NOX-PTP signalling (Sillar et al., 2019).  A greater than 10-fold increase in NOX 
derived ROS was reported in more than 60% of AML blasts causing increased 
proliferation ( Hole et al., 2013). A common ROS producing defect seen in ∼30% of AML 
patients and  associated with the poor prognosis is autophosphorylation of the FMS-like 
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Tyrosine Kinase (FLT3) receptor through the Internal Tandem Duplication (ITD) of the 
transmembrane domain, which increases ROS production via activation of AKT and 
stabilization of p22phox, a regulatory subunit for NOX1-4 ( Gilliland and Griffin, 2002b). 
Furthermore FLT3-ITD enhances NOX4 expression and ROS cysteine thiol inactivation of 
the PTP DEP-1, where inactivation of NOX4 restores DEP-1 attenuating cell 
transformation by FLT3-ITD in in vitro and in vivo models (Jayavelu et al., 2016). 
Furthermore, Prdx1 expression supresses FLT3-ITD signalling by restoring PTP activity 
and increasing survival in cell culture and mouse models (Godfrey et al., 2012). Taken 
together, these studies demonstrate the importance of redox regulation in RTK–NOX-

















Figure 1.12 Receptor Tyrosine Kinase (RTK) signalling e.g. c-KIT and FLT3 Clinically 
distinct mutations in FLT3 and c-KIT RTK result in autonomous activation of growth and 
survival signalling cascades PI3K-AKT-mTOR, RAS-RAF-MEK-ERK and JAK-STAT. PTPs 
negatively regulate these signalling cascades. PTPs in turn are negatively regulated by 








1.5.3 Nrf2 antioxidant response  
Due to high ROS levels, cancer cells are susceptible to oxidative stress induced 
cell death. In order to maintain a sublethal redox environment, high ROS production in 
cancer cells is matched by an equally high antioxidant activity, thus protecting the cancer 
cell from ROS-induced apoptosis( Gorrini, Harris and Mak, 2013). Antioxidant production 
is controlled through the activation of the redox sensitive transcription factor; nuclear 
factor erythroid 2-related factor 2 (NRF2), which activates the transcription of over 100 
cytoprotective and antioxidant genes (Sporn and Liby, 2012). Under low ROS conditions 
cytoplasmic Nrf2 interacts with Kelch-like ECH-associated protein 1 (KEAP1), whereby 
ubiquitination of the Nrf2-KEAP1 complex leads to proteasomal degradation (Tonelli, 
Chio and Tuveson, 2018). Under oxidative stress, KEAP1 undergoes cysteine thiol 
oxidation and dissociation from Nrf2 which translocates to the nucleus. Nuclear 
relocated Nrf2 heterodimerizes with small musculoaponeurotic fibrosarcoma proteins 
binding antioxidant-response elements (AREs) located upstream of multiple antioxidant 
genes, initiating transcription of targets including the GSH and Trx antioxidant systems, 
as well NADPH regeneration and haem/iron metabolism (Tonelli, Chio and Tuveson, 
2018). The Nrf2 pathway is negatively regulated by the transcriptional repressor Bach1, 
which competes with Nrf2 to bind the ARE enhancers following ROS induced nuclear 
relocalisation.  Antioxidants are reported to delay nuclear accumulation of Bach1, 
reflecting its opposing role to Nrf2 in redox regulation (Dhakshinamoorthy et al., 2005).  
Nrf2 regulates GSH levels by controlling expression of glutamate-cysteine ligase 
(GCL), which catalyses the reaction of glutamate and cysteine, the rate-limiting step in 
the synthesis of GSH (Tonelli, Chio and Tuveson, 2018). In addition, Nrf2 upregulates 
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antioxidant enzymes such as Glutathione peroxidase 2 (Gpx2), Sulfiredoxin and Trx, as 
well as Thioredoxin reductase (TrxR) and NADPH reducing equivalents through 
increased transcription of key enzymes in NADPH generation including glucose-6-
phosphate dehydrogenase (G6PD) and IDH1 (Singh et al., 2006; Zhou et al., 2015; 
Tonelli, Chio and Tuveson, 2018). As well as upregulating the antioxidant network, Nrf2 
upregulates haem oxygenase, which catalyses the breakdown of heme molecules thus 
preventing the formation of haem derived Fe2+ which could participate in Fenton based 
production of hydroxyl radicals (Surh et al., 2009). Furthermore, Nrf2 induces expression 
of the Ferritin light and heavy polypeptides of the 24 subunit ferritin complex that 
oxidises and sequesters Fe2+, making it unavailable for the Fenton chemistry (Pietsch et 
al., 2003).  
Induction of such a wide battery of cellular defences has led to the observation 
that the contribution of Nrf2 to carcinogenicity is context dependant, providing 
protection from transformative ROS insult in healthy cells, whilst preventing apoptosis 
in malignant cells. In AML, Nrf2 expression provides chemo-resistance to Ara-C and 
arsenic trioxide (ATO), where targeting Nrf2 with the inhibitor Brusatol, increased 
sensitivity to these agents, demonstrating the antioxidant network as an attractive 
therapeutic target (Olayanju et al., 2015; Karathedath et al., 2017). Disruption of 
downstream targets of Nrf2 has also proven effective, where inhibition of Trx leads to 
enhanced apoptosis and sensitivity to pro-oxidant treatment ATO in AML (Tan et al., 
2014). Thus, a similar strategy may be effective targeting the proposed antioxidant 




1.6  Hypothesis 
This study has been carried out to explore the antioxidant role of the BCAT1 CXXC 
motif in the development  and treatment of AML. The rationale for this stems from the 
fact cysteine thiol redox reactions are part of the mechanism through which cellular 
antioxidant defences eliminate excessive ROS and prevent oxidative stress. Oxidative 
stress and upregulation of antioxidant proteins such as Thioredoxin (Trx), which contains 
a redox active CXXC motif, is a feature of AML. This has been speculated to contribute 
to malignant cell pathology by the dysregulation of redox controlled processes including 
differentiation and apoptosis. Previous studies have demonstrated  the BCAT1 CXXC 
motif has a more negative reduction midpoint potential than the Trx CXXC motif 
suggesting it is a more powerful antioxidant. Moreover, overexpression of BCAT1 is 
associated with poorer prognosis, suggesting it is contributing to malignant processes in 
AML. To explore this possibility, here the CXXC motif has been mutated substituting the 
cysteine resides for serine, abolishing the putative cysteine thiol antioxidant activity. 
Overexpression of BCAT1 wild-type and CXXC motif mutant protein in immortalised 
monocytic AML cell line U937 will allow the effect of the effect of the CXXC motif to be 








 Project Aims 
The principal aim of this project is to investigate the antioxidant role of the BCAT1 
CXXC motif in the development and treatment of AML. To fulfil this aim, the specific 
objectives  are as follows: 
1. Site directed mutagenesis of the BCAT1 CXXC motif substituting amino acid 
cysteine (C) to serine (S) creating three constructs in pCMV6-Entry vector: 
a. BCAT1(WT) → CXXC 
b. BCAT1(C338S) → CXXC to CXXS 
c. BCAT1(C335/8S) → CXXC to SXXS 
This objective should abolish the potential antioxidant effect of the CXXC motif 
whilst retaining BCAT1 metabolic activity allowing the antioxidant capacity of the 
BCAT1 CXXC motif can be directly evaluated. 
 
2. Lentiviral transduction and overexpression of BCAT1(WT) and CXXC motif 
mutants in U937 cells (ATCC CRL 1293.2)  
 
3. Investigate the antioxidant effect of CXXC motif on redox environment of the cell 
and how this affects redox mediated processes in the development of AML 
including proliferation, apoptosis and differentiation in U937.  
 
4. Investigate the effect of BCAT1 CXXC motif in the treatment of AML. Evaluation 
of transgenic cell lines will be carried out in vitro with respect to proliferation 
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and viability  following incubation with standard chemotherapeutic compounds  




Chapter 2: Materials and Methods 
2.1.  Antibodies 
ECA39 (BCAT1) primary antibody (Santa Cruz SC-517185) and Rabbit anti-goat 
IgG-HRP secondary (Santa Cruz SC-2768) were obtained from Santacruz Biotechnology 
(Dallas, TX, USA). Anti-DDK (FLAG) monoclonal antibody was obtained from Origene 
(Clone OTI4C5). Recombinant Anti-Cyclophilin B HRP loading control (ab205875) was 
obtained from Abcam (Cambridge, UK). 
 
2.2 Cell Lines 
U937 human histiocytic lymphoma cell lines (ATCC® CRL-1593.2TM) and 
HEK293T (ATCC® CRL-3216™) were obtained from Public Health England (Salisbury, 
UK.). E. coli BL21(DE3) and α-Select Gold Efficiency chemically competent cells were 
obtained from BioLine (London, UK.).  
 
2.3 Plasmids and Constructs 
Lyophilised pCMV6-Entry vector (catalog no. RC229972) containing human cDNA 
clone BCAT1, cytosolic transcript variant 5 (NM_01178094) and pLenti-C-Myc-DDK-IRES-
Puro vector (catalog no. PS100069) were obtained from Origene (Rockville, Maryland, 
USA). pET-28a (catalog no. 69864) expression plasmid was obtained from Novogen 





All primers used in this project were manufactured and supplied by Eurofins Scientific 
(Ebersberg, Germany). 
BCAT1_424   5-GCA GCT AGC ATG GAT TGC AGT AAC GGA-3 
BCAT1_1582   5-GCA GCT GTC GAC TGA TCA GGA TAG CAC AAT TGT C-3  
C335 F  5-GGC TCT GGT ACA GCC TCT GTT TGC CCA-3 
C335 R  5’- TGG GCA AAC AGA GGC TGT ACC AGA GCC-3 
C338 F  5-GGT ACA GCC TGT GTT AGC CCA GTT TCT GAT ATA CTG-3’ 
C338 R  5’-CAG TAT ATC AGA AAC TGG GCT AAC ACA GGC TGT ACC-3’ 
C335/8 F  5-GGT ACA GCC TCT GTT AGC CCA GTT TCT-3 
C335/8 R  5’- AGA AAC TGG GCT AAC AGA GGC TGT ACC- 3’ 
T7 F  5’- TAA TAC GAC TCA CTA TAG GG-3’ 
T7 R  5’- GCT AGT TAT TGC TCA GCG -3’ 
V2  5’- AGA GCT CGT TTA GTG AA-3’ 
LR-50  5’- CAG AGG TTG ATT ATC GAT AAG 3-3’  
VP1.5  5’- GGA CTT TCC AAA ATG TCG-3’ 
XL-39  5’ ATT AGG ACA AGG CTG GTG GG 3’ 
BCAT1-F 5’- TGG AGA ATG GTC CTA AGC TG -3’ 
BCAT1-R 5’- GCA CAA TTG TCC AGT CGC TC -3’ 
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β2M-F   5’- ATG AGT ATG CCT GCC GTG TGA -3’ 
β2M-R  5’- GGC ATC TTC AAA CCT CCA TG-3’ 
 
2.5 Transformation of E.coli with pCMV6-BCAT1 
pCMV6-BCAT1 and CXXC mutant constructs were transformed into α-Select Gold 
Efficiency chemically competent cells (Bioline BIO-85027) according to the 
manufacturer’s instructions. Briefly, 25 µL of competent cells were mixed with 3-5 µL of 
construct DNA and incubated on ice for 30 min. The mixture was heat shocked at 42 °C 
for 40 sec using a block heater and returned to ice for 2 min. The transformation mixture 
was diluted by addition of 500 µL Luria-Bertani (LB) broth (1% tryptone, 0.5% yeast 
extract, 1% NaCl) and incubated on an orbital shaking platform at 50 rpm for 1 h at 37 
°C followed by inoculation onto LB agar supplemented with 50 µg/mL kanamycin. Plate 
cultures were incubated overnight at 37 °C. 
Single colonies were added to 10 mL LB broth supplemented with 50 µg/mL 
kanamycin and incubated overnight at 37 oC in an orbital shaker at 50 rpm. Cells were 
harvested by centrifugation at 4000 x g using a VWR MegaStar 1.6R centrifuge and 
plasmids were purified from cell pellets the Isolate II plasmid mini-prep kit (Bioline BIO-
52056) according to instructions. Briefly  cells were resuspended in 500 µL of 
resuspension buffer P1, following addition of 500 µL lysis buffer P2 the suspension was 
mixed by inversion and incubated at room temperature for 5 min. The lysis reaction was 
stopped by addition of 600 µL of neutralisation buffer P3 and lysate centrifuged at 11 
000 x g for 5 min. Following centrifugation, the supernatant was removed, added to 
Isolate II plasmid mini spin column and bound by centrifugation as previously described 
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for 1 min. The column was washed by addition of 500 µL of wash buffer P1 and 
centrifuged for 1 min. Following addition of 600 µL of wash buffer P2 and centrifugation 
for 1 min the column was dried by centrifugation for 2 min and plasmids were eluted by 
addition of 50 µL of elution buffer and centrifugation for 1 min as previously described. 
Concentration and purity of plasmid vector was determined by measuring absorbance 
at λ260/280 nm using a Nanodrop 2000c spectrophotometer (Thermo-Fisher).  
 
2.6 Site-directed Mutagenesis of the CXXC Motif 
Mutagenesis of BCAT1 CXXC motif cysteine residues C335 and C338 to serine was 
implemented in pCMV6-BCAT1 vector using the Quikchange II Site-directed 
Mutagenesis Kit (Agilent technologies, catalog no. 200523) in accordance with the 
manufacturer’s instructions. Three mutant constructs were generated as follows - 
pCMV6- BCAT1(C335S), pCMV6- BCAT1(C338S) and pCMV6- BCAT1(C335/8S) using the 
C335S, C338S and C335/8S primer pairs listed in section 2.4 and the following cycling 
parameters: Initial denaturation 95 °C for 2 min. 95 °C for 20 sec, 60 °C for 10 sec, 68 °C 
for 3 min 10 sec for 18 cycles. Final extension 68 °C for 5 min using a PCR thermocycler 
(Prime Techne). CXXC mutant constructs were transformed into competent E.coli α-
Select Gold (Bioline BIO-85027) and purified as previously described in section 2.5.  For 
long-term storage cultures containing all vectors were kept at -80 oC in 30% glycerol.  
Mutation of BCAT1 was confirmed by DNA sequence analysis. The chain 
termination reaction was carried out using the Big Dye Terminator V3.1 cycle sequencing 
kit (ThermoFisher 4337457) as per manufacturer’s instructions using the VP1.5 and 
FTAG primer set and the following cycling parameters: Initial denaturation 95 °C for 5 
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min. 96 °C for 10 sec, 50 °C for 10 sec, 60 °C for 4 min for 25 cycles. Final extension 72 
°C for 5 min. Capillary electrophoresis was performed by the Functional Genomics 
Facility at The University of Birmingham using an Applied Biosystems ABI 3730 
sequencer. Sequence fidelity was analysed using Chromas Lite 2.0 software, NCBI’s 
nucleotide BLAST and M-coffee alignment tools.   
 
2.7  Subcloning pLenti-BCAT1 Vector 
Wild-type (WT) BCAT1 and CXXC mutants were subcloned from pCMV6-BCAT1 
to pLenti-C-Myc-DDK-IRES-Puro vector using Origene’s precision shuttle system. Briefly, 
5 µg of pCMV6-BCAT1 and pLenti plasmids were each digested with 2 µL AsiSI (NEB 
R0630) and MluI (NEB R0198) restriction endonucleases in 5 µL 10x NEBuffer 2.1 (NEB 
B7002S) made up to 50 µL with nuclease free water and incubated at 37 °C for 4-6 h. 
Following digestion, linearized BCAT1(WT), CXXC mutant cDNA and pLenti vector were 
separated by gel electrophoresis in a 1.2% agarose gel at 100 V for 1 h. Agarose gels 
were stained with GelRed (Biotium 41003) nucleic acid stain prior to visualisation on a 
UVP Model M-20 transilluminator (Sigma-Aldrich). Linearized pLenti and BCAT1 cDNA 
fragments were identified as 7.6 kb and 1.1 kb fragments predicted in silico by the Serial 
Cloner software tool (http://serialbasics.free.fr/Serial_Cloner.html) . Following excision, 
fragments were gel purified using the Isolate II PCR and Gel kit (Bioline BIO-52059) 
according to the manufacturer’s instructions. Briefly, 50 ng of pLenti vector was ligated 
at a 3:1 insert to vector molar ratio with 1 µL T4 DNA ligase (NEB M202) and 2 µL of x10 
T4 DNA ligase buffer made up to a total volume 20 µL with nuclease free water and 
incubated overnight at 16 °C. The reaction was stopped by denaturation at 65 °C for 10 
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min and α-Select competent cells were transformed with the ligation mixture as 
previously described (section 2.5), followed by inoculation onto LB agar supplemented 
with 35 µg/mL chloramphenicol and incubated overnight at 37°C.  BCAT1 positive 
colonies were discriminated from colonies containing uncut or re-circularised p-Lenti by 
Colony PCR (section 2.8) using the V2 and FTAG primers (section 2.4).  
pLenti-BCAT1 positive colonies were inoculated in 5mL LB broth supplemented 
with 34 µg/mL chloramphenicol and incubated over night at 37 oC in an orbital shaker 
at 50 rpm. Plasmids were purified using the Isolate II plasmid mini-prep kit (Bioline BIO-
52056), concentration and were purity determined by spectrophotometric analysis as 
previously described (section 2.5). pLenti-BCAT1 sequence fidelity was confirmed by 
DNA sequence analysis as previously described using the V2 and FTAG sequencing 
primers. 
 
2.8 Colony PCR 
Single colonies were inoculated on to a new LB agar plate prior to suspension in 
50 µL of dH2O and heating to 95 °C for 15 min. 12.5 µL of boiled cell suspension was 
added to a PCR reaction mixture containing 12.5 µL of ReddyMix (Thermofisher AB-
0575) with V2/LR50 primers for pCMV6 vector, VP1.5/XL39 for pLenti vector and 
BCAT1_424/ BCAT1_1582 for pET28a vector  at a final concentration of 0.4 µM. The PCR 
mixture was amplified using the following cycling parameters: 95 °C for 30 sec, 50 °C  for 
30 sec and 70 °C for 1 min 40 sec for 25 cycles. PCR product was separated by gel 
electrophoresis on a 1.2% agarose gel. Images were captured using a gel doc 
transilluminator (SynGene).    
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2.9 Subcloning pET28a-BCAT1  
NheI and SalI restriction sites flanking BCAT1 cDNA in pCMV6 were introduced 
via PCR using the BCAT1_424 and BCAT1_1582 primer pair (section 2.4). 50 ng of 
pCMV6-BCAT1 template DNA was incubated with 0.2 µL  Phusion DNA Polymerase (NEB 
M0530), 4 µL 5X Phusion HF, 0.4 µL 10mM dNTPs, 1 µL 10 µM BCAT1_424 and 1 µL  10 
µM BCAT1_1582 (Final primer concentration 0.5 µM)  and made up to a final reaction 
volume of 20 µL with nuclease free H2O. The PCR reaction was performed using the 
following cycling parameters: 95 °C for 30 sec, 68.5 °C for 30 sec, 70 °C for 1 min 15 sec 
for 25 cycles. 5 µg of PCR product and pET28a were digested with 2 µL of NheI-HF (NEB 
R3131S) and SalI-HF (NEB R3138S) restriction endonucleases in 5 µL x10 CutSmart buffer 
(NEB B7204S). The total reaction volume was made up to 50 µL and incubated for 4-6 h 
at 37 °C. The digestion reaction was stopped by denaturing at 80 °C for 10 min. 
Linearised pET28a vector and BCAT1 cDNA amplicons were separated by gel 
electrophoresis, gel purified, ligated and transformed into BL21(DE3) competent cells 
(Bioline C2527H) as previously described in section 2.5. Transformed cells were selected 
on LB Agar plates supplemented with 50 µg/mL kanamycin and screened for the BCAT1 
insert via Colony PCR as described in section 2.8 using the BCAT_424 and BCAT1_1582 
primer pair. 
BCAT1 positive transformants were inoculated in 10mL LB broth supplemented 
with 50 µg/mL kanamycin and incubated at 37 °C overnight with shaking. Cell 
suspensions were pelleted by centrifugation at 4000 x g and pET28-BCAT1 plasmids 
were purified using the Isolate II plasmid miniprep kit (Bioline BIO-52056). 
Concentration and purity of plasmid was determined by spectrophotometric analysis as 
previously described (section 2.5). Full reading frame fidelity of the BCAT1 insert was 
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confirmed by DNA sequence analysis as previously described (section 2.6) using the T7F 
and T7R primers (section 2.4).  
 
2.10 Recombinant BCAT1 Protein Overexpression   
Overexpression and purification of BCAT1 proteins are described in Davoodi et 
al, 1998 whose method was adopted here. Briefly, transformed E. coli BL21(DE3) cells 
from broth culture stores were inoculated into 100 mL of sterile LB broth adjusted to 
contain 50 µg/mL kanamycin and incubated overnight on orbital shaking platform at 37 
oC and 50 rpm.  This was transferred to 1L LB broth adjusted to contain 50 µg/mL 
kanamycin and  incubated overnight at 30 oC at 50 rpm. The overexpression of BCAT1 
protein was induced using 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG)  to an 
optical density of approximately 0.8 measured at λ600 nm with a spectrophotometer 
(libra S12, Biochrom, Cambridge. UK) and incubated at 37 oC and 50 rpm for 4 h. The 
cells were pelleted by centrifugation (4000 x g) at 4 °C for 5 min and stored at overnight 
at -80 oC. 
 
2.11 Recombinant BCAT1 Protein Extraction and Purification 
The over expressed BCAT1 proteins were extracted from 5-10 g of pelleted BL21 
(DE3) cells.  Pellets were suspended in 25mL extraction buffer (0.1 M KiPO4, pH 8.0, 0.01 
M Tris-HCl, 0.035% v/v β-mercaptoethanol) prior to sonication (QSonica, model. Q125) 
on ice for 10 min at an amplitude of 35% with 15 sec intervals every 30 sec using a 6 mm 
probe.  The sonicate was centrifuged at 4000 x g  at 4 oC for 10 min using a Denley BR-
401 refrigerated centrifuge (Denley). The supernatant was stored on ice, and the pellet 
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was re-suspended in a further 25mL of extraction buffer and subjected to repeat 
sonication and centrifugation.  The supernatant was pooled and 8 mL of Ni-NTA agarose 
(Qiagen LTD, West Sussex) pre-equilibrated in extraction buffer was added.  The mixture 
was agitated gently for 1 h at 4 oC prior to being transferred to a 20 mL glass column 
(Biorad) followed by 4 column volumes of extraction buffer.  The column was subjected 
to sequential washes with buffer B (0.1 M KiPO4, pH 7.4, 0.01 M Tris-HCL, 0.5 M NaCl, 
20% w/v glycerol, 0.035% v/v β-mercaptoethanol), buffer C (0.1 M KiPO4, pH 6.0, 0.01 M 
Tris-HCL, 1.5 M NaCl, 20% w/v glycerol, 0.035% v/v β-mercaptoethanol), and buffer C50 
(0.1M KiPO4, pH 6.0, 0.01 M Tris-HCl, 0.75 M NaCl, 0.075 M imidazole, 10% w/v glycerol, 
0.035% v/v β-mercaptoethanol).  
The BCAT1 protein was eluted from the column in 10-20 mL of elution buffer (0.1 
M KiPO4, pH 6.0, 0.01 M Tris-HCl, 0.75 M NaCl, 0.75 M imidazole, 20% w/v glycerol, and 
0.035% v/v β-mercaptoethanol).  The 6-x histidine affinity tag was cleaved from BCAT1 
using (100 NIH units) thrombin in, 0.5 M Tris (pH 7.4), 0.15 M NaCl, for 1 h at 37 oC.  
Finally, ion-exchange chromatography was performed using a HiTrapTM Q HP strong 
anion column (GE Healthcare, Buckinghamshire), by means of a concentration gradient 
between 0 to 0.5 M NaCl in 0.1 M KiPO4 (pH 8.0), on ice at a flow rate of 1 mL min -1 for 
20 min.  The purified BCAT1 protein was dialysed at 4 oC in storage buffer (0.05 M Tris-
HCl pH 7.5, 0.15 M NaCl, 5 mM glucose, 1 mM EDTA, 1 mM KIC, 5 mM DTT), prior to the 
addition of 30% v/v glycerol and storing at -80 oC.  To verify purity, BCAT1 protein 





2.12 Recombinant BCAT1 Protein Quantification 
BCAT1 protein concentration was determined by the Bicinchoninic acid assay 
(BCA) as described by Smith et al, 1985.  The BCA Working Reagent was prepared as 
described by the manufacturer’s instruction (Thermofisher 23225) mixing 8 mL of 
Reagent A (bicinchoninic acid, sodium carbonate, sodium tartrate, sodium bicarbonate 
in 0.1 N NaOH, pH 11.25) with 0.16 mL part of Reagent B (4% (w/v) copper(II) sulphate 
pentahydrate). Bovine serum albumin (BSA) standards were prepared at a concentration 
of 0, 0.2, 0.4, 0.6, 0.8 and 1 mg/mL in dH2O. A 1:20 dilution BCAT1 protein extract was 
prepared from stock solutions in dH2O, all samples were stored at 4 °C prior to loading. 
10 µL of BSA standards and BCAT1 samples were added to a 96-well plate in triplicate 
followed by addition of 200 µL BCA working reagent. The plate was incubated for 30 min 
at room temperature. Absorbance at  562 nm was measured using a ThermoFisher 
Multiskan FC microplate photometer (ThermoFisher). BCAT1 protein concentrations 
were determined from the BSA standard curve. 
 
2.13 SDS-PAGE 
5-30ug of samples as determined by BCA assay were separated by SDS-PAGE on 
a 5% stacking gel (4% Bis-acrylamide, 0.13M Tris PH 6.8, 0.1% SDS, 0.1% APS, 0.001% v/v 
TEMED) electrophoresed at 100 mv / 70 mA for 15 min until the dye from had migrated 
to the 12% resolving gel  (12% Bis-acrylamide, 0.37 M Tris PH 8.8, 0.1% SDS, 0.1% APS, 
0.001% v/v TEMED), at which point the electrophoresis was increased to 180 mV / 70 
mA for a further 60 min (Sambrook and Russell, 2006). Gels were stained overnight with 
Brilliant Blue G-Colloidal (Sigma, UK.) before destaining for 1 h in a solution containing 
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10% glacial acetic acid in 40% (v/v) methanol. Gel images were taken using a Syngene 
PXi-gel-doc-system (Syngene). 
 
2.14 Western Blot Detection of Purified BCAT1 Protein 
5-30 µg of protein samples were separated by SDS-PAGE electrophoresis as 
previously described in section 2.13. Following electrophoretic separation, proteins 
were transferred to a nitrocellulose membrane by electroblotting in cold transfer buffer 
(25 mM Tris, 192 mM glycine, 20% v/v methanol, pH 8.3) for 1 h at 100V 350 mA with 
stirring. The membrane was washed in TBST (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.2% 
tween) and blocked overnight in 5% w/v dried milk in TBST. For detection of BCAT1 the 
membrane was incubated with 5% w/v dried milk supplemented with 1:2000 primary 
antibody ECA-39/BCAT1 (Santacruz SC-517185) and incubated at room temperature for 
1hr. After washing with TBST the membrane was incubated with 1:2000 secondary 
antibody rabbit-anti goat-HRP (Santacruz SC-2768) for 1h at room temperature.  The 
membrane was washed in TBST prior to elicitation of chemiluminescence using ECL Plus 
detection reagent (Amersham RPN 2132) as per manufacturer’s instructions. 
Chemiluminescent signal was captured using Syngene PXi-gel-doc-system.  
 
2.15  Spectrophotometric Analysis of Reduced Cysteine Thiol Groups  
The number of reduced cysteine (C, Cys) thiol (-SH) groups in BCAT1(WT) and 
CXXC mutant protein cysteine thiol groups were measured using the 5,5'-dithio-bis-2-
nitrobenzoic acid (DTNB) titration method as described by Conway et al. (2002). BCAT1 
proteins were exchanged into thiol assay buffer (50 mM HEPES (pH 7.2), 1 mM EDTA) by 
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desalting using a PD10 column (GE Healthcare).  The BCAT1 concentration was 
calculated after a spectrophotometric reading at λ 280 nm (ε = 86 300 M-1cm-1 per BCAT1 
monomer) as reported by Davoodi et al., 1998. A final concentration of 2 µM BCAT1 was 
incubated with 100-fold molar excess of DTNB in the dark for 20 min at room 
temperature.  The absorbance changes at  412 nm, was monitored over the course of 
the titration.  The final reduced cysteine thiol count per subunit was calculated 
stoichiometrically using ε = 14 150 M-1cm-1 for the TNB anion (Davoodi et al. 1998). 
 
2.16 Generation of Lentiviral Particles  
Lentiviral particles containing pLenti- BCAT1 vectors were generated using 
Origene’s Lenti-vpak packaging system (Origene ref: TR30022). HEK293T (ATCC® CRL-
3216™) cells were sub-cultured at 3x105 cells/mL in T75 flasks with 10mL Dulbecco’s 
Modified Eagle Media (DMEM) supplemented with 10% FCS and 2 mM L-Glutamine. 
After 24 h incubation cultures reached approximately 50% confluency. The transfection 
mixture was prepared adding 6.5 µg of pLenti-BCAT1 vector, 7.5 ug of packaging plasmid 
and 55 µL of MegaTran transfection reagent to was added to 1.25mL of Opti-MEM 
reduced serum medium (TheroFisher, no. 31985062) . The mixture was incubated for 30 
min at room temperature.  The transfection mixture was added to the T75 flask 
containing the HEK293T cells and incubated overnight. After 24 h the culture medium 
containing viral particles was harvested and stored at 4oC. Following the addition of 
fresh culture medium viral supernatant was harvested and pooled with the initial batch 
at 48 and 72 h post transfection. 30 mL of supernatant centrifuged at 3000 x g at 4 °C 
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and filtered using a 0.45um filter to remove cellular debris. The viral supernatant was 
divided into 1mL aliquots and snap frozen and stored in liquid nitrogen. 
 
2.17 Viral Titre 
Viral titre was assessed by measuring lentiviral coat protein p24 by ELISA using 
QuickTiter™ Lentivirus Titer Kit (Cell-Bio Labs, no. VPK-107-T 3), in accordance with 
manufacturer’s instruction. Briefly, Virus associated p24 was isolated from free p24 by 
pull down. 10 μL of ViraBind™ Lentivirus Reagent A was added to 1 mL of lentiviral 
sample followed by 10 μL of ViraBind™ Lentivirus Reagent B and mixed by inversion. 
Following incubation for 30 min at 37oC the mixture was centrifuged at 12 000 x g and 
the supernatant discarded. The pellet was resuspended in 250μl of sample diluent, 
vortexed and incubated at 37 °C to inactivate the virus.  
100μL of lentiviral sample was added in duplicate to anti-p24 antibody coated 
plate and incubated overnight at 4°C. Sample wells were washed x3 with 250 µL of wash 
buffer and 100 µL of FITC-conjugated Antip24 Monoclonal Antibody was added to each 
well and incubated for 1 h  at room temperature. Following incubation sample wells 
were washed as previously described with 250 µL wash buffer and 100 µL of HRP-
Conjugated Anti-FITC Monoclonal Antibody was added to each well and incubated for 
1h at room temperature with shaking. Following incubation, wells were washed with 
wash buffer before 100 µL of Substrate Solution was added to each well. The plate was 
incubated for 15 min at room temp before addition of 100 µL of stop solution and 
absorbance at was recorded at λ450 nm using a Microplate Spectrophotometer (Thermo 
Scientific™ Multiskan™ GO, Catalog no. 51119200) 
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2.18 Transcription Analysis of BCAT1 Expression 
In order to select a cell line for appropriate overexpression of BCAT1, transcript 
levels in immortalised leukaemia cell lines were analysed in HL60 (ATCC® CCL-240), K562 
(ATCC® CCL-243), U937 (ATCC® CRL-1593.2™) and THP1 (ATCC® TIB-202). Data was 
provided by https://www.proteinatlas.org/cell. U937 cells were selected based on their 
relatively low background of BCAT1 expression in combination with favourable growth 
characteristics compared to THP1. 
 
2.19 Puromycin Cytotoxicity Assay  
Prior to antibiotic selection of transduced cells sensitivity of the U937 (ATCC® 
CRL-1593.2™) cell line to puromycin was determined by cytotoxicity assay. U937 cells 
were suspended at a density of 5x105 cells/mL in complete Roswell Park Memorial 
Institute media (RPMI-1640; 2 mM L-glutamine, 200 U/mL penicillin, 200 µg/mL 
streptomycin, 10% Fetal Calf Serum) supplemented with 10, 5, 2 and 1 ug/mL Puromycin 
and added at a volume of 100 µL/per well to a 96-well plate in triplicate. After 72 h 50 
µL of Phosphate Buffered Saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Phosphate) 
and 50 µL of Viacount cell viability dye (Luminex Cat no.4000-0040) was added to each 
sample. The mixture was transferred to a 1.5 mL microcentrifuge tube and incubated in 
the dark at room temperature for 5 min prior to analysis. The viability of the cells was 
analysed by flow cytometry using a Guava Easycyte platform (MerkMillipore) running 
the Guavasoft 3.1.1 Viacount module. 3000 events were captured for each sample and 




2.20 Lentiviral Transduction 
Lentiviral aliquots stored in liquid nitrogen were thawed in a water bath for 10 
min at 37 °C immediately before use. 2x105 U937 cells were resuspended in 1mL of viral 
suspension by gentle aspiration. ‘Spinoculation’ of the transduction mixture was 
performed by centrifugation at 900 x g for 2 h at 32 °C (adapted from O’Doherty, 
Swiggard and Malim, 2000), following transduction the lentiviral supernatant was 
discarded. Cells were resuspended in 1 mL of complete RPMI-1640 (Sigma-Aldrich) and 
transferred to a 24-well plate and returned to the tissue culture incubator for 48-72 h at 
37 oC and 5% CO2. In order to select successfully transduced cells after incubation, cells 
were exchanged into fresh complete RPMI-1640 supplemented with 0.5 µg/mL 
Puromycin and transferred to a 96-well plate in 100 µL aliquots and returned to the 
tissue incubator. Fresh media containing 0.5 µg/mL Puromycin was exchanged every 3-
5 days until outgrowth of puromycin resistant clones was evident. 
 
2.21 qPCR of BCAT1 Transcript 
Puromycin resistant clones were assessed for expression of BCAT1 at the 
transcript level by relative qPCR. RNA was extracted using the Isolate II RNA mini kit 
(Bioline BIO-52072) following the manufacturer’s instructions. RNA quality was assessed 
by spectrophotometric analysis with a 260/280 nm ratio >2 indicating pure RNA. RNA 
integrity was assessed measuring 28S:18S RNA subunit ratio by gel electrophoresis, 
relative peak intensity was measured using Genetools analysis software (Syngene) with 
a 2:1 ratio indicating intact RNA. Pure intact RNA was divided into 5 µL aliquots and 
stored at -80 °C for future use. 
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   cDNA was synthesised according to the manufacturer’s instructions using PCR 
biosystems cDNA synthesis kit (PCRBiosystems, no. PB.30 11-10). Briefly 400 ng of RNA 
was incubated with 4 µL cDNA synthesis mix and 1 µL of Reverse Transcriptase made up 
to a final volume of 20 µL with dH2O. Samples were incubated at 42 °C for 30 min and 
the reaction stopped by denaturing Reverse Transcriptase at 85 °C for 10 min, following 
cDNA synthesis samples were diluted with dH2O to a final volume of 50 µL in dH2O. 
cDNA samples were interrogated for BCAT1 and β2-microglobulin (β2M) 
expression using primers BCAT1-F/R and β2M-F/R respectively (section 2.4). To 
eliminate amplification of non-specific products/ primer dimers, optimal annealing 
temperatures of each primer set was determined by gradient PCR. 2 µL of forward and 
reverse primer  at a final concentration 0.4 µM without cDNA template were incubated 
with Reddymix (Thermofisher AB-0575) as previously described (section 2.7) with a 
gradient between 55-65°C. The optimal temperature for each primer was determined 
to be the lowest temperature without any non-specific PCR product present i.e. primer 
dimers. 
 To ensure amplification fidelity, cycling efficiency of each primer was 
determined by standard curve using a 1/10 serial dilution of cDNA template and the 
reaction conditions described below. The amplification efficiency (e) was calculated 
using the equation e = 10-1/slope where 1.8 ≤ e ≤ 2.2 indicates an  efficiency between 90-
110% within acceptable limits (Schmittgen and Livak, 2008).   
For each qPCR reaction forward primer and reverse primers at a final 
concentration of 0.4 µM and 100 ng cDNA template was added to 10 µL SybGreen Blue 
mix (PCR Biosystems PB20.17-01) in a final volume of 20 µL dH2O and kept on ice prior 
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to addition to 96-well PCR microplate (Axygen CR-96-LC480-W-BC). Negative controls 
containing no cDNA were performed for each reaction. Following this the qPCR reaction 
was carried out using a Roche 480 LightCycler, cycling parameters were as follows: 1) 
Initial denaturation: 95 °C for 10 sec  2) Annealing: 63 °C for 10 sec 3) Extension 72 °C 
for 20 sec for 35-40 cycles. A final melt-curve analysis was performed to assess the PCR 
product. Relative expression of BCAT1 to reference gene β2M was calculated from 
Crossing Point (Cp) values using the -2ΔΔCp  method where --2ΔΔCp  = (Cp Gene of interest 
– Cp Internal control) Sample A – (Cp Gene of interest – Cp Internal control) Sample B.  
 
2.22 Western Blot Detection of BCAT1 in Transgenic and Control U937 Cells 
For detection of BCAT1 in whole cell lysate samples approximately 5-10 x106 
U937 cells were pelleted by centrifugation at 2500 x g for 5 min prior to washing with 
sterile PBS. Cells were resuspended in 0.5-1 mL cold RIPA buffer (Sigma: R0278) 
supplemented with Proteinase Inhibitor Cocktail (Sigma P8340) at 25 µL/mL and 
incubated on ice for 30 min with regular vortexing. Cells were pelleted by centrifugation 
at 14000 x g and the supernatant was transferred to a clean 1.5 mL microcentrifuge tube 
for BCA analysis as previously described in section 2.12.  
Following protein quantification by BCA assay 30 µg of whole cell lysate protein 
was processed by SDS-PAGE and western blot as previously described in 2.13 and 2.14 
with the following alterations. For detection of transgenic BCAT1 subsequent to blocking 
overnight at 4 °C the membrane was incubated with 5% w/v dried milk supplemented 
with 1:2000 Anti-DDK (FLAG)-HRP mAb (Origene : TA50011-100) and incubated at room 
temperature for 1 h prior to detection. For detection of native background expression 
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of BCAT1 the membrane was incubated with 5% w/v dried milk supplemented with 
1:2000 primary antibody ECA-39/BCAT1 (Santa Cruz SC-517185) as previously described 
(section 2.14). BCAT1 expression was normalised to Cyclophilin B loading control using 
Recombinant Anti-Cyclophilin B HRP Ab (Abcam EPR12703(B)). Following capture of 
BCAT1 chemiluminescent signal the membrane was washed in TBST before being 
stripped and re-blocked as per manufacturer’s instructions using Restore Stripping 
Buffer (Thermofisher 21059). For detection of Cyclophilin the membrane was incubated 
with 5% w/v dried milk TBST supplemented with 1:2000 Anti-Cyclophilin B HRP Ab and 
incubated at room temperature for 1 h prior to detection. 
 
2.23 Cell Culture of U937 BCAT1 Transgenic and Control Cells 
U937 cells were maintained in 10mL of complete RPMI-1640 in T75 flasks in a 
humidified cell culture incubator kept at 37 °C supplied with 95% air and 5% CO2. Media 
was exchanged every 3-5 days keeping cells at a density of 0.1-1.5x106 cells/mL.  
Confluent flasks were used to create frozen stocks, 1mL aliquots were 
resuspended at a density of 1x106 cells/mL in complete RPMI-1640 supplemented with 
10% DMSO. Aliquots were transferred to a freezing container and stored at -80c 
overnight to achieve slow cooling of -1 °C/min before being transferred to liquid 
nitrogen. After multiple subcultures U937 cells can gradually differentiate, therefore 
cells were discontinued approximately every 2-3 months. Revived frozen aliquots were 
pelleted by centrifugation at 300 x g for 5 min and washed with complete RPMI-1640 
before resuspension in complete RPMI supplemented with 20% FCS to facilitate 
recovery.       
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2.24 Trypan Blue Cell Viability Staining 
For all assays seeded with a specified number of cells, trypan blue staining was 
used to determine viable cell numbers. Cells from a T75 flask were pelleted by 
centrifugation (300 x g) and resuspended in 1mL of complete RPMI-1640. 10-20 µL of 
this suspension was added to an equal volume of 0.4% trypan blue solution 
(Thermofisher 15250061) in a 1.5mL microcentrifuge tube and incubated for 5 min 
before counting with a haemocytometer.  
 
2.25 U937 Transgenic and Control Cell Growth Curves 
In order asses the effect of BCAT1 overexpression on the growth dynamics of the 
U937 cell, T75 flasks were seeded at 2x105 cells/mL in a total volume 10 mL and 
incubated in a cell culture incubator (37oC, 5% CO2) as previously described in section 
2.23. Cell density and viability was measured using the Viacount module (section 2.19) 
at t=0 then at 24 h intervals from 0-96 h to capture exponential and stationary phase 
growth, followed by 168-192 h to capture death phase. At each time point 100 µL was 
removed and stained with 50 µL of Viacount reagent mixed with 150 µL PBS and 
incubated in the dark for 5 min prior to flow cytometric analysis as previously described 
(section 2.19).  
 
2.26 Cell Cycle Analysis of Transgenic and Control U937 Cells 
T75 flasks were seeded with transgenic or control U937 cells at a density of 2x105 
cells/mL in a total volume 10 mL and incubated in a culture incubator (37°C, 5% CO2) as 
previously described in section 2.23. 100 µL of sample was removed from each flask at 
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t=48, 72 and 96 h and transferred to a 1.5 mL microcentrifuge for analysis. Samples were 
pelleted by centrifugation at 400 x g for 5 min and washed in sterile cold PBS. To fix cells 
prior to staining cells were resuspended 0.5 mL ice cold 70% Ethanol and incubated at 4 
°C for 30 min. To account for cell shrinkage during fixation cells were pelleted by 
centrifugation at 850 x g for 10 min and washed in PBS. Cells were resuspended in 0.2 
mL of Propridium Iodide (50 µg/mL) and incubated for 5 min at room temperature in the 
dark before flow cytometric analysis. For each sample 10-20 000 events were captured 
using a GuavaCyte flow cytometer with Incyte software (Merck). Intact cells were 
separated from debris by relatively high Forward Scatter (FSC) / Side Scatter (SSC) gate. 
From this population a single parameter histogram was generated using the FL2 
(Yellow/Blue) channel and cell populations containing 2n, S and 4n were distinguished 
by relative Median Fluorescence Intensity (MFI) peaks where 4n>S>2n, these peaks 
were gated an analysed as a percentage of total cell population. 
 
2.27 Measuring Intracellular ROS in Transgenic and Control U937 Cells Using the DCFDA 
Flow Cytometric Assay 
Cellular ROS was measured by 2’,7’ –dichlorofluorescin diacetate (DCFDA) 
staining using the DCFDA Assay kit, in accordance with manufacturer’s instruction 
(Abcam 113815). Briefly, T75 flasks were seeded at a density of 2x105 U937 cells/mL in 
a total volume 10 mL and incubated in a culture incubator (37 °C 5% CO2) as previously 
described in section 2.23.  100 µL of sample was removed at t= 48, 96 and 168h and 
transferred to a 1.5 mL microcentrifuge tube for analysis. 100 µL of 2 µM DCFDA was 
added directly to the sample and incubated for 30 min at 37 oC prior to flow cytometric 
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analysis. For each sample 10-20 000 events were captured using a GuavaCyte flow 
cytometer with Incyte software (Merck). Intact cells were separated from debris by 
relatively high Forward Scatter (FSC) / Side Scatter (SSC) gate. From this population a 
single parameter histogram was generated using the FL1 (Green/Blue) channel and 
DCFDA was measured by MFI.  
 
2.28 Measuring Mitochondrial Membrane Potential in Transgenic and Control U937 
Cells Using the  DiOC2(3) Assay 
Mitochondrial membrane potential (ψm) was measured using the 3,3'-
Diethyloxacarbocyanine Iodide (DiOC2(3)) probe which accumulates in mitochondria 
with active membrane potentials at concentrations 100 nM and below(Bunting et al., 
1989). 100 µL samples of transgenic or control U937 cells were removed from T75 
cultures at t= 48, 96 and 168 h equating to 1-1.5x105 cells per sample. Cells were pelleted 
by centrifugation at x 300 g for 5 min and resuspended in 100 µL PBS before addition of 
1 µL of 10 µM DiOC2(3) to a final concentration of 100 nM DiOC2(3). Samples were 
incubated at 37°C, 5% CO2 for 30 min prior to pelleting by centrifugation and 
resuspension in 300-500 µL PBS. Samples were analysed by flow cytometry, for each 
sample 10-20 000 events were captured. using a GuavaCyte flow cytometer with Incyte 
software (Merck). Intact cells were separated from debris by relatively high Forward 
Scatter (FSC) / Side Scatter (SSC) gate. From this population a bivariate plot was 
generated using the FL1 (Green/Blue) and FL3 (Red/Blue) channels. Mitochondria 
associated DiOC2(3) was measured as the ratio of Red/Green MFI where a higher ratio 
indicates increased stacking in the inner membrane space. 
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2.29 Measuring the Intracellular Redox Environment in Transgenic and Control U937 
cells Using the Glutathione Assay 
Cellular glutathione was measured using the Glutathione Assay Kit (Sigma 
CS0260), in accordance with manufacturer’s instruction, subject to adjustments to 
directly quantitate oxidised glutathione (GSSG). To measure total reduced glutathione 
(GSH) content cells were washed in twice in PBS and harvested by centrifugation at 600 
x g for 5 min. In order to assess oxidised glutathione (GSSG) content cells were incubated 
with 50 mM N-Ethylmaleimide (NEM) for 20 min prior to washing with PBS and 
harvesting by centrifugation at 600 x g for 5 min. Cells were then resuspended in 150 µL 
5% 5-Sulfosalicylic Acid (SSA) Solution to deproteinise the sample prior to freeze thawing 
twice in liquid nitrogen. Following freeze/thaw samples were incubated at 4 °C for 5 min 
samples were centrifuged at 10 000 x g for 10 min and the supernatant removed prior 
to analysis. The reduction of 5,5-dithiobis (2-nitrobenzoic acid) (DTNB) to yellow 
product, 5-thio2-nitrobenzoic acid (TNB) by GSH reduction was measured 
spectrophotometrically at λ412 nm. To determine the GSH concentration a standard 
curve from 50-3.125 µM was generated by a ½ serial dilution with 5% SSA solution. 150 
µL of working mixture containing  8 mL of 1 Assay Buffer, 228 L of the diluted Enzyme 
Solution (6 units/mL) and 228 L of DTNB Stock Solution (1.5 mg/mL) was added to 10 
µL of sample in a 96-well plate. Following addition of 50 µL NADPH Solution (0.16 
mg/mL) the reaction was incubated for 10 min at room temperature before reading 
absorbance at λ412 nm. Cellular Redox potential (Eh) was calculated using the Nernst 
Equation where Eh = Em – (RT / nF)  2.303 log  [2GSH]/[GSSG] as previously 
described(Coles, Hancock and Conway, 2012). 
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2.30 Evaluating the Effects of Serum Starvation on Transgenic and Control U937 Cells 
In order to simulate in vitro stationary/ death phase oxidative stress, U937 cells 
were cultured in serum starvation conditions i.e. complete RPMI-1640 without FCS 
supplementation (0% FCS). Cells were incubated at a density of 5x105 cells/ well in a 96-
well plate in 100 µL RPMI-1646 + 0%FCS for 48-72 h. Control wells contained complete 
RPMI-1640 +10% FCS. Following incubation, cellular ROS and viability were measured by 
DCFDA assay and Viacount staining respectively as previously described (sections 2.19 
and 2.27). Cellular viability/apoptosis was confirmed by flow cytometric analysis using 
7AAD/ Annexin V FITC staining. Cells were washed twice in 1 mL sterile cold PBS and 
resuspended in 0.5 mL cell staining buffer (Biolegend 420201). 3 µL of 7AAD (Biolegend 
420404) and Annexin V FITC (Biolegend 640945) were added and gently vortexed before 
incubation for 15 min at room temperature in the dark prior to flow cytometric analysis 
using a GuavaCyte flow cytometer with Incyte software (Merck). Intact cells were 
separated from debris by relatively high Forward Scatter (FSC) / Side Scatter (SSC) gate. 
Bivariate analysis in the FL1 (Blue/Green) and FL3 (Blue/Red) channels identified 
percentage populations of apoptotic/non-apoptotic and viable/non-viable cells.  
 
2.31 Evaluating the Effect of Mitochondria ROS in Transgenic and Control U937 Cells  
In order to generate mitochondrial ROS induced oxidative stress, transgenic or 
control U937 cells were treated with the complex I inhibitor Rotenone (Fato et al., 2009). 
A Rotenone dose response curve was generated by a ½ dilution series ranging from 0-
1000 nM.  Cells were incubated at a density of 5x105 cells/ well in a 96- well plate for 
t=72 h in a cell culture incubator (37°C, 5% CO2) as previously described (section 2.23). 
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Following incubation, cellular ROS and viability were measured by DCFDA assay and 
viacount staining respectively as previously described (section 2.19 and 2.27). 
 
2.32 Differentiation of Transgenic and Control U937 Cells Using PMA 
In order to differentiate U937 cells from monocytes to macrophage, 1x106 
cells/mL were incubated with complete RPMI-1640, supplemented with a final 
concentration of 10-100 nM phorbol 12-myristate 13-acetate (PMA, Sigma Aldrich 
P1585) in 24-well plates for 48 h in a cell culture incubator (37 °C 5% CO2). PMA was 
dissolved in DMSO to create  stocks concentration of 10-100 µM. 1 µL of PMA stock was 
added to 1 mL of media ensuring a final concentration of DMSO of 0.1% and final 
concentrations of PMA between 10-100 nM respectively. To control for the effect of 
DMSO on cellular differentiation, control wells were supplemented with 0.1% DMSO 
without PMA. In order to control for the metabolic contribution of BCAT1 to 
differentiation control, wells were supplemented with 20 mM Gabapentin, a 
competitive inhibitor of BCAT1 aminotransferase activity(Goto et al., 2005). To control 
for the contribution of cellular ROS in differentiation, the reducing agent 10 mM N-
acetyl-L-cysteine (NAC, Sigma Aldrich A7250) was added prior to incubation. NAC stocks 
were dissolved in complete RPMI-1640 at a concentration of 1M and stored at -20 °C 
before use.  
Following incubations, a 100 µL sample was removed and analysed for ROS by 
DCFDA staining as previously described (section 2.27). For analysis of U937 cellular 
differentiation, 1 x105 cells were  harvested and subjected to centrifugation at 400 x g 
and washed twice in sterile cold PBS and once with flow stain buffer (PBS, 10% FCS), 
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before resuspension in 0.1 mL flow stain buffer. To examine cellular differentiation, 
samples were incubated at 4 °C for 5 min with 3 µL of anti-CD36 PE (Biolegend 336206) 
and anti-CD11b FITC (Biolegend 301330) prior to flow cytometric analysis using a 
GuavaCyte flow cytometer with Incyte software (Merck). Intact cells were separated 
from debris by relatively high Forward Scatter (FSC) / Side Scatter (SSC) gate. Bivariate 
analysis in the FL2(Yellow/Blue) and FL1 (Blue/Green) channels identified percentage 
populations of CD36 positive/negative and CD11b  viable/non-viable cells respectively .  
 
2.33. Evaluating the Pharmacological Effect of Chemotherapeutic Agents on Transgenic 
and Control U937 Cells 
Dose Responses for Gabapentin, Cytarabine, Rapamycin and Rotenone were 
performed in a 96-well format at a cell density of 5x104  cells/ well. Transgenic or control 
U937 cells were incubated for 72 h in a cell culture incubator (37 °C 5 % CO2), in the 
presence of increasing drug concentration. Following incubation, the viability of the cells 
was analysed using Viacount reagent as previously described (section 2.19).  
 
2.34 Data Handling and Interpretation 
All data was analysed and in GraphPad prism version 5.01.  Statistical averages 
were calculated as mean ± standard error of the mean. Statistical differences between 
mean values were calculated using a one-way or two-way ANOVA and Bonferroni post-
test. Dose response relationships were analysed by non-linear regression and LD50 
values compared using the extra sum of squares F-test. For all tests a p value of ≤0.05 
was considered significant. 
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Chapter 3: Site-directed mutagenesis of BCAT1 
CXXC motif 
3.1 Introduction 
The BCAT1 CXXC motif contains two redox active cysteine thiol groups (-SH), 1) 
an N-terminal at position C335 and 2) a C-terminal at position C338. These thiols can be 
oxidised through S-Glutathionylation, which can be reversed by the Glutaredoxin (Grx) 
and Glutathione (GSH) antioxidant couple, linking BCAT1 to the wider cellular 
antioxidant network (Conway et al., 2008). Moreover, it has been demonstrated that 
the BCAT1 CXXC has a reduction midpoint potential analogous to the thioredoxin (Trx) 
family of oxidoreductases, suggesting BCAT1 may function as a novel antioxidant. To 
evaluate this possibility, mutational studies of the BCAT1 CXXC motif were carried out 
(Collet and Messens, 2010; Coles, Hancock and Conway, 2012). 
Site directed mutagenesis of the BCAT1 CXXC motif in pCMV6-Entry vector 
(Origene PS100001) altering the C335 codon from ACA to AGA  and C338 codon from 
GCA codon to GCT results in a cysteine to serine amino acid substitution. Serine differs 
from cysteine by a single atom, replacing the Sulphur containing thiol (-SH) group with 
an Oxygen containing hydroxyl (-OH) group (Figure 3.1, panel A). Oxygen has a higher 
electronegativity value than Sulphur (3.44 compared to 2.58) on the Pauling scale (χr), 
which translates into an increased bond dissociation energy (BDE). For example, 
methanethiol (CH3SH) has a BDE of 366 kJ/mol, compared with methanol (CH3OH), 
which has a BDE of 440 kJ/mol (Ouellette and Rawn, 2018),  consequently hydroxyl 




Figure 3.1 Cysteine to Serine site directed mutagenesis of the pCMV6-BCAT1 vector 
Site directed mutagenesis the CXXC motif was performed in the pCMV6-Entry vector 
(OriGene cat no. PS100001). A) Alteration of the C335 codon ACA to AGA should result 
in a cysteine to serine amino acid substitution. Cysteine to serine modification of C338 
is achieved by altering the GCA codon to GCT. B) Cysteine to serine substitution changes 
the amino acid functional group from a Sulphur containing thiol (-SH) group to an 





example Methanol (CH3OH) has a pKa of 15.3 compared with Methanethiol (CH3SH) 
which has pKa of 10.3 (Serjeant & Dempsey, 1979). Thus, mutating the CXXC motif 
residues from cysteine to serine (CXXC → SXXS) i.e. changing the ‘thiol’ functional group 
‘hydroxyl’, thus reduces the capacity for deproteination effectively eliminating the 
antioxidant capacity of the motif. Mutation of the CXXC motif in such a way is therefore 
essential to evaluate whether the BCAT1 CXXC motif has antioxidant capacity. 
Previously the mechanistic details of the BCAT1 mitochondrial homologue - 
BCAT2 CXXC motif, have been explored by site directed mutagenic conversion of 
cysteine to serine and alanine (Myra E Conway, Poole and Hutson, 2004). This study 
demonstrated that mutation of the N-terminal cysteine residue (C315) resulted in a 26-
33% reduction in the Kcat values compared to wild-type BCAT2, moreover the C315 
mutants lost their sensitivity to redox regulation by H2O2. However, by contrast the 
enzyme kinetics were largely unaffected by mutation of the C-terminal residue (C318), 
whilst reaction with H2O2 led to a complete loss of catalytic activity. Analysis of the N-
terminal cysteine in the C318 single mutant revealed irreversible C315 thiol oxidation to 
sulfenic (-SO2H) and sulfonic acids(-SO3H). These results demonstrated that the N-
terminal C315 cysteine residue acts as a redox sensor, that is initially oxidised to a 
sulfenic intermediate (-SOH) upon H2O2 oxidation before C318 acts as the ‘resolving 
cysteine’ reducing the C315 residue and forming a disulphide bond in the process. Site 
directed mutagenesis of the C318 residue to serine abolishes the capacity of the C-
terminal amino acid to reduce the N-terminal cysteine and therefore the C315 residue 
becomes irreversibly oxidised. 
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Redox active cysteine thiols can be examined by titration with 5’5 –dithiobis (2-
nitrobenzoic) acid (DTNB), which results in nucleophilic attack of a protein cysteine 
thiol/ate on the disulphide bond of DTNB, splitting the molecule and forming a mixed 
disulphide between the protein and TNB anion (Figure 3.2). Therefore, the number of 
cysteine thiol/ate(s) can be determined spectrophotometrically from the simultaneous 
liberation of the TNB anion, which absorbs light at λ412 nm, by using the molar 
extinction co-efficient ε = 14 150 M-1 cm-1 for TNB(Winther and Thorpe, 2014). Using this 
method, previous analysis has revealed that BCAT1 contains 6 reactive cysteine thiols 
including the 2 thiols of the CXXC motif at position 335 and 338 respectively (Davoodi et 
al. 1998).  
Mutational studies of the BCAT1 CXXC motif revealed that mechanistically it 
functions in manner similar to BCAT2, i.e. the N-terminal C335 residue functions as the 
redox sensor whilst the C-terminal C338 residue acts as the resolving cysteine (Conway 
et al., 2008). However, the BCAT1 CXXC motif has been demonstrated to have a lower 
overall reduction midpoint potential, that is the redox potential at which 50% of CXXC 
motif thiols are oxidised, compared to BCAT2 (Coles, Hancock and Conway, 2012). 
Analysis of CXXC motif thiols status by DTNB titration, found that CXXC motif has a redox 
midpoint potential of -310mV, which is significantly lower than the BCAT2 CXXC motif 
which has a midpoint potential of -225mV. This suggests a potential antioxidant role for 
the BCAT1 motif, since these values indicate that the BCAT1 CXXC motif may provide 
‘reducing power’ at lower cellular redox potentials (Coles, Hancock and Conway, 2012). 










Figure 3.2 DTNB modification of reactive cysteine thiol/ate(s). A nucleophilic attack of 
a protein cysteine thiol/ate on the disulphide bond of the DTNB molecule results in a 
mixed disulphide bond between protein cysteine-TNB and liberation of the TNB anion 
which absorbs light at λ 412 nm. The number of cysteine thiol/ate(s) can be determined 
spectrophotometrically using ε = 14 150 M-1 cm-1 for TNB. (Adapted with permission 
from Coles 2008)  
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Like BCAT2, the N-terminal cysteine (C335) of the BCAT1 CXXC motif, which 
primarily exists as a thiolate (-S-) anion even under highly reduced conditions (around -
320mV), is more sensitive to oxidation than the C-terminal cysteine (C338) (Goto et al., 
2005; Coles, Hancock and Conway, 2012). Relating this to the cell, at physiological redox 
potentials as determined by the reduced/oxidised glutathione ratio (GSH/GSSG) (Coles, 
Hancock and Conway, 2012), the binding of GSH (S-glutathionylation) to C335 of the 
BCAT1 CXXC motif occurs readily, where mutational studies have ascertained the C335 
residue is S-glutathionylated first at -275mV followed by C338 between -260- -160mV 
(Coles, Hancock and Conway, 2012). In the HL60 AML cell line, this mV change denotes 
a shift from a proliferative state at -239 mV, through differentiation at -210mV, to 
apoptosis at -167mV  (Freya Q. Schafer and Buettner, 2001).   
Whilst the precise nature of this modification is unknown, it has been suggested 
the CXXC motifs may act as a GSH buffer during periods of oxidative stress (Grek et al., 
2013). Therefore it may be that the BCAT1 CXXC motif also plays a role in this process, 
whereby the redox sensor N-terminal cysteine at C335 may form mixed-disulphides with 
GSH (or other proteins with redox active cysteines) under periods of oxidative stress, 
thus providing a novel antioxidant role. Furthermore, in the GSH scenario, the C-
terminal resolving cysteine of the BCAT1 CXXC motif at C338 can form an intra-subunit 
disulphide bond with C335 releasing free GSH back into the cellular environment. 
Subsequently once redox homeostasis has been restored this intramolecular disulphide 
bond of the BCAT1 CXXC motif can be reversed by the Grx or Trx oxidoreductases using 
NADPH as a cofactor (Figure 3.3)(Conway et al., 2008).This process mediated by BCAT1 
may therefore serve to maintain the cellular pool of GSH during periods of oxidative 
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stress, therefore placing BCAT1 in the centre of a wider antioxidant network. This 
hypothesis is explored in more detail through the work presented in this thesis, which 
could in theory impact on cellular growth and development(Ye et al., 2015).  
To explore the putative antioxidant role of the BCAT1 CXXC motif, the potential 
canonical metabolic effect mediated BCAT1 through the generation of α-KG, needs to 
be mitigated (section 1.3.1 and 1.3.3). Importantly in this regard, the wild-type BCAT1 
and C338S single mutants retain remarkably similar enzymatic activity following the 
binding of GSH (S-glutathionylation) at 90 and 85 IU (IU= µmol of valine formed per min), 
thus allowing a direct comparison of the CXXC motif between the two mutants (Conway 
et al., 2008). Therefore, the CXXC motif may be mutated in a way that exclusively 
evaluates its role as a putative cellular antioxidant, whilst having very little impact on 
BCAT1 aminotransferase activity.  
Previous studies by Conway and Coles support the rationale for site directed 
mutagenesis of the BCAT1 CXXC motif. Published data show that mutation of the C-
terminal C338 residue from cysteine to serine results in the preservation of the BCAT1 
metabolic aminotransferase activity, yet terminates the ability for the intramolecular 
CXXC motif to form, thereby preventing release of GSH(Conway et al., 2008). 
Furthermore, if both C335 and C338 of the BCAT1 CXXC motif are mutated, almost 
complete abolition of the catalytic activity and the antioxidant capacity is 
observed(Conway et al., 2008). Therefore, to explore the hypothesis that the BCAT1 
CXXC motif may have an antioxidant role the analysis of wild-type BCAT1, C338S and 
C335/8S mutants is needed for separation of the metabolic effects of BCAT1 and 




Figure 3.3 Redox reactions of the wild-type BCAT1 CXXC motif and C-terminal CXXS 
mutant. A) Following H2O2 oxidation the wild-type CXXC motif the N-terminal C335 is 
oxidised forming a sulfenic acid (-SOH) intermediate. The resolving C-terminal C338 
residue forms an intramolecular disulphide which can be regenerated to the original 
reduced form by GrX/GSH. B) Substituting the C338 cysteine for serine abolishes the 
regenerative antioxidant properties of the resolving residue causing either irreversible 
oxidation to sulfinic(-SO2) then sulphonic(-SO2) acids or S-glutathionylation  (adapted 
from Conway 2004).   
 




3.2 Aims  
The aim of this chapter is to abrogate the antioxidant capacity of the BCAT1 CXXC 
motif by site directed mutagenesis substituting amino acid cysteine (C) to serine (S) 
creating three constructs in PCMV6-Entry vector: 
1) BCAT1(WT) → CXXC 
2) BCAT1(C335S) → CXXC to SXXC 
3) BCAT1(C338S) → CXXC to CXXS 
4) BCAT1(C335/8S) → CXXC to SXXS 
Substitution of CXXC motif amino acids C→S results in exchanging a redox active 
thiol (-SH) group for a hydroxyl group (-OH) eliminating the ability of the Hydrogen to 
act as an electron donor and therefore abolishing the antioxidant activity of the CXXC 
motif. These mutated BCAT1  gene constructs will then be subcloned to  pET28a protein 
expression vector to allow overexpression, purification and functional characterisation 










The following objectives are required to fulfil this aim. 
• C→S site-directed mutagenesis of the BCAT1 CXXC motif in the pCMV6-Entry 
vector (Origene), creating three mutant constructs; BCAT1(C335S), 
BCAT1(C338S) and BCAT1(C335/8S). Successful mutagenesis at the genetic level 
will be confirmed by DNA sequence analysis. 
 
• Subcloning BCAT1(WT) and CXXC motif mutants from pCMV6 to pET28a 
expression vector. Successful ligation into pET28a will be confirmed by digestion 
with pET28a specific endonucleases and fragment analysis by agarose DNA 
electrophoresis. Reading frame and BCAT1 sequence fidelity will be confirmed 
by DNA sequence analysis.    
 
• To verify that BCAT1 protein is produced, overexpression and purification of 
BCAT1(WT) and CXXC motif mutants was carried out. pET28a-BCAT1 constructs 
are overexpressed using the pET system (Novagen) in E.coli BL21(DE3) cells and 
purified using Ni-NTA and Hi-trap anion exchange chromatography using the 






• DTNB titration of BCAT1(WT) and CXXC motif mutant protein in vitro. To confirm 
C→S substitution at the protein level the number of reactive cysteine thiol 





3.3 Methods  
3.3.1 Site-directed Mutagenesis of the CXXC motif 
Mutagenesis of BCAT1 CXXC motif cysteine residues to serine was implemented 
in pCMV6-BCAT1 vector using the Quikchange II Site-directed Mutagenesis Kit (Agilent). 
Three mutant constructs were generated pCMV6-BCAT1(C335S), pCMV6- BCAT1(C338S) 
and pCMV6- BCAT1(C335/8S) using the C335S, C338S and C335/8S primer pairs 
described in section 2.4 and the cycling parameters outlined in section 2.6. BCAT1(WT) 
and CXXC motif mutant constructs were transformed into competent E.coli α-Select 
Gold cells where plasmids were cloned, purified and mutation of BCAT1 cDNA confirmed 
by DNA sequence analysis as previously described in section 2.5 and 2.6. Sequence 
fidelity was analysed using Chromas Lite 2.0 software, NCBI’s nucleotide BLAST and M-
coffee alignment tools.   
 
3.3.2 Subcloning pET28a-BCAT1  
For the subcloning of BCAT1(WT) and CXXC mutant cDNA from the pCMV6-
BCAT1 vector to pET28a expression vector, NheI and SalI restriction sites flanking BCAT1 
cDNA were introduced via PCR using the BCAT1_424 and BCAT1_1582 primer pair 
described in section 2.4 and the cycling parameters outlined in 2.9. pET28a  vector and 
BCAT1 cDNA amplicons were digested with NheI-HF and SalI-HF restriction 
endonucleases and separated by gel electrophoresis, gel purified, ligated and 
transformed into E.coli BL21(DE3) competent cells as previously described in section 2.5. 
Transformed cells were selected on LB Agar plates supplemented with 50 µg/mL 
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kanamycin and screened for the BCAT1 insert via Colony PCR as described in section 2.8 
using the BCAT_424 and BCAT1_1582 primer pair. BCAT1 positive transformants 
containing pET28a-BCAT1(WT) and CXXC motif mutant plasmids were cloned, purified 
and verified for reading frame and sequence fidelity by DNA sequence analysis using the 
T7F and T7R primer pairs as previously described in section 2.9.  
 
3.3.3 BCAT1 overexpression, purification and verification by Western blot 
Overexpression and purification of BCAT1 proteins is described in section 2.10. 
To confirm the presence of pure BCAT1 and to assess detection limits 1, 2, 5 and 10 µg 
of BCAT1 protein was loaded onto a 12% SDS-PAGE and separated by electrophoresis as 
previously described in section 2.13. BCAT1 protein was visualised on the SDS-PAGE gel 
following Coomassie blue staining, where BCAT1 appears as an enriched 43 kDa band. 
To confirm enriched 43kDa band as BCAT1 western blotting was performed as described 
in section 2.14.  
 
3.3.4  Spectrophotometric analysis of reduced cysteine thiol groups  
To verify that the mutated gene translates to the mutation of cysteine at the 
protein level  the number of reduced cysteine thiol (-SH) groups in BCAT1(WT) and CXXC 
mutant protein was measured using the 5,5'-dithio-bis-2-nitrobenzoic acid (DTNB) 
titration method as described in section 2.15. It was expected that BCAT1(WT) titrated 
6 cysteine thiols, with BCAT1(CXXS) titrating 5 cysteine thiols and BCAT1(SXXS) titrating 




3.4.1 Site directed mutagenesis of pCMV6-BCAT1 
In order to exchange the N-terminal (C335) and C-terminal (C338) cysteine 
residues of the BCAT1 CXXC motif to serine, site-directed mutagenesis was employed 
using the C335S, C338S and C335/8S primer pairs (section 2.4) and cycling parameters 
previously described in section 2.6. This resulted in a single base pair substitution of the 
C335 cysteine codon from GCA to GCT and the C338 cysteine codon from ACA to AGA. 
Base pair substitutions were confirmed by DNA sequencing and analysed using the 
Chromas program. Chromatograms reveal successful substitution reaction at C335 and 
C338 codons creating three mutant constructs, which include - the N-terminal mutated 
pCMV6-BCAT1(C335S), the C-terminal mutated  pCMV6-BCAT1(C338S) and the N+C 
terminal mutated pCMV6-BCAT1(C335/8S) (Figure 3.4). Full reading frame analysis was 
performed using the NCBI-Blast webtool, alignment of sequenced pCMV6-BCAT1 
constructs with the full pCMV6-BCAT1 sequence revealed no additional spontaneous 








 Figure 3.4 Site directed mutagenesis of BCAT1 CXXC motif in pCMV6 vector. CXXC 
motif base pair substitutions of BCAT1 cDNA (OriGene) in the pCMV6-Entry vector. 
Chromatograms illustrate the mutation sites of A) C335S, B) C338S and C) C335/8S 
mutants. Full reading frame analysis shows no additional mutations. (data not shown). 
D). Corresponding cysteine (C) to serine (S) amino acid changes flanking tandem valine 
(V) residues are shown BCAT1(WT), C335S, C338S and C335/8S mutants respectively  
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3.4.2 Subcloning BCAT1 and CXXC motif mutants to pET28a expression vector. 
To produce BCAT1 containing pET28a expression vectors, BCAT1(WT) and BCAT1 
CXXC mutant cDNA was PCR amplified from the respective pCMV6- Entry vectors and 
isolated by gel electrophoresis (Figure 3.5 Panel A). Successful insertion of BCAT1(WT) 
and respective CXXC mutant cDNA into pET28a expression vectors was confirmed by the 
presence of 1.16 kb fragment isolated by agarose gel electrophoresis, following 
digestion with NheI and SalI (Fig.3.5 Panel B). Full BCAT1(WT) and respective BCAT1 
CXXC mutant cDNA sequence and reading frame fidelity was confirmed by DNA 
sequence analysis and NCBI-Blast alignment with pET28-BCAT1 sequence generated in 
silico using the Serial Cloner (Serial Basics Version 2.6) program (Appendix A). The BCAT1 
CXXC mutant sequence variations were highlighted using the M-Coffee multiple 












Figure 3.5 Subcloning BCAT1(WT) and BCAT1 CXXC motif mutants from pCMV6-Entry 
vector to pET28a expression vector.  A) BCAT1(WT) cDNA and respective BCAT1 CXXC 
motif mutants (C335S, C338S, C335/8S) were PCR amplified from the pCMV6-Entry 
vector and separated by agarose gel electrophoresis prior to ligation. B) To verify 
successful BCAT1(WT) and BCAT1 CXXC motif mutant subcloning into pET28a, the 
purified pET28a-BCAT1 constructs were NheI/SalI restriction digested and analysed by 
agarose gel electrophoresis to confirm BCAT1 insertion.  Gel loading is as follows: 
A) Lanes 2-5 20μl loads. Lane 1: 5μl 1 kb Plus DNA ladder. Lane 2: BCAT1(WT) 
amplicon Lane 3: BCAT1(C335S) amplicon Lane 4: BCAT1(C338S) amplicon and  
Lane 5: BCAT1(C335/8S) amplicon. 
B) Lanes 2-7 100ng loads.  Lane 1: 5μl 1 kb Plus DNA ladder. Lane 2: undigested 
pET28a vector control Lane 3: digested pET28a control Lane 4: digested pET28a-
BCAT1(WT) construct Lane 5: digested pET28a-BCAT1(C335S) construct Lane 6: 










Figure 3.6 Sequence alignment of pCMV6-Entry, pET28a and pLenti constructs 
containing BCAT1 and CXXC motif mutants. BCAT1(WT) and CXXC motif mutants were 
subcloned from A) pCMV6-Entry into expression vectors B) pET28a. Sequences were 
analysed using M-Coffee multiple sequence alignment tool. CXXC motif base 
substitutions are highlighted in white. Full reading frame analysis of each construct 













PCMV6-BCAT  177 CTTTGTACAGTATATCAGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAACATCT 
C335S       177 CTTTGTACAGTATATCAGAAACTGGGCAAACAACAGAGGCTGTACCAGAGCCAAACATCT 
C338S       181 CTTTGTACAGTATATCAGAAACTGGGCTAACAACACAGGCTGTACCAGAGCCAAACATCT 
C335/8S     176 CTTTGTACAGTATATCAGAAACTGGGCTAACAACAGAGGCTGTACCAGAGCCAAACATCT 
 
pET28-BCAT   232 CAGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCC 
C335S        240 CAGAAACTGGGCAAACAACAGAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCC 
C338S        232 CAGAAACTGGGCTAACAACACAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCC 





3.4.3 Expression and purification of BCAT1 and CXXC mutants 
To overexpress BCAT1 and CXXC mutant protein, pET28-BCAT1 and CXXC mutant 
constructs were transformed into E.coli BL21-DE3 cells and induced with IPTG. 
Uninduced and induced whole cell lysates were collected and analysed by SDS-PAGE. 
The expression of BCAT1 was denoted by the presence of a large band at 43KDa (Figure 
3.7). Expressed protein was harvested and purified from bacterial cultures using Ni-NTA 
and Ion exchange chromatography on the AKTA platform. Successive stages of 
purification were analysed by SDS-PAGE, increasingly pure BCAT1 is displayed from left 
to right in Lanes 2-7 denoted by the gradual disappearance of extraneous banding 
(Figure 3.8). Elution of purified protein samples following Ion exchange chromatography 
was measured using the AKTA pure system (Figure 3.9) Purified BCAT1 protein was 
confirmed by western blot analysis. Increasing loads of pure BCAT1 protein was loaded 














Fig 3.7 SDS-PAGE gel displaying protein expression of BCAT1(WT) and CXXC mutants 
in BL21 (DE3) cells. Following transformation into E.coli BL21(DE3) BCAT1(WT) and CXXC 
mutants were maintained in liquid cultures before induction with IPTG. Samples were 
harvested immediately pre-induction and 4 h post induction. Whole cell lysate loads 
were normalised to 0.15 OD600 units. Lane 1: 5μl Full Range Rainbow Marker Lane 2: 
BCAT1(WT) Lane 3: BCAT1(WT) + IPTG Lane 4: BCAT1(C335S) Lane 5: BCAT1(C335S) + 
IPTG Lane 6: BCAT1(C338S) Lane 7: BCAT1(C338S) + IPTG Lane 8: BCAT1(C335/8S) Lane 
























Figure 3.8 Chromatogram profiles displaying BCAT1(WT) and BCAT1 CXXC mutant 
proteins purified by ion exchange. Following Ni-NTA purification, BCAT1 proteins were 
purified using HiTrap
TM
 Q HP strong anion columns using the AKTA pure protein 
purification system. Samples were eluted by 0-0.5M NaCl concentration gradient (green 
line) and pooled for future analysis by SDS-PAGE and western blot. Blue peaks represent 
purified protein elution: A) BCAT1(WT)  B) BCAT1(C335S), C) BCAT1(C338S) and D) 








Fig 3.9 SDS-PAGE displaying purification of BCAT1(WT) and BCAT1 CXXC mutant 
proteins. BCAT1(WT) and BCAT1 CXXC mutants were purified from 2-5 g E.coli BL21(DE3) 
cell pellets following sonication by Ni-NTA affinity chromatography and Ion Exchange 
chromatography. Whole cell lysates were (WCL) normalised to 0.15 OD600 units prior to 
loading. Lane 1: 5μl Full Range Rainbow Marker Lane 2: WCL BCAT1 Lane 3: WCL Induced 
BCAT1 Lane 4: Ni-NTA unbound flow through Lane 5 : Ni-NTA purified BCAT1  Lane 6: 
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Figure 3.10 Detection of BCAT1(WT) and BCAT1 CXXC motif mutants by western blot 
analysis. BCAT1(WT) and BCAT1 CXXC motif mutant purified proteins were validated by 
western blot analysis. In order to define detection parameters, increasing loads of 
BCAT1(WT) and respective CXXC motif mutants were incubated with (1:2000) ECA39 
polyclonal primary Ab.  Lane 1: 5μl Full Range Rainbow Marker Lane 2: 1µg BCAT1  Lane 
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3.4.4 Assessment of purified BCAT1(WT) and BCAT1 CXXC mutated protein cysteine thiol 
groups 
To confirm mutation of the BCAT1 CXXC motif was displayed at the protein level, 
assessment of the number free solvent accessible cysteine thiol groups was performed 
by DTNB titration. Initial reaction rates varied between the proteins, after 120 sec 
BCAT1(WT) and BCAT1(C338S) had 4.29±0.1 and 3.96±0.2 labelled thiols whilst 
BCAT1(C335S) and BCAT1(C335/8S) had just 3.18±0.1 and 2.84±0.14 respectively 
demonstrating the cysteine thiol at C335 is more reactive than C338. After 15 min 
incubation with DTNB a total of 6.25±0.2 free cysteine thiols were labelled for 
BCAT1(WT), 5.03±0.1 for BCAT1(C335S), 5.22±0.2  for BCAT1(C338S) and 3.95±0.2  for 
BCAT1(C335/8S). This result confirms the mutation of C→S by site directed mutagenesis 

















Figure 3.11 DTNB cysteine thiol titration of BCAT1(WT) and BCAT1 CXXC mutant 
protein.  To verify the site directed mutagenesis of the CXXC motif translates to the 
protein level, purified BCAT1(WT) and BCAT1 CXXC motif mutants were titrated against 
DTNB.  The graph illustrates the number of titratable cysteine thiols for BCAT1(WT) 
(circles), BCAT1(C335S) (squares), BCAT1(C338S) (triangles) and BCAT1(C335/8S) 
(inverted triangle). Data presented are mean ± SEM(n=3). 
  


































The aim of this chapter was to abrogate the antioxidant capacity of the BCAT1 
CXXC motif by site directed mutagenesis substitution of amino acid Cysteine (C) to Serine 
(S) exchanging a thiol (-SH) group  for a hydroxyl group (-OH) eliminating the ability of 
the Hydrogen to act as an electron donor and therefore abolishing the antioxidant 
activity of the CXXC motif.  
The data presented show that the BCAT1 CXXC motif was successfully mutated 
in pCMV6-Entry vector as confirmed by DNA sequence analysis (Figure 3.4). In order to 
assess whether mutagenic substitution transferred to the protein level, BCAT1(WT), 
BCAT1(C335S), BCAT1(C338S) and BCAT1(C335/8S) mutant genes were transferred to a 
pET28a protein expression vector, where successful insertion was confirmed by 
NheI/SalI restriction enzyme digestion and DNA fragment analysis by agarose gel 
electrophoresis (Figure 3.5). To ensure that  BCAT1 proteins will be correctly translated 
from pET28a-BCAT1, reading frame and sequence fidelity was verified by DNA sequence 
analysis (Figure 3.6). Induced overexpression of BCAT1(WT) and CXXC mutant proteins 
in E.coli BL21(DE3) cells was demonstrated by comparison to un-induced cells (Figure 
3.7). Subsequently BCAT1(WT) and BCAT1 CXXC motif mutant(s) were purified by Ni-
NTA and Ion exchange chromatography using the AKTA platform. Purification at various 
stages was monitored by SDS-PAGE (Figure 3.8), ultimately pure BCAT1 was confirmed 
by and western blot analysis (Figure 3.10).   
To confirm that the CXXC cysteine mutations at the genomic level translated to 
the protein level, cysteine thiol analysis of the BCAT1(WT) and BCAT1 CXXC motif mutant 
proteins was quantitated by DTNB titration as illustrated in Figure 3.3. By using this 
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method, previous studies revealed that BCAT1(WT) contains 6 reactive cysteine thiols, 
including the 2 cysteine thiols of the CXXC motif (Davoodi et al. 1998). The results 
presented here agree with Davoodi et al. The DTNB titration data presented confirms 
the presence of 6 cysteine thiols for BCAT1(WT) as well as the successful elimination of 
C335, C338 and C335/8 from the CXXC motif mutated BCAT1 vector contracts (Figure 
3.11). Interestingly, after just 120 sec the BCAT1(C338S) protein titrated an average of 
3.96±0.2 cysteine thiols compared with 3.18±0.1 for the BCAT1(C335S) CXXC motif 
mutant protein (Figure 3.11). This relates to approximately 1 less labelled thiol group 
per molecule demonstrating the N-terminal C335 is more reactive than the C-terminal 
C338, supporting previous biochemical characterisation of the motif  which identified 
C335 is more sensitive to oxidation than C338 (Coles, Hancock and Conway, 2012). 
As well as differentially affecting the redox activity of the BCAT1 CXXC motif, 
previous studies demonstrated that mutagenesis of the motif differentially affects the 
aminotransferase metabolic activity of BCAT1 (Conway et al., 2008), this is perhaps 
unsurprising given that the CXXC motif is located just 10 angstroms from the 
aminotransferase active site(Goto et al., 2005).  Conway et al., 2008, showed that 
substitution of the BCAT1 C335 cysteine to serine resulted in a large decrease in the 
catalytic activity of the enzyme, reducing the Kcat/Km from 108 x 103 M-1 s -1 for 
BCAT1(WT) to 43 x 103 M-1 s -1 for BCAT1(C335S), a reduction of 60% catalytic activity 
when measuring glutamate and using α-ketoisovalerate as the fixed substrate. This 
finding highlights the importance of the N-terminal CXXC motif cysteine (C335) with 
respect to the metabolic activity of BCAT1. By contrast the mutation of C338 residue 
resulted in an activity of 62 x 103 M-1 s –1, a reduction of 30%, whilst mutation of both 
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the C335 and C338 results in a Kcat/Km of 31 x 103 M-1 s -1, a reduction of 71% (Conway 
et al., 2008).  
Whilst CXXC motif mutation results in a significant reduction in enzymatic 
turnover in vitro, under physiological GSH/GSSG ratios, the majority of the N-terminal 
C335 is largely S-glutathionylated, which protects BCAT1 enzymatic turnover (Conway 
et al., 2008). The data presented by Conway et al., 2008 indicate that the enzymatic 
activity of S-glutathionylated BCAT1(WT) and BCAT1(C338S) protein relates to 90 IU and 
85 IU respectively (IU= µmol of valine formed per min), a reduction of just 5%. This 
highlights an important role for cellular GSH in maintaining the enzymatic activity of 
BCAT1 physiological settings.  
These studies demonstrate mutation of the CXXC motif from C→S results in the 
change of only one atom in the BCAT1 protein, substituting Sulphur to Oxygen, however 
the effect on the and enzymatic and antioxidant capacity of the protein can vary 
depending on whether the N or C-terminal residue is altered. In the presence of 
physiological levels of GSH mutation of the BCAT1(C338) retains enzymatic capacity 
comparable to BCAT(WT) whilst eliminating the antioxidant capacity, whilst 
BCAT1(C335/8) shows decreased enzymatic and antioxidant capacity. To elucidate the 
antioxidant role of the CXXC motif a comparison will be made  between BCAT1(WT), 
BCAT1(C338S) and BCAT(C335/S) following overexpression in the AML cell line U937 





Chapter 4: Lentiviral transduction and 
overexpression of BCAT1(WT) and BCAT1 CXXC 
motif mutants in the myeloid cell line U937 
4.1 Introduction 
The ability to overexpress proteins in immortalised human cell lines has formed 
the backbone of leukaemia research over the last 30 years (Nuñez et al., 1990; 
Thorsteinsdottir et al., 2002). Retroviral vectors that integrate into the host genome are 
used to introduce transgenes to a wide range of cellular models (Spector et al., 1990). 
Lentiviral vectors have become a popular choice because they infect both dividing and 
non-dividing cells due to their ability to cross the nuclear membrane (Naldini et al., 1996; 
Kobiler et al., 2012). Modern lentiviral vectors are the 3rd generation of modified HIV-1 
virus, that have been iteratively engineered to reduce pathogenicity. The parental HIV 
genome containing nine genes has been reduced to three spread across four separate 
plasmids, that is aimed at eliminating the possibility of a replicative virus which could be 
reconstituted in vivo through a recombination event (Zufferey et al., 1998). 
The first generation of lentiviral vectors consisted of a two-plasmid system that 
separated the viral gene env, encoding envelope glycoproteins that facilitate 
attachment and entry into a host cell, and the remainder of the viral genome plus the 
transgene. Additionally, HIV-1 env genes were replaced or pseudo-typed with 
glycoprotein G of the Vesicular stomatitis virus (VSV-G), which recognizes the 
ubiquitously expressed low-density lipoprotein (LDL) receptor allowing the lentiviral 
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vector to transduce a wide range of cells (Cronin, Zhang and Reiser, 2005; Finkelshtein 
et al., 2013). 
Further safety improvements with the second generation eliminated virulence 
factors Vpr, Vif, Vpu, and Nef as well as separating essential replication and structural 
genes Gag, Pol and Rev from the transgene vector (Dull et al., 1998). Finally, in the 3rd 
generation the 5’ Long Terminal Repeat (LTR) was truncated, removing the viral 
promotor and Trans-activation response elements, which bind tat and stimulates 
promotor activity. This sequence was replaced with a recombinant 5’LTR driven by a 
Cytomegalovirus (CMV) promotor, that produces strong constitutive overexpression of 
the transgene (Miyoshi et al., 1998). Production of infectious viral particles is achieved 
by co-transfection of transgene vector and packaging plasmids into a viral packaging cell 
line e.g. HEK293T (ATCC CRL-3216), which provide the components necessary for the 
cell line to manufacture infectious, replication incompetent virions (Merten, Hebben 
and Bovolenta, 2016). Over several days HEK293T cells produce the lentiviral particles, 
which are harvested from the culture medium. Upon viral transduction of the host cell, 
viral RNA is reverse transcribed and integrated into the host genome where co-
expression of antibiotic resistance genes allows selection of stable transformants, see 
figure 4.1 (Merten, Hebben and Bovolenta, 2016). 
During a transduction reaction the ratio of effective infectious viral particles and 
target cell number is known as the Multiplicity of Infection (MOI), where a 1:1 ratio 
represents a MOI equal to one (MOI = 1). The transduction efficiency for a given MOI 
varies depending on cell type, which itself may be dependent on the number LDL 
receptors available for interaction with VSV-G (Zhang et al., 2004). It is recognised that 
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the transduction of leukaemia cell lines present a particular challenge, and generally 
require a higher viral titre compared to non-immune cells or undifferentiated 
hematopoietic cells (Swainson et al., 2008). Although macrophages are a target for wild 
type HIV-1, myeloid cells in general are relatively refractory to infection by HIV-1 derived 
Lentivirus (Aquaro et al., 2002). The reason for this is the myeloid-specific hydrolase 
(SAMHD1) that functions by dephosphorylating cellular dNTPs, reducing the cellular 
pool to a level that blocks reverse transcription of viral RNA (Hrecka et al., 2011). Wild-
type HIV-2 encodes a Vpx accessory protein, which binds SAMHD1 causing its 
degradation.  However, the related Vpr protein as introduced in Lentivirus expression 
systems does not have the ability to degrade SAMHD1 in the same way as Vpx. 
Moreover, Vpx cannot be engineered to into a lentiviral system as the lentiviral virion 
cannot package Vpx (Bobadilla, Sunseri and Landau, 2013). Taken together, infection of 
monocytic cell lines such as THP1 (ATCC TIB-202) and U937 (ATCC CRL 1293.2) with 
Lentivirus requires MOIs an order of magnitude higher than many cell lines(Zhang et al., 
2004).  
Integration of the lentivirus cDNA into the host genome is a semi-random event 
governed by the accessibility of nuclear chromatin, which varies depending on the cell 
type, cell cycle and proximity to the nuclear pore (Ciuffi, 2008). Additionally, the viral 
pre-integration complex (PIC) has been found to interact with a number of host proteins 
that facilitate integration (Ciuffi, 2008). For example, Lentiviral integrase associates 
with lens epithelium-derived growth factor (LEDGF), a transcriptional co-activator which 
contains a DNA binding AT hook motif that directs the PIC to relatively AT-rich regions 






Figure 4.1 Production of Lentivirus using the third-generation system.  Adherent 
HEK293T(ATCC CRL-3216)  packaging cells are co-transfected with the pLenti envelope 
and packaging plasmids of the third-generation system. Viral particles containing the 
transgene are produced by HEK293T cells and secreted into the culture supernatant, 
which is collected, and filter purified. VSV-G pseudo-typed virions enter the cells via 
endocytosis mediated by the ubiquitously expressed low-density lipoprotein (LDL) 





modulated by LEDGF which is proposed to act as a tether guiding PIC integration (Ciuffi 
and Bushman, 2006). 
Quantification of lentiviral induced gene expression in transgenic cells at the 
transcript level is commonly performed by qPCR, which uses fluorescently labelled 
nucleotides to track the PCR amplification cDNA derived from target gene mRNA (Arya 
et al., 2005). The quantitative end point of the reaction is the ‘Crossing point’ (Cp), the 
value at which fluorescence of the sample rises above the background noise. The Cp 
value is directly related to gene expression, since the Cp depends on the initial 
concentration of cDNA i.e. a sample with a higher initial concentration cDNA will take 
fewer cycles to cross the Cp threshold (Schmittgen and Livak, 2008). Although qPCR 
can be used to measure absolute transcript levels or copy numbers, this is not 
particularly relevant when examining gene overexpression, where relative change 
from the wild-type (WT) gene expression level is more pertinent 
 To this end, relative basic quantification, where fold change in gene expression 
is calculated using -2ΔΔCp method is widely used (Schmittgen and Livak, 2008). The 
equation  -2ΔΔCp  = (Cp Gene of interest – Cp Internal control) Sample A – (Cp Gene of 
interest – Cp Internal control) Sample B,  compares differences in Cp values  between 
the overexpression sample (Sample A) and the WT  control (Sample B). Given each 
cycle equates to a double the RNA content the fold change in target (gene of interest) 
mRNA is calculated by 2(x) where x= ΔΔCp. To account for variation between sample 
concentrations both Sample A and B are normalised to a stably expressed internal or 
reference  control.  
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Post transcriptional interference of mRNA can result in drastically reduced 
expression at the protein level (Schoenberg and Maquat, 2012). Therefore, it is advised 
that transgene expression change (qPCR) is supported by translation to protein. Protein 
expression is frequently validated through detection of a recombinant epitope tag that 
is affixed to the N or C-terminal of the transgene (Munro and Pelham, 1984). The pLenti 
Origene system used in this study employs a Myc/DDK FLAG system that allows 
detection post translation through western blotting, with an Anti-Myc/DDK (FLAG)-HRP 
mAb raised to DYKDDDDK epitope (Figure 4.2) (Einhauer and Jungbauer, 2001).  
Using the techniques introduced above this part of the study aimed to stably 
transduce and overexpress BCAT1(WT) protein and the BCAT1 CXXC motif mutants 
BCAT1(C338S) and BCAT1(C335/8S), in U937 cells (a monocytic cell line of the myeloid 
lineage) using Origene’s Lentiviral system (Figure 4.2) (Sundström and Nilsson, 1976). In 
this way, the hypothesised novel antioxidant capacity of the BCAT1 CXXC motif may be 







4.2 pLenti plasmid system for cellular transduction. A) Orgine’s pLenti plasmid 
features puromycin resistance gene(Puro) for selection of transgenic cells post 
transduction and a DDK epitope tag for transgenic protein detection transcription of 
which is driven by a CMV promoter. B) pLenti forms part of a third  generation 4 plasmid 
system that separates viral packing genes Gag/Pol, Rev and Env onto separate elements. 
Only the pLenti element between 5’ and 3’ LTR is integrated into the genome of the host 





4.2 Aims and Objectives 
The aim of this chapter is the stable overexpression Empty Vector(EV), BCAT1(WT) 
and CXXC disrupted BCAT1(C338S) and (C335/8S) protein in immortalised monocyte 
cell line U937 (ATCC CRL 1293.2). In this way, 4 cell lines can be generated that will 






 The BCAT1(C338S) mutant was selected on the basis that BCAT1 
aminotransferase activity is preserved under physiological conditions, whereas the 
putative antioxidant activity is predicted to be  diminished compared with BCAT1(WT). 
The BCAT1(C335/8S) mutant was selected since both BCAT1 aminotransferase and 
antioxidant activity is diminished, therefore, by comparing these cells lines the relative 
contributions of BCAT1 enzymatic and CXXC motif mediated effects can be 
distinguished. Finally, EV control cells, will evaluate the effect of the puromycin 
resistance gene which is under CMV bicistronic regulation. Overexpression of 
puromycin may affect cell growth parameters and must be controlled with respect to 







• Subclone BCAT1(WT) and respective BCAT1 CXXC motif mutant genes from the 
pCMV6-Entry construct to the Origene Lentiviral pLenti vector (Figure 4.2) and 
confirm successful ligation by DNA sequence analysis. 
 
• Generate infectious Lentiviral particles containing the various pLenti-BCAT1 
constructs – BCAT1(WT), BCAT1(C338S), BCAT1(C335/8S) and Control(EV), using 
the viral packaging cell line, HEK293T (ATCC CRL-3216). Successful production of 
viral particles in culture supernatant will be determined by ELISA, targeting the 
p24 viral coat protein. 
 
• Transfect U937 cells (ATCC CRL 1293.2) with respective Lentiviral particles 
creating four transgenic cell lines 1) U937-Control(EV), 2) U937-BCAT1(WT), 3) 
U937-BCAT1(C338S) and 4) U937-BCAT1(C335/8S). Puromycin will be used to 
select transgenic cells and ensure stable transfection. 
 
• Validate stable transfection by evaluating BCAT1 expression at the transcript 
level via qPCR. Confirm expression of BCAT1 protein in WT, CXXC motif mutant 






4.3.1  Subcloning pLenti-BCAT1 vector 
BCAT1(WT) and CXXC motif  mutants – BCAT1(C338S) and BCAT1(C335/8S) were 
subcloned from the respective pCMV6-BCAT1 constructs (generated by site directed 
mutagenesis Section 2.6) into a pLenti destination vector (Figure 4.2, A) using Origene’s 
precision shuttle system. Briefly 5 µg respective pCMV6-BCAT1 construct and pLenti 
plasmids were digested with 2µL AsiSI and MluI restriction endonucleases for 4-6 h. 
Following digestion, excised BCAT1(WT) and respective BCAT1 CXXC motif mutant cDNA 
and linearized pLenti were separated by gel electrophoresis prior to gel purification and 
ligation. Competent E.coli α-Select Gold Efficiency cells (Bioline BIO-85027) were 
transformed with the ligation mixture and inoculated onto LB agar supplemented with 
35µg/mL chloramphenicol to select for pLenti positive colonies.  pLenti-BCAT1 construct 
positive colonies were discriminated from colonies containing uncut or re-circularised 
pLenti by Colony PCR using the V2 and FTAG primers (Section 2.4) . pLenti-BCAT1 
positive colonies were expanded and pLenti-BCAT1 plasmids purified prior to DNA 
sequence analysis using the V2 and FTAG sequencing primers. See section 2.5 to 2.8. 
 
4.3.2 Transcription analysis of BCAT1 expression 
In order to select a model cell line appropriate for overexpression, BCAT1 
transcript levels were analysed in HL-60 (ATCC CCL-240), K562(ATCC CCL-243), 
U937(ATCC CRL1593.2) and THP1(ATCC TIB-202). Data was provided by 
https://www.proteinatlas.org/cell. U937 cells were selected based on their relatively 
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low background of BCAT1 expression in combination with favourable growth 
characteristics compared to THP1. 
 
4.3.3 Stable Transduction of BCAT1(WT) and CXXC Motif Mutant U937 Cells 
Lentiviral p’articles containing the pLenti empty vector (EV) control, BCAT1(WT), 
BCAT1(C338S) and BCAT1(C335/8S) vector constructs were generated using Origene’s 
Lenti-vpak packaging system as described in Section 2.16. Viral titres were performed 
prior to U937 cell transduction as described in Section 2.17. To ensure maximum 
lentiviral transduction, U937 cells were subject to ‘spinoculation as described in Section 
2.20. Successful transfection of U937 cells was confirmed following puromycin selection 
by qPCR as described in Section 2.21. To confirm stable transfection and overexpression 
of  BCAT1(WT), BCAT1(C338S) and BCAT1(C335/8S), transgenic U937 cells were verified 
by Western Blot analysis using the Anti-Myc/DDK (FLAG)-HRP mAb (OriGene) as 
described in Section 2.22. The BCAT1(WT), BCAT1(C338S), BCAT1(C335/8S) and EV 
control transgenic U937 cells were maintained in culture under 0.5 μg/ml puromycin 






4.4  Results 
4.4.1 Subcloning BCAT1(WT) and respective CXXC motif mutant clones to pLenti vector  
To produce pLenti- BCAT1 vectors, BCAT1 and respective CXXC mutant cDNA was 
excised from the previously synthesised pCMV6 Entry vector constructs (see chapter 3), 
by restriction endonuclease digestion and isolated by gel electrophoresis. Successful 
excision of each BCAT1 clone from respective pCMV6 Entry vectors was confirmed by 
the presence of 1.16 kb and 4.9 kb bands representing BCAT1 and linearized pCMV6 
respectively (Fig 4.4 Panel A). Successful insertion of BCAT1 into destination vectors was 
confirmed by the presence of 1.16 kb and 6.9 kb fragment representing BCAT1 and 
linearised pLenti respectively. (Fig.4.4 Panel B). pLenti-BCAT1(WT) and respective CXXC 
motif mutant cDNA sequence and reading frame fidelity was confirmed by DNA 
sequence analysis and NCBI-Blast alignment with pLenti sequence generated in silico 
using the Serial Cloner program (Appendix A). Mutant CXXC sequence variations were 
highlighted using the M-Coffee multiple sequence alignment tool (CRG, France) (Fig 4.5). 
 
4.4.2 Transcription analysis of BCAT1 expression 
To determine the best cellular model for overexpression of BCAT1(WT) and CXXC 
motif mutants, native transcript levels on BCAT1 in the myeloid cell lines - HL-60, K562, 
U937 and THP1 were examined using data from https://www.proteinatlas.org/cell. The 
analysis show that HL-60 and K562 both displays relatively high expression of BCAT1 at 
81.9 and 78.9 transcripts per million (TPM) (Figure 4.5). U937 displays lower expression 
at 48 TPM, a 41% reduction compared to HL-60. THP1 displays an even lower basal 
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expression of 29.5 TPM a 64% reduction compared to HL-60. On the basis of the data 













Figure 4.3 Subcloning BCAT1 WT and CXXC motif mutants from pCMV6-Entry vector to 
pLenti destination vector. A) pCMV6-BCAT1(WT) and respective CXXC motif mutants 
(C335S, C338S, C335/8S) were AsiSI and MluI digested and separated by agarose gel 
electrophoresis prior to ligation into pLenti destination vector. B) Recombinant pLenti-
BCAT1 constructs were digested and analysed by agarose gel electrophoresis to confirm 
BCAT1 insertion. Gel loading was as follows: 
A) Lane 2-9 100ng DNA per well. Lane 1: 5μl 1 kb Plus DNA ladder. Lane 2: pCMV6-
BCAT1(WT) (6 kb). Lane 3: digested pCMV6-BCAT1(WT) Lane 4: pCMV6-
BCAT1(C335S) Lane 5: digested pCMV6-BCAT1(C335S) Lane 6: pCMV6-BCAT1(C338S) 
Lane 7: digested pCMV6-BCAT1(C338S Lane 8: pCMV6-BCAT1(C335/8S) Lane 9:  
pCMV6-BCAT1(C335/8S)  
B) Lane 2-7 100ng DNA per well. Lane 1: 5μl 1 kb Plus DNA ladder. Lane 2: pLenti Lane 
3:digested pLenti Lane 4: digested pLenti- BCAT1(WT) Lane 5: digested pLenti- 










Figure 4.4 Sequence alignment of pCMV6-Entry and pLenti constructs containing 
BCAT1(WT) and CXXC motif mutants. BCAT1(WT) and respective CXXC motif mutants 
were sub cloned from A) pCMV6-Entry constructs into B) pLenti destination vectors 
(Origene). Sequences were analysed using M-Coffee (OmicX, France) multiple sequence 
alignment tool. Base substitutions highlighted in white shows CXXC mutations carried 
over successfully following subcloning process. Full reading frame analysis of each 
construct shows no additional mutations, orientation and fidelity of the insert was 
verified against in silico pLenti-BCAT1 using NCBI’s BLAST tool (Data not shown). 
A) 
 
pCMV6-BCAT  177 CTTTGTACAGTATATCAGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAACATCT 
C335S       177 CTTTGTACAGTATATCAGAAACTGGGCAAACAACAGAGGCTGTACCAGAGCCAAACATCT 
C338S       181 CTTTGTACAGTATATCAGAAACTGGGCTAACAACACAGGCTGTACCAGAGCCAAACATCT 







pLenti-BCAT  174 CGCCTTTGTACAGTATATCAGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAACA 
C335S        178 CGCCTTTGTACAGTATATCAGAAACTGGGCAAACAACAGAGGCTGTACCAGAGCCAAACA 
C338S        179 CGCCTTTGTACAGTATATCAGAAACTGGGCTAACAACACAGGCTGTACCAGAGCCAAACA 












Figure 4.5 BCAT1 transcript expression in immortalised leukaemia cell lines. 
Comparison of BCAT1 transcript levels in HL-60, K562, U937 and THP1. To select the 
appropriate model for transfection available cell lines were examined for basal BCAT1 










































4.3.2 Lentiviral titre quantification  
Following generation of infectious lentiviral particles containing the respective 
pLenti-BCAT1 constructs generated by the HEK293T viral packaging cell, viral titre was 
assessed by measuring lentiviral coat protein p24 by ELISA using QuickTiter™ Lentivirus 
Titer Kit (Cell-Bio Labs no. VPK-107-T3) and sample titres were determined by 
comparison to p24 standard curve (Figure 4.6). The number of Lentiparticles is based on 
the assumption each viral particle contained an average of 2000 p24 coat protein 
molecules. The 4 viral constructs pLenti-BCAT1(WT), pLenti-BCAT1(C338S), pLenti-
BCAT1 (C335/8S) and pLenti(EV) were measured at a density of 1.71 x108 , 1.25 x108 1.49 
x108   and 1.69 x108 lentiparticles/mL respectively (Table 4.1). 
 
 
Lentiviral construct  p24(ng/mL) Lentiparticles/mL TU/mL 
pLenti-BCAT1(WT)-Myc-DDK  13.68 1.71E+08 1.71E+05 
pLenti-BCAT1(C338S)-Myc-DDK 10.02 1.25E+08 1.25E+05 
pLenti-BCAT1(C335/8S)-Myc-DDK 11.92 1.49E+08 1.49E+05 





Table 4.1 Transducing units (TU) lentiviral titre 




4.4.3 Generation of BCAT1 transgenic U937 cells 
U937 cells were transduced with pLenti-BCAT1 containing Lentivirus that 
integrates into the genome and induces constitutive expression of the BCAT1 gene. 
Stable integration was selected for by puromycin resistance provided by the pLenti 
plasmid (Figure 4.2). A puromycin dose-response curve showed the lowest lethal dose 
of puromycin for U937 cells grown in a 96 well plate at a density of 0.5 x106 cells/mL is 
0.5µg/mL (Fig 4.8, Panel A), therefore post transduction U937 cells were grown in 
complete RPMI supplemented with 0.5µg/mL puromycin for several weeks until 
confluence demonstrating stable transduction. To confirm selection wild-type and 
transgenic U937 cells were grown in a 96 well plate at a density of 0.5 x106 cells/mL 
supplemented with 0.5µg/mL puromycin and viability was measured after 72 hours. 
Control U937 cells (non-transduced) display significantly reduced viability (12.1%) 
compared to EV, BCAT1(WT), BCAT1(C338S) and BCAT1 (C335/8S) cells which retained 











Figure 4.6 Generation and quantification of Lentivirus. Generation of infectious pLenti-
BCAT1 viral particles produced in HEK293T cells. A) Transduction of pLenti-BCAT1 and 
packaging plasmids was carried out at approximately 70% confluence (100x 
magnification). Lentiviral particles were harvested from culture medium 2-3 days after 
transfection. B) Standard curve of p24 viral coat protein. Lentiviral concentration was 
determined by ELISA assay targeting Lentiviral associated p24 viral coat protein. ½ serial 
dilution was used to generate p24 standard curve plotted against absorbance at λ450nm. 
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Figure 4.7 Antibiotic selection of transgenic cell lines.  U937 puromycin cytotoxicity 
assay. A) Dose response curve for control U937 cells treated with 0-1ug/mL puromycin 
for 72h (n=3, R2= 0.9981 as determined by non-linear regression). Minimum inhibitory 
concentration for selection of transgenic cell lines was determined as 0.5 µg/mL. B) 
Stable transduction of each transgenic cell line was confirmed through incubation with 
0.5 µg/mL puromycin for 72h. Cell viability was determined by flow cytometric analysis 





































































4.3.5 Relative quantification of BCAT1 expression 
BCAT1(WT) and respective CXXC mutant motif transcript overexpression in 
Lentiviral transduced U937 (ATCC CRL1593.2) cells  was measured by qPCR. Prior to the 
assay, total RNA was extracted from respective transgenic U937 cells using Bioline’s 
isolate II RNA mini kit (BIO-52072) and checked for degradation by gel electrophoresis. 
The presence of distinct bands representing the 28S:18S ribosomal RNA subunits in a 
ratio ≥2 indicates intact RNA suitable for downstream analysis (Schroeder et al., 2006) 
(Figure 4.8). The qPCR primers - BCAT1-F/BCAT1-R targeting BCAT1, and reference gene 
primers β2M-F/ β2M -R (Section 2.4), targeting reference gene Beta-2-microglobulin 
(β2M), were assessed in silico by the NCBI primer blast tool, which predicted specific PCR 
products of 90 and 101 bp respectively (Figure 4.9, panel A), as well as potential non-
specific primer dimer (Figure 4.9 panel B). Therefore, a gradient PCR to optimise assay 
annealing temperatures and eliminate non-specific products was performed. Non-
specific products were detected by the presence of a low weight band in t=e 
amplification of BCAT1 at 57, 59 and 61°C. No PCR product was seen at 63 and 64°C 
(Figure 4.9 panel A). Similarly, β2M amplification displayed non-specific bands at 57, 59 
and 61°C and no PCR product was seen at 63 and 64°C (Figure 10 panel B). Another 
important parameter governing qPCR reliability is the relative cycling efficiency of the 
target and reference primers, therefore a calibration curve was generated for each 
primer pair. The amplification efficiency was calculated using the equation e = 10-1/slope, 
where 1.8 ≤ e ≤ 2.2 represents acceptable limits (Schmittgen and Livak, 2008). The data 
illustrate that BCAT1 displays a cycling efficiency of 110% (Figure 4.11 panel A. e= 2.21, 
r2= 0.99) compared to 100% for β2M (Figure 4.11 panel B, e=2.0, r2= 0.99). Expression 
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fold change was calculated using the 2
-ΔΔCp 
method (Section 2.21), where BCAT1 
expression is normalised to β2M and compared between U937 non-transduced controls 
and respective transgenic U937 cells. The data show that mean expression increased 
5.57±0.76 fold for BCAT1(WT) and 5.93±1.52  fold for BCAT1(C338S) which was 
significantly higher than the Empty Vector control, which increased modestly by 
0.79±0.48  fold (Figure 4.13 n=3, One-way ANOVA p<0.05). BCAT1(C335/8S) displayed a 
fold change of 8.75±4.19, the highest average increase, although this increase was not 




Representative qPCR amplification curves for fold expression change show where 
Cp threshold (horizontal red line) is breached at Cp=21 for U937-BCAT1(WT) (Dark Blue) 
vs Cp= 24 for U937 non-transduced controls (Blue) (Figure 4.12, panel A). Given β2M 
reference genes (Orange/Yellow) are relatively stable for both U937 non-transduced 
controls and U937-BCAT1(WT), this represents approximately an 8x fold increase in 
relative BCAT1 expression. The data also show template controls (Purple), which display 





non-specific amplification of BCAT1 primers after 27 cycles, denoting the detection limits 
of the assay at 63°C annealing temperature. Melt curve analysis reveals two distinct PCR 
products representing BCAT1 (Blue) and β2M (Orange) and non-specific PCR product 


















Figure 4.8 Analysis of RNA integrity extracted from U937 cell. A)  Densitometric analysis 
of RNA agarose gels. Total RNA was extracted from transgenic and non-transgenic U937 
cells using the isolate II RNA extraction kit (Bioline). Bands represent ribosomal subunits 
28S and 18S. A 28S:18S rRNA ratio ≥2 indicates intact RNA suitable for downstream 
analysis(Full RNA analysis see Appendix B). Representative graphical presentation of 
band intensity displays desired 2:1 ratio. B) Representative agarose gel from RNA 
extracted from each transgenic U937 cell line. Gel loading is as follows: 
Lane 1. 1ul 1kb plus DNA ladder Lane 2-4. 100ng U937-EV RNA Lane 5-7. U937-
BCAT1(WT) RNA Lane 8-10 100ng U937-BCAT1(C338S) RNA Lane 11-13. 100ng U937-
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Figure 4.9  qPCR primer pair optimisation.  A) Sequence alignment of qPCR primers vs 
BCAT1 transcript variant 5 (NM_01178094) and β2M templates. qPCR Primers pairs 
BCAT1-F/R and β2M -F/R PCR product was verified in silico using the NCBI primer-BLAST 
tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast). Predicted product lengths of 90 
and 101 base pairs respectively confirmed suitable target sequences. Predicted 
dimerisation of BCAT1 primers. B) BLAST alignment predicted two possible dimer 
formations therefore a gradient PCR to optimise annealing temperatures and eliminate 
non-specific amplification was performed. BCAT1 and β2M primer sequences were 




1 dimer for: BCAT1R 
          5-gcacaattgtccagtcgctc-> 




Cross Primer Dimers: 
 
BCAT1F with BCAT1R 
BCAT1F 
         5-tggagaatggtcctaagctg-> 
         |||| ||| || | 
<-ctcgctgacctgttaacacg-5 
>NM_005504.7 Homo sapiens branched chain amino acid transaminase 1 (BCAT1), transcript variant 1, mRNA 
 
product length = 90 
Forward primer  1     TGGAGAATGGTCCTAAGCTG  20 
Template        1233  ....................  1252 
 
Reverse primer  1     GCACAATTGTCCAGTCGCTC  20 
Template        1322  ....................  1303 
 
>XM_017019768.2 PREDICTED: Homo sapiens branched chain amino acid transaminase 1 (BCAT1), transcript variant X2, 
mRNA 
 
product length = 90 
Forward primer  1     TGGAGAATGGTCCTAAGCTG  20 
Template        4011  ....................  4030 
 
Reverse primer  1     GCACAATTGTCCAGTCGCTC  20 
Template        4100  ....................  4081 
 
>NM_001178094.1 Homo sapiens branched chain amino acid transaminase 1 (BCAT1), transcript variant 5, mRNA 
 
product length = 90 
Forward primer  1     TGGAGAATGGTCCTAAGCTG  20 
Template        1484  ....................  1503 
 
Reverse primer  1     GCACAATTGTCCAGTCGCTC  20 
Template        1573  ....................  1554 
 
>NM_001178093.1 Homo sapiens branched chain amino acid transaminase 1 (BCAT1), transcript variant 4, mRNA 
 
product length = 90 
Forward primer  1     TGGAGAATGGTCCTAAGCTG  20 
Template        1187  ....................  1206 
 
Reverse primer  1     GCACAATTGTCCAGTCGCTC  20 
Template        1276  ....................  1257 
 
>NM_001178092.1 Homo sapiens branched chain amino acid transaminase 1 (BCAT1), transcript variant 3, mRNA 
 
product length = 90 
Forward primer  1     TGGAGAATGGTCCTAAGCTG  20 
Template        1408  ....................  1427 
 
Reverse primer  1     GCACAATTGTCCAGTCGCTC  20 
Template        1497  ....................  1478 
 
>NM_001178091.1 Homo s piens branched chain amino acid transaminase 1 (BCAT1), transcript variant 2, mRNA 
 
product length = 90 
Forward primer  1     TGGAGAATGGTCCTAAGCTG  20 
Template        1480  ....................  1499 
 
Reverse primer  1     GCACAATTGTCCAGTCGCTC  20 
Template        1569  ....................  1550 
Self-Dimers: 
 
1 dimer for: BCAT1R 
          5-gcacaattgtccagtcgctc-> 




Cross Primer Dimers: 
 
BCAT1F with BCAT1R 
BCAT1F 
         5-tggagaatggtcctaagctg-> 




>NM_004048.4 Homo sapiens beta-2-microglobulin (B2M), mRNA 
 
product length = 101 
Forward primer  1    ATGAGTATGCCTGCCGTGTG  20 
Template        317  ....................  336 
 
Reverse primer  1    GGCATCTTCAAACCTCCATG  20 





Figure 4.10 Optimisation of qPCR cycling parameters. Representative DNA agarose gel 
of gradient PCR products. Optimal annealing temperatures of qPCR primer pairs were 
determined by gradient PCR with no template to examine non-specific interactions e.g. 
primer dimers. PCR products were electrophoresed on a 1% agarose gel for 1 h. The 
minimum annealing temperature that produced ‘no’ non-specific product was selected 
for later qPCR runs. A) BCAT1-F and BCAT1-R primers. B) β2M -F and β2M -R. Loading for 
both gels is as follows: Lane 1: 1kb Ladder. Lane 2: 57°C Lane 3: 59°C Lane 4: 61°C Lane 







Figure 4.11 Calibration curves of BCAT1 and β2M primers. PCR amplification efficiency 
of the A) BCAT1 target gene and B) β2M reference gene was determined by generation 
of calibration curves. Following cDNA synthesis, a 10-fold serial dilution was performed 
and used as template for each data-point. Log cDNA concentration was plotted against 
the Crossing Point (Cp) value. Melt curve analysis confirmed target specific amplification 
(See appendices). Cycling efficiency was determined using the equation E = 10 
(-1/m)
 
where E =  efficiency, m = the slope of the standard curve. Data represents mean (n=2). 
Linear regression analysis was used to determine R2 and gradient. 
 
BCAT1 Standard curve  
Gradient = -2.909 
Error= ± 0.0907 
Efficiency =2.211 
R² = 0.9971 











β2M Standard curve  
Gradient = -3.342 
Error= ± 0.05311 
Efficiency =2.004 
R² = 0.9977 















Figure 4.12 qPCR amplification curves and melt-curve analysis. A) Representative qPCR 
assay plot displaying comparative amplification of BCAT1 target genes in U937 non-
transduced control cells and U937-BCAT1(WT) overexpressing cells. Lines represent 
increasing fluorescence intensity U937 non-transduced (Blue), U937-BCAT1(WT) (Dark 
Blue), β2M reference genes (Orange/Yellow), Crossing-point fluorescence threshold 
(horizontal red line). No template controls (Purple) display non-specific amplification of 
BCAT1 primers after 27 cycles denoting the detection limit of the assay. B) Melt-curve 
analysis reveals two distinct PCR products representing BCAT1 and β2M and non-specific 

















Figure 4.13 Fold expression change of BCAT1(WT) and CXXC motif mutants in 
transgenic U937 cells Fold expression change of transgenic cells compared to U937 
transgenic EV control was quantified using relative quantification qPCR. Expression of 
BCAT1 was calibrated against the reference gene Beta-2 Microglobulin (β2M). Melt curve 
analysis confirmed amplification of two distinct products (Figure 4.12).  Fold change was 
calculated using the 2
-ΔΔCp 
method (Data are mean ± SD and analysed by one-way ANOVA 
































































4.3.6 Western blot detection of BCAT1 in U937 
 To ensure transcript overexpression translates to protein level, evaluation of 
BCAT1 transgenic protein from whole cell lysate was assessed by western blot analysis 
utilising the Anti-DDK (FLAG)-HRP mAb (OriGene). In order to define optimal detection 
parameters increasing loads of whole cell lysate from U937-BCAT1(WT) cells was 
incubated with different concentrations of Anti-DDK (FLAG) mAB (Origene clone OTI4C5) 
BCAT1 transgenic protein was detected in the range 1:1000 – 1:4000 therefore 
concentration of 1:2000 was selected for future experiments which concurred with the 
manufacturer’s instructions (Figure 4.14). Following protein quantification by BCA assay, 
30µg of whole cell lysate was loaded for each sample and separated by SDS-PAGE (Figure 
4.15 Panel A). Presence of a 43kDa band signifies expression of transgenic Myc-DDK 
tagged BCAT1 protein in U937. BCAT1(WT) and BCAT1(C338S) was detected whilst no 







Figure 4. 14 Anti-Myc/DDK (FLAG) mAb titration by Western Blot analysis. In order to 
define optimal detection parameters, increasing loads of whole cell lysate from U937-
BCAT1(WT) cells was incubated with different concentrations (A = 1:1000, B = 1:2000, C 
= 1:4000 and D = 1:10 000) of Anti-Myc/DDK (FLAG) mAB. Blots were loaded as follows: 
Lane 1: 5μl Full Range Rainbow Marker (Amersham) Lane 2: 30µg whole cell lysate, Lane 
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A) 1 : 1000 
C) 1 : 4000 
B) 1 : 2000 




Figure 4.15 Protein expression validation of BCAT1(WT) and respective CXXC motif 
mutants in transgenic U937 cells SDS-PAGE and western blot analysis of U937 wild-type 
and transgenic cells. A) SDS-PAGE gel displays uniform equal sample loading prior to 
blotting. B) Detection of transgenic Myc/DDK tagged BCAT1 from whole cell lysate was 
by the BCAT1 Anti-Myc/DDK (FLAG) mAb. SDS-PAGE gels and Western blots were loaded 
as follows:  Lane 1. 5ul Rainbow Ladder Lane 2. 30 µg U937 non-transgenic whole cell 
lysate Lane 3. 30 µg U937(EV) whole cell lysate Lane 4. 30 µg U937-BCAT1(WT) whole 
cell lysate Lane 5. 30 µg U937- BCAT1(C338S) whole cell lysate Lane 6. 30 µg U937-
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The aim of this section was to generate a panel of transgenic AML cells that stably 
overexpress  Control(EV), BCAT1(WT), BCAT1(C338S) and BCAT1(C338S) for subsequent 
in vitro characterisation (Chapter 5). Immortalised human cell line gene expression 
profiles reflect their underlying genetic abnormalities and correlate with cytogenetically 
analogous primary cell signatures, demonstrating them to be robust models for studying 
leukaemia (Andersson et al., 2005; Rücker et al., 2006). Since AML is characterised as a 
block in myeloid cell differentiation, the immortalised myeloid leukaemia cell lines, 
U937, HL-60, K562 and THP1, have all been successfully used to study differentiation of 
immature myeloid cells in vitro (Birnie, 1988; Park et al., 2007; Yamamoto et al., 2009; 
Huang et al., 2014). Therefore, these cell lines are the ideal model to study the effect of 
BCAT1(WT) and BCAT1 CXXC motif mutant overexpression in AML. Despite all these cell 
lines being myeloid in origin, significant variation in morphology, growth and expression 
profiles exist between cell lines, which must be considered when planning in vitro 
studies.  
Expression of BCAT1 mRNA transcript levels in the afore mentioned cell lines was 
examined using expression data provided by ‘The Human Protein Atlas’ 
(http://www.proteinatlas.org). Here it was theorised that the best cell model to 
examine the effect of BCAT1(WT) and respective CXXC motif mutant overexpression 
would a cell line with a relatively low native BCAT1 expression, and therefore the highest 
expression delta post over-expression. Therefore,  U937 was selected as the model cell 




Infectious Lentiviral particles containing the pLenti-EV control, pLenti-
BCAT1(WT), pLenti-BCAT1(C338S) and BCAT1(C335/8S), were subsequently generated 
in the HEK293T viral packaging cells using Origene’s third generation Lenti-vpak 
packaging system (Origene ref: TR30022). Successful production of the virus in HEK293T 
cells was confirmed by physical titration utilising an ELISA which targeted viral coat 
protein p24 and quantified viral concentration by comparison against a known standard 
(Figure 4.6). However, physical viral titre i.e. the number of viral particles/mL, is notably 
different from functional viral titre which is quantified in Transducing Units (TU) and is 
the number of viral particles required to successfully transduce 1 cell (Klasse, 2015). 
Functional titre across various cell lines has been calculated using vector encoded 
reporter genes, for example green fluorescent protein (GFP) reporters are used to titrate 
viral concentration against the number of successfully transduced cells by flow 
cytometry. Using these methods the transduction efficiency of Lentiviral systems has 
been estimated to be 100-1000 fold lower than the physical titre (Kutner, Zhang and 
Reiser, 2009; Merten, Hebben and Bovolenta, 2016). Myeloid cells are relatively 
refractory to HIV-1 based Lentiviral infection due to myeloid-specific hydrolase SAMHD1 
that that blocks reverse transcription of viral RNA (Hrecka et al., 2011). Consequently 
Multiplicity of Infection (MOI) ratios required for the successful transduction of U937 
cells are in the range of 80-100 (Recommended lentivirus MOI for common cell lines, 
Origene). 
Given the refractory nature of myeloid U937 cells, a functional titre yield was 
calculated here by dividing physical yield by 1000, thus producing an estimated 
functional yield which ranged from 1.25 - 1.71x105  TU/mL across all pLenti vectors 
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(Table 4.1). This figure was comparable to the initial yield reported of HIV-1 based 
systems which ranged from 1x105-7 TU/mL (Dull et al., 1998). In order to reach the 
recommended MOI of 80-100 for infection of refractory myeloid cells, a common step 
is to concentrate the viral suspension by ultracentrifugation at 80 000 x g increasing viral 
concentration 80-300 fold (Kutner, Zhang and Reiser, 2009). In place of this, centrifugal 
infection or ‘spinoculation’ where the initial transduction reaction is performed at up to 
1200 x g was performed here. This technique has been reported to increase viral 
transduction efficiency up to 40 fold, however other studies have reported more modest 
increases in efficiency (Tenser and Dunstan, 1980; O’Doherty, Swiggard and Malim, 
2000).  
Thus, using the ‘spinoculation’ method U937 cells were successfully transduced 
with Lentivirus containingpLenti-BCAT1 and CXXC motif constructs. Successful 
transduction, where integration into the host genome and constitutive expression of 
CMV regulated genes, was confirmed by puromycin resistance for each transgenic U937 
cell line (Figure 4.7). However, the number of Lentiviral integration events can vary in a 
dose dependant manner, resulting in different degrees of expression (Charrier et al., 
2011), therefore the level of BCAT1 mRNA by qPCR was assessed. Fold changes in BCAT1 
transcript were significantly higher when compared with U937 non-transduced controls 
for BCAT1(WT) (5.57±0.76 fold) and BCAT1(C338S) (5.93±1.52 fold) whilst 
BCAT1(C335/8S) showed higher (8.75±4.19 fold), with slight increase for pLenti-
Control(EV) (0.79±0.48 fold), which did not reach significance (Figure 4.13 and Table 
4.2).   
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 Gene expression under control of the Cytomegalovirus (CMV) promotor is widely 
used for ectopic gene overexpression, due to the relatively strong expression compared 
to other commonly used promotors (Xia et al., 2006; Qin et al., 2010). For example, CMV 
promotors were found to enhance expression 2-4 fold higher over Murine Leukaemia 
Virus (MLV) and 3-4 fold higher over Rous Sarcoma Virus long terminal repeat (RSV-LTR) 
(Pasleau et al., 1985; Martin-Gallardo et al., 1988). However, analysis of GFP reporter 
under CMV promotor control has shown that whilst CMV driven expression compares 
favourably to contemporary alternatives, such as the simian vacuolating virus 40 (SV-40) 
promotor, expression varies significantly depending on the gene and cell type (Qin et al., 
2010). A comparable study that used the CMV promotor driven vector and a lentiviral 
delivery system to overexpress the target genes in U937 reported a 5-10 fold increase 
in expression measured by qPCR (Kang et al., 2014). These data reflect the fold-change 
gene expression of BCAT1 as presented here (Table 4.2). 
To confirm translation of BCAT1 mRNA into protein, Western blot analysis was 
performed.  These data revealed comparable levels of BCAT1(WT) and BCAT1(C338S) 
protein, reflecting the qPCR transcript expression data (Figure 4.16). However, 
BCAT1(C335/8S) expression was barely detectable and does not correlate with the qPCR 
data, which indicated relatively high yet variable expression of BCAT1(C335/8S) mRNA. 
Taken together, this may indicate that mutating both C335 and C338 residues results in 
post-transcriptional degradation by ribonucleases or post-translation degradation.  The 
former explanation is previously demonstrated, where elimination of mRNA molecules 
by ribonucleases that are deemed ‘non-functional’ because they lack specific sequences, 
is demonstrated to play a role of transcriptional quality control (Sokhi et al., 2013; 
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Chanfreau, 2017). In relation to the BCAT1(335/8S) transcript, is it possible that RNA 
interference by microRNAs or small interfering RNAs directed to the CXXC motif may, 
result in post-transcriptional silencing, which accounts for the more variable transcript 
expression of BCAT1(C335/8S) observed here (Dana et al., 2017; O’Brien et al., 2018). 
Alternatively, substitution of the N-terminal C335 residue of the CXXC motif which is S-
glutathionylated at ≥ -280mV protecting the cysteine thiol from over oxidation and 
subsequent degradation, may have increased post-translation proteolysis (Grek et al., 
2013; Zhang et al., 2018). Taken together, these combined theories potentially explain 
the variation in BCAT1(C335/8S) mRNA and lack of protein expression in the transgenic 
U937 cell model. 
In summary, this chapter has demonstrated successful transduction and stable 
overexpression BCAT1(WT) and CXXC motif mutant BCAT1(C338S) at the transcript and 
protein level in the immortalised monocytic cell line U937. Degradation of 
BCAT1(C335/8S) either the transcript or protein level in U937 makes it unsuitable for 
examining the effect of abolishing the antioxidant capacity of the CXXC motif. 
Conversely the comparable expression levels BCAT1(WT) and BCAT1(C338S) detailed 
here and the comparable enzyme kinetics detailed in chapter 3 makes the transgenic 
U937- BCAT1(WT) and U937- BCAT1(C338S) a suitable model to evaluate the CXXC motif 





Chapter 5: The antioxidant role of the BCAT1-CXXC 
motif in oxidative stress induced differentiation 
and apoptosis in U937 
5.1 Introduction 
The metabolic role of BCAT1 in the cellular pathophysiology of cancer has been 
the subject of increasing interest in recent years and has been studied in various cancer 
models including AML (Zheng et al., 2016; Raffel et al., 2017; Thewes et al., 2017; Xu et 
al., 2018). BCAT1 catalyses the reversible deamination of Branched Chain Amino Acids 
(BCAA) Leucine, Isoleucine and Valine by transfer of an α-amino group to α-
Ketoglutarate (α-KG) resulting in the production of Glutamate and Branched Chain Keto 
acids (BCKA). (Jamshid Davoodi et al., 1998) BCKA are decarboxylated through the 
branched chain keto acid dehydrogenase complex (BCKADH) to Acetyl-CoA, which 
replenishes the Citric Acid Cycle (TCA) to produce ATP, however, where there is a build-
up of BCKA, BCAT1 will favour the reverse reaction, generating BCAA and α-KG.  
Through modulation of these key metabolites, BCAT1 has been demonstrated to 
exert diverse effects on key processes including proliferation, differentiation and 
epigenetic remodelling. For example in blast crisis CML (BC-CML), blocking BCAT1 
expression or enzymatic activity induced cellular differentiation and impaired 
propagation in vitro and in vivo( Hattori et al., 2017). In this model, BCAT1 drives 
leukaemia development through expression by increasing the intracellular pool of 
leucine, activating the mammalian target of rapamycin complex 1 (mTORC1), a key 
signalling complex that integrates upstream nutrient availability to downstream changes 
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in cell growth and survival (Laplante and Sabatini, 2009). Conversely in a published AML 
model, BCAT1 expression has been demonstrated to increase BCAA catabolism by 
restricting α-KG, leading to a DNA hypermethylation signature which is similar to IDH 
mutant cells, that produce the D-2-hydroxyglutarate (D-2-HG) oncometabolite, which is 
a competitive inhibitor of α-KG (Raffel, et al., 2017). In another study this phenotype 
was associated with increased resistance to Reactive Oxygen Species (ROS) inducing 
Tyrosine Kinase Inhibitor therapy by BCAT1 mediated glutamate production, a precursor 
for the production major small molecule antioxidant GSH (Wang et al., 2019). Whist the 
metabolic effects of BCAT1 have received significant attention the antioxidant potential 
of BCAT1 CXXC motif has not been explored. 
 BCAT1 and the mitochondrial isoform BCAT2 both feature a conserved CXXC 
motif, which is characterised by two cysteine amino acids (C) separated by two other 
amino acids (X) located 10 angstroms from the active site. The metabolic activity of 
BCAT2 can be modulated by oxidation of CXXC motif cysteine thiol (-SH) groups, which 
form an intramolecular disulphide bond resulting in a conformational change that 
inactivates the enzyme (Myra E Conway, Poole and Hutson, 2004). Using the Nernst 
equation, Coles et al calculated the redox midpoint potential (Em), that is the 
intracellular redox potential (Eh) at which the ratio of reduced/oxidised CXXC motif 
cysteines is equal to 1, was 80mV lower for BCAT1 CXXC motif compared to BCAT2 
(Coles, Hancock and Conway, 2012). This demonstrated that the BCAT1 CXXC motif is 
more sensitive to oxidation or put another way it is more antioxidant (reductive) in 
nature than BCAT2.  
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Whilst oxidation of the BCAT2 CXXC motif results in enzymatic inactivation, 
oxidation of BCAT1 results in S-glutathionylation of the CXXC cysteine thiol groups, 
preventing disulphide bond formation and protecting the enzyme from inactivation 
(Conway et al., 2008). Moreover, S-glutathionylation of BCAT1 links it to a wider 
antioxidant network, and importantly, deglutathionylation of BCAT1 using the 
GSH/glutaredoxin system suggests it may play an important role in cellular redox 
regulation. Interestingly, both BCAT1 and BCAT2 are reported to have equivalent 
sensitivities to reactive nitrogen species (RNS), suggesting that the decreased sensitivity 
of BCAT1 to ROS may be due to a putative oxidoreductase-like activity, similar to the 
human Glutaredoxin (Grx) and Thioredoxin enzymes (Rex) (Coles et al., 2009, Coles et 
al., 2012). 
Redox systems such as the Grx and Trx systems are often dysregulated in 
malignant disease, which leads to defective control of redox homeostasis and 
consequent oxidative stress (Hanschmann et al., 2013). Elevated ROS production 
promotes cellular growth through ROS regulated signalling pathways, however an 
excess of ROS can induce cellular differentiation and ultimately cell death as levels 
increase (Hole et al., 2013; Lam et al., 2018). In response to ROS, AML cells upregulate 
antioxidant enzymes such as Trx, which facilitate the reduction of other proteins by 
cysteine thiol-disulphide exchange, where interestingly the Trx oxidoreductase capacity 
is derived from its CXXC motif (Arnér and Holmgren, 2000; Collet and Messens, 2010; 
Kamal et al., 2016). Trx expression is thus correlated with higher ROS production, which 
relates to poorer patient prognosis in AML (Chen et al 2010). Moreover, inhibition of Trx 
increases AML cell sensitivity to the pro-oxidant Arsenic Trioxide (ATO), suggesting Trx 
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is protecting AML cells from ROS induced cell death (Jiang et al 2014). Whilst canonical 
antioxidants such as the Grx and Trx have been extensively studied, how the CXXC motif 
of BCAT1 affects the redox state of the cancer cell and how this impacts redox regulated 
















5.2 Aims & Objectives 
The aim of this chapter was to investigate the putative antioxidant effect of the 
BCAT1 CXXC motif on redox environment of the cell and how this affects redox mediated 
processes critical to the development of AML including, proliferation, apoptosis and 
















5.2.1 Objectives    
• In vitro growth characterisation of U937-(EV), U937-BCAT1(WT) and U937-
BCAT1(C338S) cell lines. At each phase of growth (exponential/stationary/death) cell 
density and viability will be assessed by flow cytometric analysis. Concurrently the 
effect of the CXXC motif on redox environment of the cell will be analysed by 
comparison of intracellular ROS, redox potential (Eh), mitochondrial membrane 
potential (ψm) and GSH content in each cell line.  
 
• Evaluate the capacity BCAT1 CXXC motif to ameliorate ROS induced apoptosis. 
U937-Control(EV), U937-BCAT1(WT) and U937-BCAT1(C338S) cell lines will be placed 
under serum starvation conditions inducing mitochondrially derived oxidative stress. 
Cellular survival will be monitored by flow cytometric analysis following 7AAD/Annexin 
V. Cellular ROS will be measured by 2’,7’ –dichlorofluorescin diacetate (DCFDA) 
staining.  
 
• Evaluate the capacity BCAT1 CXXC motif to resist ROS induced differentiation. 
U937-Control(EV), U937-BCAT1(WT) and U937-BCAT1(C338S) cell lines will be induced 
to differentiate from monocyte to macrophage’s using PMA. Following addition of 
PMA intracellular ROS will be measured by DCFDA staining. The level of cellular 
differentiation in each cell line will be compared by flow cytometric assessment of 




5.3 Methods  
5.3.1 Characterisation of BCAT1(WT) and CXXC Motif Mutant Transgenic Cells. 
U937-Control(EV), U937-BCAT1(WT) and U937-BCAT1(C338S) transduced cells 
were cultured in T75 flasks seeded at 2x105 cells/mL in a total volume 10 mL and 
maintained at 37 oC and 5% CO2 in complete RPMI-1640 for a total of 192 h. 100µL 
samples were taken at t=0 and at 24 h intervals from 0-96h and from 168-192 h. The 
number of viable/non-viable cells was determined by flow cytometry using Viacount 
staining as described in section 2.19. For each sample a minimum of 3x103 events were 
captured and cell viability and density were determined using the Easyfit algorithm 
(EasyCyte Software, Merck-Millipore). 
Cellular proliferation during exponential phase was calculated using the 
equation: doubling time  =   (t1-t2)* log(2)  /  (log(n1) -log(n2). Doubling time describes 
the time taken for cell number(n) to increase by a factor of two (2n) where t1= initial 
time point, t2=final time point and n1 = initial cell concentration and n2=final cell 
concentration (Roth, 2006 http://www.doubling-time.com/compute.php).Cell cycle 
analysis was performed for each transgenic cell line by Propidium Iodide (PI) staining as 
outlined in section 2.26. To evaluate intracellular ROS for each transgenic U937 cell line, 
DCFDA analysis was performed as described in section 2.27, following various 
treatments, including, serum starvation (section 2.30), Rotenone (section 2.31) and PMA 
induced differentiation (section 2.32). To monitor mitochondrial ROS levels following 
treatment, DiOC2(3) assays were performed as outlined in section 2.31. Measurements 
of cellular ‘reduced’ to ‘oxidised’ glutathione levels (GSH/GSSG) were performed for 
each cell line following treatment as described in section 2.29. 
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5.3.2. Evaluation of the BCAT1 CXXC Motif in Myeloid Differentiation 
To evaluate the effect of the BCAT1 CXXC motif on ROS mediated cellular 
processes, such as cellular differentiation, 1x106 cells/mL of each transgenic cell line was 
suspended in 0.5 mL complete RPMI ± 1 to 10 ng/mL PMA and incubated for 72 h as 
described in section 2.32. To control for the contribution of cellular ROS in 
differentiation, 10 mM N-acetyl-L-cysteine (NAC) was added prior to incubation. Cellular 
differentiation was monitored for each transgenic U937 cell line over the 72 h period 
though expression of the myeloid markers CD11b and CD36 by flow cytometry (section 
2.32 for flow cytometry gating strategy). CD11b+ and CD36+ positive cells were evaluated 




5.4 Results   
5.4.1 Growth characterisation: Cell growth and density     
To investigate the effect of the BCAT1 CXXC motif on the redox environment of 
the cell and how this impacts redox mediated processes critical to AML development 
including proliferation, apoptosis, and differentiation cell lines were initially 
characterised by in vitro flask cultures. U937-Control(EV), U937-BCAT1(WT) and U937-
BCAT1(C338S) transgenic cells were cultured in T75 flasks seeded at 2x105 cells/mL in a 
total volume 10 mL and incubated in a cell culture incubator (37c 5% CO2) for a total of 
192 h. The data presented show that U937-BCAT(WT) and U937-BCAT1(C338S) reached 
significantly higher peak viable cell density at the end of the exponential growth phase 
(t=96h) compared to U937-(EV) control cells (Figure 5.1, p<0.001). U937-BCAT(WT) cells 
plateaued at 1.57x106 ± 8.53x104 cells/mL compared to 1.51x106 ± 8.16x104 cells/mL for 
U937-BCAT1(C338S), and 1.01x106 ± 7.71x104 cells/mL for U937-Control(EV), equating 
to a relative increase in cell density of 155 % for BCAT1(WT) and 150 % for BCAT1(C338S) 
compared to the control (Figure 5.1, panel A).  Analysis of cell proliferation over the 
exponential phase (t=24-72), revealed that both BCAT1 overexpressing U937 transgenic 
cell lines had significantly reduced doubling times compared to the control(p<0.001, 
Figure 5.1, panel B). The data presented show that the doubling time for U937-
BCAT1(WT) was 25.6±0.7 h compared to 27.4±0.6 h for U937-BCAT1(C338S) and 






Figure 5.1 Growth profile of BCAT1 overexpressing and control U937 cells in culture.  
A) T75 flasks were seeded with 2x10
6
 BCAT1(WT), BCAT1(C338S) and Control(EV) U937 
cells and cultured in 10mL of complete RPMI-1640. Viable cell counts were measured at 
0h and after 24h, 48h,72h ,96h, 168h and 192h. B) Doubling time was calculated 
between 24-72h. Data presented are mean± SEM (n=5). Data analysed by one/two-way 







5.4.2 Growth characterisation: Cell cycle  analysis   
Analysis of DNA content at mid exponential phase (t=48), using PI staining shows 
that, both U937-BCAT1(WT) and U937-BCAT1(C338S) display a significantly higher 
proportion of cells in G2M phase 23.19±1.4 % and 23.72±1.2 % respectively, compared 










Figure 5.2 Effect of BCAT1(WT) and BCAT1(C338S) overexpression on cell cycle in U937 
cells. A) Stacked bar chart displaying percentage of cells in G, S and G2M for U937 cell 
lines, proportion of G2M phase cells is significantly different between  BCAT1(WT) and 
U947-BCAT1(C338S) compared to U937-Control(EV). B) Flow cytometry histograms 
displaying representative cell cycle data. U937-BCAT1(WT) (Dotted lines, no fill) and 
U937-BCAT1(C338S) (Dotted lines, red fill) cells display visibly higher proportion of 
dividing G2M cells represented by the 4n peak compared to the U937-Control(EV) 
(Dashed lines, green fill). Data presented are mean values (n=4) and analysed by One-






5.4.3 Growth characterisation: Cell viability  
To examine the effect of the BCAT1 CXXC motif on apoptosis in culture, the 
percentage of viable cells was measured by Viacount staining. Cell viability varied 
significantly between respective U937 transgenic cell lines from the late exponential 
phase (t=72) through to death phase (t=168/192). The data reveal that U937-BCAT1(WT) 
cells display consistently higher viability compared to U937-Control(EV) from t=72 
onwards (Figure 5.3). U937-BCAT1(WT) cells were also significantly more viable 
(69.1±5.5%) compared to U937-BCAT1(C338S) (57.4.42±4.8%, p<0.001) and U937-
Contolr(EV) (32.6±3.17%, p<0.001) at t=192 (Figure 5.3). 
 
 






Figure 5.3 Viability profile of BCAT1 overexpressing and control U937 cells.  A) T75 
flasks were seeded with 2x10
6
 cells and cultured in 10mL of complete RPMI. The 
percentage of viable cells was measured at 0h and after 24h, 48h, 72h, 96h, 168h and 
192h. B) Bar chart displaying cellular viability in culture after 192h. U9937-BCAT1(WT) 
displays a significantly higher proportion of viable cells compared to U937-BCAT1(C338S) 
and U937-Control(EV) cells. Data presented are mean ± SEM (n=4) Data analysed by 






5.4.4 Growth characterisation: Intracellular redox environment  
The effect of the BCAT1 CXXC motif on the intracellular redox environment of 
the cell was evaluated at mid-exponential (t=48), stationary (t=96) and death phase 
(t=168). Mitochondrial membrane potential (ψm) was measured by staining with 
DiOC2(3) as previously described.  A higher ψm is associated with increased 
mitochondrial ROS leakage, and therefore may impact the cellular redox environment 
(Suski et al., 2012). Interestingly, the data show that ψm was consistently higher in 
U937-BCAT1(WT) and U937-BCAT1(C338S) cell lines compared to the U937-Control(EV) 
across all time points (Figure 5.4), although these data did not reach statistical 
significance. Next, intracellular ROS was measured using the DCFDA probe, where both 
U937-BCAT1(WT) and U937-BCAT1(C338S) displayed significantly decreased 
intracellular ROS compared to the U937-Control(EV) cells at t=96 and t=168 (Figure 5.5, 
p<0.001 & p< 0.01 respectively). Moreover, these data correspond with intracellular 
redox potential (Eh), as measured calculating GSH/GSSG, which was significantly lower 
in U937-BCAT1(WT) and U937-BCAT1(C338S) cells compared to U937-Control(EV) at 
t=96 and t=168 (Figure 5.6, Panel B). The data show that total glutathione (GSH) content 
was also significantly increased in both BCAT1 overexpressing U937 transgenic cell lines 





Figure 5.4 Effect of BCAT1(WT) and BCAT1(C338S) overexpression on mitochondrial 
membrane potential (ΔΨm). T75 flask culture samples were removed at exponential 
(48h), stationary (96h) and death phase (168h) and stained with DiOC2(3). A) 
Representative FSC vs SSC flow cytometric profile of DiOC2(3) treated U937 cells. B) 
Representative Green/Blue(FL1) vs Red/Blue(FL3) bivariate analysis gated on R1 after 
96h. C) Bar chart displaying ΔΨm (red/green MFI) of U937 cells. U937-BCAT1(WT) [blue] 
and U937-BCAT1(C338S) [red] display consistently increased ΔΨm across all time points 
compared to U937-Control(EV) cells [green]. Data presented as mean±SEM (n=3). Data 





































Figure 5.5 Effect of BCAT1(WT) and BCAT1(C338S) overexpression on Reactive Oxygen 
Species (ROS). A) Representative FSC vs SSC flow cytometric profile of DCFDA treated 
U937 cells. B) Representative green/blue(FL1) histograms gated on R1 after at 
exponential (48h), stationary (96h)  and exponential (168h) showing U937-Control(EV) 
BCAT1(WT) [blue] and U937-BCAT1(C338S) cells.  C) Bar chart displaying mean DCF signal 
(green/blue MFI ) that equates to intracellular ROS levels. U937-BCAT1(WT) [blue] and 
U937-BCAT1(C338S) [red] display significantly decreased intracellular ROS at 96h and 
168h compared to U937-Control(EV) cells [green]. Data presented as mean ± SEM (n=4) 











Figure 5.6 Effect of BCAT1(WT) and BCAT1(C338S) overexpression on intracellular 
glutathione and redox potential. A) Bar chart displaying total intracellular glutathione 
(GSH) content of viable cells. U937-BCAT1(WT) [blue], U937-BCAT1(C338S) [red] and 
U937-Control(EV) cells [green] measured at 48h, 96h and 168h. B) Bar chart displaying 
redox potential (Eh) of viable cells. Eh calculated from the Nernst equation using the ratio 
reduced/oxidised glutathione (GSH/GSSG). U937-BCAT1(WT) [blue], BCAT1(C338S) [red], 
and U937-Control(EV) [green]. were measured at 48h. 96h and 168h. Data presented as 
mean ± SEM (n=3) and analysed by two-way ANOVA with Bonferroni post-hoc test 







5.4.5 The Antioxidant Effect of the CXXC Motif on Serum Starved Transgenic U937 cells 
In order to observe the potential antioxidant effect of the CXXC motif, each 
respective transgenic cell line was placed under an endogenous oxidative stress elicited 
by serum starvation (Scherz-Shouval et al., 2007; Lee et al., 2010). Cells were placed in 
complete RPMI ±10% FCS and ± 10mM NAC for 72h, and intracellular ROS levels were 
measured by DCFDA staining and flow cytometry. The data show that serum starvation 
resulted in increased the DCFDA signal across all cells lines, however U937-BCAT(WT) 
cells displayed a significantly lower overall DCFDA signal (1532±50 MFI) overall, 
compared to either U937-BCAT1(C338S)(2553±93 MFI) or U937-Control(EV) cells 
(3589±154) (Figure 5.7, p<0.001). Importantly, this effect was abrogated by the addition 
of 10mM of the antioxidant NAC, which significantly reduced DCFDA to ‘normal’ level 
signals and eliminated the observed differences between cell lines (Figure 5.7). 
Next the effect of serum starvation on cell viability and apoptosis was measured 
by 7AAD/Annexin-V analysis. The data in Figure 5.8 and Table 5.1 illustrate that serum 
starvation significantly increases the percentage of non-viable cells (7AAD+ve) across all 
transgenic U937 cell lines, however U937-BCAT1(WT) cells display a substantially lower 
proportion of 7AAD+ve cells (22.9±2.5%) compared to either U937-BCAT1(C338S) 
(38.3±2.7%, p<0.01) or U937-Control(EV) cells (74.6±1.2%, p<0.001). Representative 
flow cytometric plots of this data show U937-BCAT1(WT) display a higher proportion of 
viable cells (lower left quadrant), with correspondingly lower levels of apoptotic (upper 
left quadrant) and dead cells (upper right quadrant) compared to U937-BCAT1(C338S) 
and U937-Control(EV) (Figure 5.8, Panel C ). As with the intracellular ROS signal this 
effect was abrogated by the addition of NAC which significantly reduced the 7AAD+ve 
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population across all cells lines and abrogated the difference between BCAT1(WT) and 
BCAT1(C338) (Figure 5.8 Panel A). 
Finally, the effect of serum starvation on cellular proliferation was examined. 
Cells were seeded at 5x105 cells/mL and proliferation was determined by total cell 
number after 72h in culture.  The data show that U937-BCAT1(WT) and U937-
BCAT1(C338S) cells display a final cell density of 1.04x106±5.5x104 cells/mL and 
1.04x106±5.5x104, respectively, which represent a 108.4% (p<0.001) and 102.2% 
(p<0.01) increase in cell number (Figure 5.9). This finding is in contrast to U937-
Control(EV) cells, which display a relative decrease in number by 17.42% to 
4.13x105±6.7x104cells/mL after the same amount of time in culture (Figure 5.9). This 
demonstrates BCAT1 overexpressing cells underwent approximately one doubling 







Figure 5.7 Effect of BCAT1(WT) and BCAT1(C338S) overexpression on intracellular ROS 
following serum starvation. Bar chart displaying Reactive Oxygen Species (ROS) 
generation following serum starvation. 5x10
4
 cells per well were suspended in a 96 well 
plate with complete RPMI +/- 10% foetal calf serum (FCS) and +/- 10mM N-acetyl 
cysteine (NAC) and incubated for 72h prior to staining with intracellular ROS probe 
DCFDA. Serum starvation increases ROS signal across all cell lines, U937-Control(EV) 
[green], U937-BCAT1(WT) [blue] and U937-BCAT1(C338S) [red]. Addition of the 
antioxidant NAC abolishes differences in ROS signal across all cell lines. Data presented 









Figure 5.8 Effect of BCAT1(WT) and BCAT1(C338S) overexpression on 7AAD/Annexin in 
U937 cells following serum starvation. A) Bar chart summarising U937-Control(EV) 
[green], U937-BCAT1(WT) [blue] and U937-BCAT1(C338S) [red] cells cultured under 
serum starved conditions for 72h ± 10mM NAC prior to viability analysis using 
7ADD/Annexin-V. B) Data displaying fold change in Annexin-V following serum 
starvation, where U937-BCAT1(WT) and U937-BCAT1(C338S) display a significantly 
decreased fold change in Annexin-V signal compared to U937-Control(EV) cells. C) 
Representative bivariate flow cytometric plots for each cell line following serum 
starvation displaying  percentage viable (lower left quadrant), apoptotic (upper left 
quadrant) and dead (upper right quadrant) cells (each plot represents 5000 events). Data 
presented as mean ±SEM n=3, One/two-way ANOVA Bonferroni post-test (*p<0.05, 




















Table 5.1 Cell viability determined by 7AAD/ Annexin V staining following 















Figure 5.9 The effect of BCAT1(WT) and BCAT1(C338S) overexpression on cellular 
proliferation following serum starvation. 5x10
4
 cells per well were suspended in a 96 
well plate with complete RPMI - 10% fetal calf serum (FCS) and incubated for 72h prior 
to staining with Viacount reagent. U937-BCAT1(WT) [blue] and U937-BCAT1(C338S) [red] 
display increased proliferation compared to U937-Control(EV) cells [green]. Data 







5.4.6 The effect of the BCAT1 CXXC motif on PMA mediated cellular differentiation 
To examine the effect of BCAT1(WT) and BCAT1(C338S) overexpression on 
monocyte to macrophage differentiation, cellular morphology was examined by flow 
cytometry. Differentiated macrophages display increased granularity as a result of an 
increase in membrane bound organelles, which can be detected as an increase in side 
scatter (SSC) (Daigneault et al., 2010).  The data shows that U937-BCAT1(WT) and U937-
BCAT1(C338S) cells display decreased SSC intensity compared to U937-Control(EV) cells 
in resting culture, indicating BCAT1 expression mediates a less differentiated U937 
ground state (Figure 5.10).   
 To evaluate the effect of the BCAT1 CXXC motif on induced cellular 
differentiation, the transgenic U937 cells were incubated with PMA. PMA has been 
demonstrated to  mediate differentiation in U937 cells in a ROS dependant manner 
(Yamamoto et al., 2009), therefore PMA induced differentiation was explored across all 
cell lines. Intracellular ROS ± PMA was measured by DCFDA staining, where the data 
shows that PMA increases DCFDA signal across all cell lines, however U937-BCAT1(WT) 
cells display significantly lower PMA induced DCFDA signal compared with U937-








Figure 5.10 The effect of BCAT1(WT) and BCAT1(C338S) overexpression on cellular 
morphology. Bar charts displaying effect of BCAT1 overexpression on A) forward (FSC) 
and B) side scatter (SSC) measured by flow cytometry.  BCAT1 overexpression has no 
effect on cell size as measured by forward FSC however U937-BCAT1(WT) and U937-
BCAT1(C338S) display significantly reduced granularity as measured by SSC. C) 
Representative bivariate FSC vs SSC flow plots.U937-BCAT1(WT) [middle] and U937-
BCAT1(C338S) [bottom] display visibly reduced side scatter compared to U937-
Control(EV) [top] cells (each plot represents 5000 events).  Data presented as mean ± 
SEM, n=3. Analysed by One-way ANOVA Bonferroni post-test (***p<0.001). 
A) 
B) 
Control (EV)       BCAT1 (WT)     BCAT1 (C338S) 










Figure 5.11 The effect of BCAT1(WT) and BCAT1(C338S) overexpression on Phorbol 12-
myristate 13-acetate (PMA) induced Reactive Oxygen Species (ROS). Transgenic U937 
cells were differentiated using PMA and intracellular ROS measured by DCFDA. Data 
show DCFDA signal before and after PMA treatment for U937-Control(EV) [green], U937-
BCAT1(WT) [blue] and U937-BCAT1(C338S) [red]. Data presented as mean± SEM n=3 and 
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The effect of the BCAT1 CXXC motif on cellular differentiation was analysed by 
expression of cell surface markers CD36 and CD11b, which distinguish a macrophage-
type immunophenotype (Huh et al., 1996; Misharin et al., 2013). Here U937-BCAT1(WT) 
and U937-BCAT1(C338S) display significantly decreased baseline levels of CD36+ cells 
compared to U937-Control(EV) cells (P<0.001), with CD36+ significantly lower in U937-
BCAT1(WT) cells compared to U937-BCAT1(C338S) (p<0.01, Figure 5.12, Panel C). PMA 
induced differentiation increases CD36 expression across all transgenic U937 cell lines, 
however U937-BCAT1(WT) displays a reduced percentage of CD36+ cells compared to 
U937-BCAT1(C338S) and U937-Control(EV). Moreover, PMA induced CD11b+ expression 
is also significantly reduced for U937-BCAT(WT) and U937-BCAT1(C338S) expressing cells 
compared to U937-Control(EV) cells. (p<0.05, Figure 5.12, Panel D). 
Given CD36 is known to play a role in monocyte and macrophagic cell to cell 
adhesion through receptor Thrombospondin-1 (TSP-1), cellular morphology was 
examined by phase contrast microscopy (Savill et al., 1992; Ho Young Huh et al., 1995). 
Following addition of PMA, visual examination revealed that U937-BCAT1(WT) cells 
displayed less cellular aggregation compared with U937-Control(EV) cells, a finding 
consistent with lower CD36 cell surface expression (Appendix D). 
Finally, to confirm that the observation in myeloid differentiation markers 
CD36/CD11b was due to the CXXC motif, and not BCAT1 aminotransferase activity, cells 
were pre-treated with the BCAT1 competitive inhibitor, Gabapentin (Goto et al). The 
maximal non-lethal inhibitory concentration of Gabapentin of 20 mM was determined 
by dose-response analysis (See Chapter 6). The data demonstrated that the addition of 
20 mM Gabapentin was unable to restore the either CD36 or CD11b immunophenotype 
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to baseline, however the phenotype is effectively rescued by addition of 10mM of the 
antioxidant NAC demonstrating PMA mediated differentiation is primarily a redox driven 








Figure 5.12 The effect of PMA treatment on the markers of myeloid differentiation 
CD36 and CD11b. A) Representative FSC vs SSC plot displaying gating of viable cells 
following PMA treatment. B) Representative green/blue (FL1) bivariate analysis gated 
on R1. CD36/CD11b- (lower left quadrant), CD36+(upper left quadrant) and CD11b+ 
(upper right quadrant). Bar charts displaying percentage of C) CD36+ and D) CD11b+ cells 
under different treatment conditions where Control(EV) [green], U937-BCAT1(WT) 
[blue] and U937-BCAT1(C338S) [red]. Data presented as mean± SEM n=3 and analysed 










The aim of this chapter was to determine the effect of the BCAT1 CXXC motif on 
the development of AML. To achieve this, it was necessary to attempt to separate the 
canonical metabolic activity and CXXC motif derived effects of BCAT1,  in the model used 
here the differences between BCAT1(WT) and BCAT1(C338S) overexpressing U937 
transgenic cell lines is taken to be indicative of this contribution. The rationale for this 
comes from the observation that cysteine to serine site directed mutagenesis of the 
C338 residue of the CXXC motif (i.e. CXXS) preserves the metabolic activity of the 
enzyme under physiological conditions (Conway et al., 2008), whilst potentially 
abolishing the putative antioxidant activity compared to BCAT1(WT). Given 
development of AML results from a dysregulation of oncogenic processes such as 
cellular differentiation, proliferation and apoptosis (Testa and Riccioni, 2007; Olsson et 
al., 2009; Akinduro et al., 2018), these were the characteristics that were compared 
between the cell lines to explore the hypothesis that the BCAT1 CXXC motif contributes 
to the pathogenesis of AML, through modulation of ROS, a central component in AML 
development(Zhou, Shen and Claret, 2013; Sillar et al., 2019). 
 The data presented here show that in vitro growth profiles for the transgenic cell 
lines, show an increased cell density for U937-BCAT1(WT) and U937-BCAT1(C338S) 
overexpressing cells compared to U937-Control(EV)(Figure 5.1). Additionally, cell cycle 
analysis during exponential growth phase revealed this was accompanied by a 
significant decrease in doubling time and G2M phase cells for both U937-BCAT1(WT) 
and U937BCAT(C338S) cells (Figure 5.2). However no significant difference in cell density 
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or cell cycle was observed between U937-BCAT1(WT) and U937-BCAT(C338S), 
demonstrating that this difference is due to the metabolic contribution of the enzyme.   
Previous biochemical studies using in vitro enzyme kinetic data, demonstrate 
that BCAT1 metabolism favours the production α-KG and leucine (Davoodi et al., 1998), 
however the current literature indicates that the direction of the reaction in vivo is 
context dependant. For example, in myeloid leukaemia, rapidly dividing blast crisis cells 
favour the forward reaction, whilst more quiescent leukemic stem cell populations in 
AML have been found to favour reverse reaction i.e. the production of glutamate and 
BCKA (Hattori et al., 2017 and Raffel et al., 2017). In transformed proliferating cells α-
KG, anaplerotically replenishes the TCA cycle, whilst leucine activates mTOR stimulating 
growth and survival (Owen, Kalhan and Hanson, 2002; Laplante and Sabatini, 2009; 
Altman, Stine and Dang, 2016). Although direct measurements of these processes were 
beyond the scope for this study, it has been previously demonstrated BCAT1 
overexpression promotes growth via mTOR by increasing the BCAA pool in a myeloid 
and  breast cancer cell model (Hattori et al., 2017; Zhang and Han, 2017). Therefore it is 
reasonable to speculate that increased cellular proliferation (Figure 5.1) and concurrent 
increase in G2M phase cells (Figure 5.2) observed  from U937-BCAT1(WT) and U937-
BCAT1(C338S) compared to U937-Control(EV) is due to increased levels of  α-KG which 
feeds into the TCA cycle increasing ATP production. Supporting this idea, cell cycle has 
been demonstrated to be dependent on ATP production, where increasing ATP 
concentration induces depolymerization of the interphase microtubular network 
initiating cellular mitosis(Marcussen and Larsen, 1996). 
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Another factor to consider when examining the data presented in Figures 5.1 and 
5.2 is the production of toxic ammonia. Cells in closed cultures experience a decrease in 
nutrient availability and an increase in toxic waste products, which ultimately limit 
growth and survival. An important waste product is ammonia, which has been reported 
to inhibit growth in cell cultures (Schneider, Marison and Von Stockar, 1996). The 
ammonium ion (NH4+) is produced as a by-product of glutamate metabolism through 
glutamate dehydrogenase, which also produces α-KG, however this reaction can also be 
performed by aminotransferases including BCAT1 without the producing toxic 
ammonium (Altman, Stine and Dang, 2016). Thus the significantly higher cell density 
observed from U937-BCAT1(WT) and U937-BCAT1(C338S) cells compared with the 
U937-Control(EV) after 96 h in culture (Figure 5.1) may be due to an increase in α-KG 
and leucine and a decrease in NH4+ metabolites. 
Closer examination of cell viability at stationary (t0 - 96h) and death phase (t96 - 
192) shows that U937-BCAT1(WT) and U937-BCAT1(C338S) cells display an increased 
proportion of viable cells compared to U937-Control(EV) cells (Figure 5.3). Furthermore 
increased viability at these time points is related to a decrease in intracellular ROS 
(Figure 5.5) and increased GSH content (Figure 5.6), suggesting that during the 
stationery and death phase, the BCAT1 overexpressing cells may favour the reverse 
metabolic reaction, producing glutamate and BCKA (Hattori et al., 2017 and Raffel et al., 
2017).  This notion may be supported by previous studies which demonstrate that during 
stationary phase exhaustion of glutamine, which is supplemented in the culture medium 
and converted to glutamate via Glutaminase, would lead to a rapid decrease in the 
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availability of glutamate, shifting the reaction equilibrium of BCAT1 in favour of 
glutamate synthesis (Cluntun et al., 2017). 
The data presented in Figure 5.6 show an increase in total GSH for BCAT1 
transgenic cells. GDH the most abundant low molecular weight thiol and integral part of 
cellular antioxidant defences (Lu, 2013). Cellular antioxidant enzymes including 
Glutathione peroxidase (GPx) and Peroxiredoxins (Prx) require GSH to act as an electron 
donor during the reductive elimination of H202, as well as to regenerate antioxidant 
enzymes to their reduced active forms (Forman, Zhang and Rinna, 2009). Glutamate is a 
precursor to the synthesis of the GSH, therefore, the increase in GSH observed for U937-
BCAT1(WT) and U937-BCAT1(C338S) could be explained by the increased glutamate 
production via BCAT1 metabolic activity in these cells, as discussed previously.  
GSH is known to modulate intracellular ROS and apoptosis, whereby inhibition 
of GSH synthesis in a human B lymphoma cell line leads to an increase in ROS and 
activation of apoptotic signalling cascades (Armstrong et al., 2002; Circu and Aw, 2012). 
Interestingly, Hongbin et al demonstrate that BCAT1 overexpression increases cellular 
GSH content and that BCAT1 knockdown results in decreased GSH and increased ROS in 
human lung cancer cell lines PC-9 (Wang et al., 2019). Thus, taken together, the in vitro 
characterisation of BCAT1 overexpressing U937 cell lines as presented here, seems to 
support hypothesis that the direction of the BCAT1 enzymatic reaction is dynamic and 
context dependant. During exponential phase, BCAT1 overexpression probably favours 
the forward reaction producing metabolites that support growth whilst during 
stationary phase the reverse reaction appears to be favoured producing glutamate and 
supporting GSH synthesis. 
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Whilst the metabolic contribution of BCAT1 accounts for the variation seen 
between BCAT1 overexpressing and EV control, U937-BCAT1(WT) also display 
significantly increased proportion of viable cells compared to BCAT1(C338S) at various 
time points (Figure 5.3). This observation may indicate CXXC derived protection from 
ROS mediated cell death, which is reported to impact cells in culture(Halliwell, 2003). 
The data presented in Figure 5.3 shows the difference in cell viability between U937-
BCAT1(WT) and U937-Control(EV) at t=192 h is 36.5 %, whilst BCAT1(WT) and U937-
Control(C338S) at t=192 h is 11.7 %. Therefore, the protective effect of BCAT1 on 
apoptosis may be quantified as 24.8% metabolic and 11.7% CXXC motif, roughly 
equating to 1/3rd of the effect measured. I hypothesised this effect would be due to 
exhaustion of media serum which is known to induce oxidative stress and apoptosis 
through mitochondrial ROS production. (Lee et al., 2010; Braun et al., 2011; Li, Chen and 
Gibson, 2013)Therefore in order to further interrogate the ability of the CXXC motif to 
protect against ROS mediated cell death I induced oxidative stress by serum starvation.  
The ROS reactive probe, DCFDA was introduced to the culture to quantitate ROS 
production(Eruslanov and Kusmartsev, 2010). The data presented in Figure 5.7 show 
that following serum starvation, U937-BCAT1(WT) DCF signal was than less the U937-
Control(EV) cells (p<0.001) and also significantly less that the U937-BCAT1(C338S) cells 
(p<0.001). Both BCAT1 overexpressing cells showed less ROS compared to the EV 
controls, however the data indicate that the CXXC motif may be responsible for 
approximately half the reduction in ROS (Figure 5.7). The metabolic activity of BCAT1 
may also contribute to this effect by increasing the cellular pool of GSH, as previously 
discussed (Wang et al., 2019). 
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The decrease in ROS observed in Figure 5.7 related to a decrease in cell death 
(Figure 5.8 and Table 5.1), where U937-BCAT1(WT) cells display a substantially lower 
proportion of 7AAD +ve cells compared to either U937-BCAT1(C338S) or U937-
Control(EV) cells. Interestingly, addition of the cellular antioxidant ‘NAC’ equalised the 
DCF signal across all cell lines and nullified the percentage change in cell death seen 
between U937-BCAT1(WT) and U937-BCAT1(C338S) (Figure 5.7 and 5.8) demonstrating 
that these effects are redox mediated.  
Serum starvation was used in this study to mediate an increase in endogenous 
cellular ROS. This technique has been widely used to study apoptosis in response to 
oxidative stress. HeLa cells deficient in mitochondrial electron transport chain display 
significantly reduced levels of superoxide in response to serum starvation, 
demonstrating that serum depleted induced ROS is mitochondrially derived (Li, Chen 
and Gibson, 2013). Another study demonstrated serum starvation increased DCF signal, 
which was rescued by the addition of NAC and catalase, supporting the notion serum 
starvation induces ROS and that the effects can be rescued by antioxidants (Scherz-
Shouval et al., 2007). The data here supports these observations where the DCF signal 
increases following serum starvation, moreover this increase in ROS is CXXC motif 
dependant where BCAT1(C338S) displays approximately a 50% reduction in  ROS 
compared to BCAT1(WT) indicating the CXXC motif is functioning as an antioxidant 
against ROS mediated cell death . 
The effect of CXXC motif’s in ROS mediated cell death has been examined in the 
widely studied antioxidant protein Thioredoxin (Trx). Trx CXXC motif’s form a catalytic 
reaction centre which acts as a protein disulphide oxidoreductase, reducing 
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intermolecular and intramolecular disulphide bonds of oxidised proteins (Collet and 
Messens, 2010). Thioredoxin can restore Peroxiredoxin to the reduced active form, and 
in the process the Trx CXXC motif becomes oxidised and forms an intramolecular 
disulphide bond, which is subsequently restored by Thioredoxin reductase (TR) using 
NADPH as reducing equivalent (Lee, Kim and Lee, 2013). Increased intracellular Trx is 
associated with reduced ROS and a decreased sensitivity to pro-oxidant treatment, 
whereby inhibiting Trx in a U937 AML model restores susceptibility to Arsenic Trioxide 
treatment (Wangpaichitr et al., 2012; Tan et al., 2014). Moreover Trx expression is 
increased by serum starvation induced oxidative stress in the monocytic AML cell line 
THP1, where it protects the cell from apoptosis by reducing the levels of ROS (Kim et al., 
2008).   
Whilst the antioxidant effects of CXXC containing Trx system have been 
extensively studied, the potential antioxidant properties of the CXXC motif in proteins 
outside this canonical antioxidant system is less well understood. Recently cysteine to 
serine site directed mutagenesis of a CXXC motif in Mesencephalic astrocyte-derived 
neurotrophic factor (MANF) demonstrated that the motif provides protection from 
oxidative stress induced apoptosis and reduces intracellular ROS (Božok et al., 2018). 
Whilst this study was performed in a neuronal cell model, it strongly supports the 
hypothesis that the CXXC motif can mediate ROS induced apoptosis.  
The protective effect of the BCAT1 CXXC motif from oxidative stress induced 
apoptosis is clearly demonstrated here, however exactly how the CXXC motif functions 
as an antioxidant is yet to be fully understood. Previous work has demonstrated that the 
majority the BCAT1 CXXC motif is S-glutathionylated at cellular redox potentials that 
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relate to processes dysregulated in cancer i.e. proliferation (-260 to -210mV,) 
differentiation (-210 to 180mV) and apoptosis (-180 to -160 mV) (Schafer and Buettner, 
2001 and Coles et al., 2012), indicating the that BCAT1 CXXC motif may be buffering the 
cellular antioxidant network, by reducing intracellular GSSG to GSH. This notion is 
supported by an earlier biochemical study, which linked BCAT1 directly to the Trx and 
GSH redox networks (Conway et al., 2008;). Furthermore, unpublished data from our 
group at the University of Worcester suggests that that BCAT1 CXXC motif can directly 
reduce H202 in vitro and can be regenerated by NADPH, suggesting a peroxidase like 
activity rather than a Trx like protein disulphide oxidoreductase role, although the 
precise activity in vivo remains to elucidated. Taken together, with the data presented 
for the transgenic U937 cells in this chapter, the evidence is mounting for BCAT1 as a 
cellular antioxidant. 
Resisting differentiation is a feature of AML and occurs at a relatively oxidised 
intracellular redox potential (Schafer and Buettner, 2001). Therefore, it was 
hypothesised that the putative antioxidant properties of the BCAT1 CXXC motif would 
result in a more ‘reduced’ cellular environment and therefore less cellular 
differentiation would occur. To investigate this hypothesis, the ability of the BCAT1 CXXC 
motif to resist ROS mediated differentiation was examined by induction with PMA. 
Previous work in U937 cell line has shown that PMA induces expression of monocyte to 
macrophage markers CD36 and CD11b through generation of H202 increasing 
intracellular ROS as measured by DCF signalling. Moreover addition of catalase reduced 
intracellular H202 and blocked differentiation whilst ROS scavenger NAC decreased PMA 
induced expression of CD11b by 70%(Yamamoto et al., 2009).  
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Initially, the effect of PMA in mediating cellular ROS was investigated. The DCFDA 
data shows that PMA treatment was linked with an increase in cellular ROS (Figure 5.11), 
where U937-BCAT1(WT) cells display significantly lower levels of ROS compared with 
both U937-BCAT1(C338S) and U937-Control(EV). This finding supports previous work 
linking ROS to PMA treatment (Yamamoto et al., 2009) and further supports a role for 
the BCAT1 CXXC motif as an antioxidant. Interestingly, BCAT1 overexpressing transgenic 
cells display less granularity (Figure 5.10), suggesting that BCAT1 may be affecting the 
ability of U937 cells to differentiate. This finding is supported by the data presented in 
Figure 5.12, which illustrate that the percent of CD11b+ cells was significantly lower for 
BCAT1 overexpressing transgenic U937 cells compared with U937-Control(EV) following 
addition of PMA. However, there was no significant difference between U937-
BCAT1(WT) and U937-BCAT1(C338S), suggesting that CD11b expression in part, may be 
due to the aminotransferase metabolic effect mediated by BCAT1 overexpression.  
To investigate this further, the BCAT1 competitive inhibitor Gabapentin, which 
blocks the metabolic active site and not the CXXC motif (Goto et al., 2005), was added 
to the system. When treated with PMA + Gabapentin U937-BCAT1(C338S) cells display 
increased proportion of CD11b+ cells compared with U937-BCAT1(WT), suggesting that 
this phenotype is in part driven by ROS. The addition of NAC restored the basal CD11b+ 
cell numbers, thus confirming PMA induced CD11b+ expression is mediated by ROS 
levels, which is supported by previous work (Yamamoto et al., 2009).  
The data presented here shows basal number of CD36+ cells (not PMA treated) 
is significantly higher for U937-BCAT1(C338S) compared with U937-BCAT1(WT) cells 
(Figure 5.12). This finding does not relate basal ROS levels observed by DCFDA analysis, 
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which was not significantly different across transgenic U937 cell lines (Figure 5.11), 
therefore, the percent CD36+ cell before PMA treatment does not appear to be a ROS 
mediated. However, CD36 has been found to be regulated in part by antioxidant 
transcription factor Nrf2, where under conditions of oxidative stress, Nrf2 translocates 
to the nucleus and initiates transcription of a number of antioxidant response genes, 
including CD36 (Ishii et al., 2004). It is possible Nrf2 has been activated in U937-
BCAT1(C338S) cells causing an increase in CD36+ cells and a concurrent decrease in ROS 
to levels comparable with U937-BCAT1(WT).  Alternatively, it may be that substitution 
of the C338 cysteine to serine of the BCAT1 CXXC motif has initiated an oxidative stress 
signalling response. Work by Conway et al. demonstrated under reducing conditions, 
BCAT1 binds to several redox sensitive proteins that are associated with cytoskeletal 
remodelling, including, β-tubulin, Septin-4 and, Myosin-6 (Conway et al., 2008). 
Importantly under oxidative stress, these proteins no longer bind to BCAT1, therefore it 
is possible that CD36 lies downstream of this response, which may account for the 
change in basal CD36+ seen here, however this needs further investigation.  
Following addition of PMA, the DCF signal increases in a CXXC dependant manner 
(Figure 5.11), which is reflected by an increase in CD36+ cells (Figure 5.12). Moreover, 
the addition of Gabapentin had a negligible effect on the frequency of CD36+ cells, whilst 
the addition of NAC partially restored the baseline phenotype  supporting the notion 
that this is a ROS mediated process.  Examination of cell-cell adhesion by phase contrast 
microscopy revealed U937- BCAT1(WT) cells are visibly less aggregated compared to 
U937-Control(EV) following PMA treatment (Appendix D).  These images support the 
flow cytometric data in Figure 5.12 which shows U937- BCAT1(WT)  display a decrease 
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in CD36+ cells compared to U937- Control(EV) as CD36 is known to facilitate intracellular 
adhesion in monocytes(Pietsch, Erl and Lorenz, 1996). Given treatment with the CD36 
ligand thrombospondin-1 has been demonstrated to induce apoptosis in primary 
leukaemia cells and cell lines (K. Li et al., 2003), understanding the role of BCAT1 in redox 
mediated CD36 expression may be important for future treatment strategies targeting 
BCAT1, therefore the data presented in this chapter warrant further investigation. 
In summary, here it has been demonstrated that BCAT1 overexpression may 
provide a metabolic proliferative advantage during exponential phase in vitro, whilst 
providing a survival advantage during stationery and death phase through a decrease in 
intracellular ROS and increase GSH content, which correlates with lowered cellular redox 
potentials. The data also demonstrate that the CXXC motif is able to modulate 
intracellular ROS in response serum starvation and PMA induced oxidative stress, where 
the CXXC motif provides protection from apoptosis and resists differentiation, both 
features of which are oncogenic processes dysregulated in the development of AML. 
Therefore, it may be possible to ameliorate these effects by targeting the metabolic 
activity and the CXXC motif antioxidant contribution of BCAT1 with competitive 
inhibitors and pro-oxidant therapies. This therapeutic possibility will be subject to 
investigation in chapter 6.  
The work presented in this chapter was accepted for presentation at the 60th 
Annual American Society of Haematology Meeting, San Diego, USA (Nov, 2018) and the 
abstract was published in the Blood(Hillier J et al., 2018). 
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Chapter 6: The effect of BCAT1 CXXC motif on 
treatment with Cytarabine and the pro-oxidant 
Rotenone in U937 cells. 
6.1 Introduction  
Acute Myeloid Leukaemia (AML) has a U.K. incidence of around 3,100 new 
cases/year approximately, which is ~30% of all leukaemia and survival remains below 
15% for patients over the age of 60  (Leukemia and Lymphoma Society, 2020). Standard 
treatment for AML is a two-stage process that involves 1) an ‘induction’ stage, which 
aims to kill as many AML blast cells as possible to achieve minimum residual disease 
(MRD) and 2) a ‘consolidation’ stage, which aims to prevent relapse(Dombret and 
Gardin, 2016). During induction phase, high dose chemotherapeutic agents are 
administered, which interrupt cell division and therefore halt the proliferation of 
malignant cells. However these therapies are non-specific and target healthy and 
malignant dividing cells indiscriminately i.e. by disrupting DNA synthesis(Sigal et al., 
2010). For example, the widely used AML chemotherapeutic agent Cytarabine (1β-
arabinofuranosylcytosine, aka Ara-C), is a nucleoside analogue of the nucleic acid 
cytosine, where the ribose sugar of the sugar phosphate backbone for arabinose is 
substituted producing cytosine arabinose(Jimenez, Wilke and Costa-Lotufo, 2018). Ara-
C is randomly incorporated into DNA during semiconservative replication in S-phase 
interrupting daughter strand synthesis, thus inhibiting all cell growth (Momparler, 
2013). Older AML patients in particular respond poorly to this type of non-specific 
chemotherapy, and are therefore often put on low dose chemotherapy regimens that 
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are less effective at eradicating the disease, therefore there is a need to develop 
alternative targeted therapies for this cohort of patients in particular(Löwenberg et al., 
2011; Burnett, 2018). 
Recently, pro-oxidant therapy, which kills cancer cells through generation of 
cytotoxic levels of ROS has emerged as an alternative effective treatment strategy to 
target cancer cells, for which AML cells with particular molecular mutations have 
responded to such therapies(Agathanggelou et al., 2015). Whilst pro-oxidant therapy 
does not target cancer cells specifically, malignant cells are considered more sensitive 
to oxidative stress (Zhang, Fang and Wang, 2014). Moreover, quiescent leukaemia stem 
cells (LSC’s), which are not effectively targeted by agents that interrupt cell cycle, can be 
induced by ROS to exit the stem cell niche. Given these quiescent LSC’s are the major 
cause of MRD (i.e. where a small proportion of leukemic cells remain post-induction 
therapy) and relapse in AML, targeting these cells with pro-oxidants is an attractive 
proposition (Jang and Sharkis, 2007). The pro-oxidant Arsenic Trioxide (ATO), is currently 
used to induce cell death and differentiation in Acute Promyelocytic Leukaemia (APL), 
and functions by inducing oxidative stress, DNA damage and the mitochondrial pathway 
of apoptosis i.e. Cytochrome-C release and activation of the caspase cascade(Zhang et 
al., 2001; Kumar, Yedjou and Tchounwou, 2014).  
 Alternative ROS agents are currently under investigation for the treatment of 
AML, which induce ROS in a variety of ways including inhibition of antioxidant 
transcription factor NF-κB, GSH depletion and inhibition of oxidative phosphorylation 
(Zhang, Fang and Wang, 2014). Inhibition of oxidative phosphorylation may represent a 
particularly attractive target, as AML cells are known to possess a reduced spare 
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respiratory chain reserve capacity, that is the amount of extra ATP that can be produced 
in response to increased energy demands (Sriskanthadevan et al., 2015). 
Rotenone is a naturally occurring compound found in the roots of several plant 
species that inhibits mitochondrial complex I, causing a reduction in ATP generation and 
incomplete transfer of electrons to oxygen resulting in ROS generation (Heinz et al., 
2017). Inhibition of oxidative phosphorylation by Rotenone has previously been 
demonstrated to induce cell death in a number of cancer models, including AML (N. Li 
et al., 2003; Deng, Huang and Lin, 2010; Hu et al., 2016). In these studies, Rotenone 
addition was found to initiate mitochondrial apoptosis following cell cycle arrest through 
activation of caspases, p53 and the pro-apoptotic downstream effector Bax, all of which 
are known to be redox regulated (Lee et al., 2008). Moreover, in HL-60 cells, Rotenone 
induced apoptosis could be rescued by addition of antioxidant compounds, such as, 
NAC, GSH and Vitamin C, reinforcing the role of ROS in Rotenone mediated cell death(N. 
Li et al., 2003). It has been demonstrated Ara-C initiates apoptosis through the same 
redox modulated signalling pathway as Rotenone following cell cycle arrest, for example 
siRNA mediated knockdown of the p53 targets ‘Bax’ and ‘Puma’ result in diminished 
apoptotic response to Ara-C (Vincelette and Yun, 2014). 
In Chapter 5 it was demonstrated that BCAT1 expression reduces cellular ROS 
levels and decreases apoptosis in response to serum starvation induced oxidative stress. 
Because treatment with Ara-C and Rotenone can alter cellular ROS and induce 
mitochondrial apoptosis, I hypothesised that BCAT1 in AML may impact on these 
processes. Therefore, this Chapter investigated whether BCAT1 overexpression provides 
protection from apoptosis in Ara-C / Rotenone treated U937 transgenic cells. Since the 
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BCAT1 mediated protection from ROS appeared to involve both the antioxidant effect 
of the CXXC motif, as well as the metabolic contribution of BCAT1 enzyme, the BCAT1 
metabolic inhibitor Gabapentin (Goto et al., 2005) was also investigated. Rapamycin, an 
inhibitor of the downstream metabolic regulator of cell growth and survival ‘mTOR’  was 
also included, since BCAT1 was demonstrated to provide protection against apoptosis 
(Chapter 5)(Seto, 2012). In this way, knowledge of the pharmacological impact of these 
drug treatments with respect to BCAT1 overexpression may lead to the potential 













6.2 Aims and Objectives 
The aim of this study is to examine the effect of the BCAT1 CXXC motif in the 
treatment of AML. In the previous chapter it was demonstrated BCAT1 overexpression 
increases survival of U937 cells in response to oxidative stress by a combination of 
enzymatic and CXXC motif derived antioxidant mechanisms. Therefore, here the efficacy 
of inducing apoptosis with pro-oxidant therapy and the contribution of the CXXC motif 
to this process will be evaluated by treatment Rotenone, an inhibitor of mitochondrial 
complex I that generates endogenous ROS. Given targeted pro-oxidant treatment 
regimens will be delivered in combination with other therapeutic agents i.e. Cytarabine, 
Gabapentin and Rotenone, the effect of these agents, which target BCAT1 specifically, 












• Examine the anti-apoptotic effect of BCAT1 and the CXXC motif to treatment 
with standard chemotherapeutic Ara-C. Dose-response curves will be generated 
examining cell viability and cell density from which IC50 calculations were made 
which will allow for direct comparisons of Ara-C sensitivity between U937-
BCAT1(WT), U937-BCAT1(C338S) and U937-Control(EV) cell lines.  
 
 
• Examine the anti-apoptotic and antioxidant effect of the BCAT1 CXXC motif to 
treatment with pro-oxidant therapy. Rotenone dose-response curves examining 
cell viability and cell density from which C50 calculations will be generated for 
U937-BCAT1(WT), U937-BCAT1(C338S) and U937-Control(EV) cells. Rotenone 
induced ROS levels was monitored by flow cytometric analysis following DCFDA 
staining. 
 
• Examine the anti-apoptotic effect of the BCAT1 CXXC motif on treatment with 
Gabapentin, a direct competitive inhibitor of BCAT1 and Rapamycin, inhibitor of 
downstream metabolic target mTOR. Gabapentin and Rapamycin dose-response 
curves and IC50 calculations will be generated for U937-BCAT1(WT), (U937-
BCAT1(C338S) and U937-Control(EV) allowing direct evaluation of the BCAT1 





6.3.1. Dose Response Curves 
Dose Response curves for Ara-C, Gabapentin, Rapamycin, H202 and Rotenone 
were generated by a ½ dilution series performed in a 96 well format at a cell density of 
5x104 cells/ well. Cells were incubated for 72 h in a cell culture incubator (5 % CO2 and 
37 oC). Following incubation absolute cellular density and viability was determined by 
flow cytometric analysis using the Viacount stain and Easy Fit cluster analysis algorithm, 
as described in Section 2.19. All data was normalised to the ‘no treatment’ control prior 
to calculation of IC50 values using GraphPad Prism version 5.01 by non-linear regression.  
 
6.3.2 Rotenone Generated ROS by DCFDA Assay 
 To confirm the involvement of ROS in Rotenone treated transgenic U937 cells, 
the DCFDA assay was performed as described in Section 2.27. A ½ dilution series of 
Rotenone was set up and seeded at a density of 5x104 cells/well prior to incubation for 
72 h in a cell culture incubator (5% CO2 and 37 oC ). Following incubation, 100µL of 2 µM 
DCFDA was added directly to the sample and incubated for a further 30 min at 37 °C, 
prior to flow cytometric analysis. For each sample 10-20 000 events were captured with 
Incyte software (Merck). Morphological changes were also examined by phase contrast 





6.4.1. Cytarabine Dose Response  
To investigate the effect of BCAT1 and the CXXC motif on traditional 
chemotherapeutic treatment, U937-Control(EV), U937-BCAT1(WT) and U937-
BCAT1(C338S) cells were incubated with Ara-C in a ½ dilution series in order to generate 
a dose response curve. IC50 values were generated against cell density normalised to the 
‘no treatment control’ i.e. the concentration required to reduce cell numbers by 50% 
(Sebaugh, 2011), show that U937-BCAT1(WT) (0.42±0.13 µM) and U937-BCAT1(C338S) 
(0.54±0.07 µM) were significantly more sensitive to Cytarabine treatment compared to 
U937-Control(EV) (2.4±0.07 µM) (Figure 6.1 and Table 6.1, p<0.001). Overall analysis of 
cell viability reveals that U937-BCAT1(C338S) cells are significantly more sensitive to 
treatment with Ara-C, compared with either U937-BCAT1(WT) and U937-Control(EV) at 
all concentrations, suggesting the CXXC motif is providing a protective effect against 
apoptosis when challenged with Ara-C (Figure 6.1, p<0.001). An increase in the 
percentage of viable cells at 25-50 µM across all cell lines indicates the presence of Ara-







Figure 6.1. Cellular density and viability in response to Ara-C treatment.  A) Dose 
response curve displaying cell density in response to Ara-C treatment normalised to no 
treatment control. Non-linear regression performed shows the IC50 concentration for 
BCAT1(WT) is 0.42±0.13 µM, BCAT1(C338S) is 0.54±0.07 µM and BCAT1-Control(EV) is 
2.4±0.07 µM, p<0.001. B) Bar chart representing cell viability following Ara-C treatment 
for U937-BCAT1(WT), U937-BCAT1(C338S) and U937-Control(EV). Data presented as 







6.4.2. Gabapentin Dose Response  
To investigate the effect of blocking BCAT1 metabolism on cell density and 
viability, U937-Control(EV), U937-BCAT1(WT) and U937-BCAT1(C338S) cells were 
incubated with the BCAT1 metabolic activity inhibitor Gabapentin in a ½ dilution series 
to generate a dose response curve. Data presented in Figure 6.2 and summarised in 
Table 6.1 indicate that the IC50 value for U937-BCAT1(WT) (28.7±1.1mM) is significantly 
lower for Gabapentin compared with either U937-BCAT1(C338S) (32.4±2.6mM) and 
U937-Control(EV) (33.8±1.2mM)(p<0.001). Analysis of cell viability supported this 
finding, where U937-BCAT1(WT) displays significantly reduced survival across multiple 
concentrations, compared with U937-Control(EV) cells. The U937-BCAT1(C338S) 












Figure 6.2 Cellular density and viability in response to Gabapentin treatment. A) Dose 
response curve displaying cell density in response to Gabapentin treatment normalised 
to no treatment control. Non-linear regression performed shows the IC50 concentration 
for U937-BCAT1(WT) is 28.7±1.1mM, U937-BCAT1(C338S) is 32.4±2.6mM and U937-
Control(EV) is 33.8±1.2mM, p<0.001). B) Bar chart representing cell viability following 
Gabapentin treatment for U937-BCAT1(WT), U937-BCAT1(C338S) and U937-Control(EV) 
cells. Data presented as mean ±SEM n=3 and analysed by 2-way ANOVA with Bonferroni 





6.4.3. Rapamycin Dose Response  
To investigate blocking the downstream metabolic effects of BCAT1 on cell 
density and viability, U937-Control(EV), U937-BCAT1(WT) and U937-BCAT1(C338S) cells 
were incubated with the mTOR inhibitor ‘Rapamycin’ in a ½ dilution series in order to 
generate a dose response curve.  Data presented in Figure 6.3 and Table 6.1, show that 
IC50 for U937-Control(EV) (36.9±25.9µM), U937-BCAT1(WT) (27.3±2.7µM), U937-
BCAT1(C88S)(25.7±0.9µM) were not significantly different. Although Rapamycin had an 
overall effect of decreasing cell viability across all transgenic U937 cell lines the 
difference observed  between cell lines for each treatment did not reach significance 

















2.4 ± 0.07 
 
33.8 ± 1.2 
 
36.9 ± 25.9 
 
20.7 ± 1.2 
U937-BCAT1(WT) 0.42 ± 0.13 28.7 ± 1.1 27.3 ± 2.7 40.4 ± 1.1 
U937-BCAT1(C338S) 0.54 ± 0.07 32.4 ± 2.6 25.7 ± 0.9 20.8 ± 1.1 
Table 6.1 Mean (±SEM ) IC50 values for therapeutics 





Figure 6.3 Cellular density and viability in response to Rapamycin treatment. A) Dose 
response curve displaying cell density in response to Rapamycin treatment for U937-
BCAT1(WT), U937-BCAT1(C338S) and U937-Control(EV). IC50 values for each cell line as 
calculated by non-linear regression analysis were as follows:  27.3±2.7µM, 36.9±25.9µM 
and 25.7±0.9µM respectively, p>0.05. B) Bar chart representing cell viability following 
Rapamycin treatment for U937-BCAT1(WT), U937-BCAT1(C338S) and U937-Control(EV). 
Data presented as mean ±SEM n=3 and analysed by 2-way ANOVA with Bonferroni post-
hoc test (p>0.05). 
































































6.4.4. Rotenone Dose Response  
To investigate the effect of pro-oxidant treatment on cell density and cell 
viability, U937-Control(EV), U937-BCAT1(WT) and U937-BCAT1(C338S) cells were 
incubated with the complex I inhibitor, Rotenone, in a ½ dilution series in order to 
generate a dose response curve. The data presented in Table 6.1, show that the IC50 
value for U937-BCAT1(WT) at 40.4±1.1nM, was significantly higher than that of U937-
BCAT1(C338S) at 20.8±1.1nM and U937-Control(EV) cells at 20.7±1.2nM (p<0.001). 
Additionally, the data shows that U937-BCAT1(C338S) cells show significantly less 
viability than U937-BCAT1(WT) cells across multiple Rotenone concentrations (Figure 
6.4). Moreover U937-BCAT1(C338S) cells display significantly reduced levels of 
intracellular ROS at 60 nM Rotenone compared to U937-BCAT1(WT) (Figure 6.5, p<0.05), 
where ROS levels inversely correlate with viability, indicating that the CXXC motif 













Figure 6.4 Cellular density  and viability in response to Rotenone treatment. A) Dose 
response curve displaying cell density in response to Rotenone treatment for U9367-
BCAT1(WT), U937-BCAT1(C338S) and U937-Control(EV). Non-linear regression analysis 
generated the IC50 values for each as, 40.4±1.1nM, 20.8±1.1nM and 20.7±1.2nM, 
respectively (p<0.001). B) Bar chart representing cell viability following Rotenone 
treatment for U937-BCAT1(WT), U937-BCAT1(C338S) and U937-Control(EV). Data 
presented as mean ±SEM n=3 and analysed by 2-way ANOVA with Bonferroni post-hoc 
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Figure 6.5 The effect of BCAT1overexpression on intracellular ROS following Rotenone 
treatment. 5x10
4
 cells per well were suspended in a 96 well plate with complete RPMI + 
Rotenone and incubated for 72 h prior to staining with DCFDA. Data presented show DCF 
signal for U937-BCAT(WT), U937-BCAT1(C338S) and U937-Control(EV). At 60 nM 
BCAT1(WT) displays significantly decreased intracellular ROS compared BCAT1(C338S) 
control. Data presented as mean± SEM n=4 and analysed by 2-way ANOVA Bonferroni 







The aim of this chapter was to examine the effect of the BCAT1 CXXC motif in the 
treatment of AML with a view to proposing a treatment strategy for AML patients 
stratified according to BCAT1 expression level i.e. BCAT1high and BCAT1low. Frontline 
treatment for AML involves intensive courses of non-specific drugs that are in many 
cases unsuitable for patients over 75(Oran and Weisdorf, 2012),the age group for which 
AML diagnosis is most common, therefore there is need to identify more specific 
targeted therapies that can be administered in conjunction with lower dose traditional 
treatments (Leukemia and Lymphoma Society, 2020).  For this reason, the growth and 
survival following treatment with pro-oxidant Rotenone, BCAT1 metabolic inhibitor 
Gabapentin and downstream inhibitor of mTOR Rapamycin, alongside common 
chemotherapeutic agent Ara-C was examined here. 
The data presented in this chapter demonstrate that BCAT1 overexpressing U937 
cells, were more sensitive to Ara-C treatment, displaying reduced IC50 values compared 
to U937-Control(EV) cells (Table 6.1). As outlined in section 6.1, Ara-C is a nucleoside 
analogue that interrupts DNA synthesis preventing cell division stalling DNA replication 
during S-phase (Momparler, 2013). In Chapter 5, it was demonstrated that BCAT1 
overexpressing cells display a significantly higher percentage of cells in G2M 
phase(Figure 5.2). This previous finding coupled with notion that Ara-C targets S-phase, 
would explain the increased sensitivity exhibited by BCAT1 overexpressing cells as 
demonstrated here in Figure 6.1. Additionally, the data here shows that U937-BCAT(WT) 
cells display significantly higher viability than U937-BCAT1(C338S) at all treatment 
concentrations when challenged with Ara-C (Figure 6.1), therefore the CXXC motif 
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appears to be providing a partial protective effect. To the best of knowledge, this is the 
first study of its kind to demonstrate this. 
Previous studies show Ara-C induces cell death through the DNA damage 
response system via the ATR-Chk1-p53 pathway, resulting in cell cycle arrest and 
activation of mitochondrial apoptosis (Schenk et al., 2012; Siddiqui et al., 2013). To 
support this model,  siRNA mediated knockdown of p53 targets BAX and Puma resulted 
in diminished apoptotic response to Ara-C (Vincelette and Yun, 2014).  This pathway is 
ROS regulated through redox sensitive proteins upstream and downstream of the 
mitochondria, for example both p53 and the Cysteine-Aspartic proteases (Capase) 
family of apoptotic effector proteins, are susceptible to oxidation of catalytic cysteine 
thiols in response to oxidative stress(Baker, Santos and Powis, 2000). Moreover, 
procaspase-9, procaspase-3 and caspase-3 are susceptible to S-glutathionylation, which 
decreases accessibility for proteolytic cleavage, resulting in resistance to apoptosis 
(Simon, Haj-Yehia and Levi-Schaffer, 2000; Redza-Dutordoir and Averill-Bates, 2016). 
Similarly it has been demonstrated that p53 is S-glutathionylated after oxidant 
treatment, decreasing DNA binding affinity, a process which was ameliorated by 
treatment with antioxidants (Sun et al., 2003). These studies demonstrate a more 
reductive redox environment may protect against ROS induced mitochondrial apoptosis. 
Taken together with the data presented in Chapter 5, where it was demonstrated that 
metabolic and CXXC mediated BCAT1 effects lowers cellular ROS and increases the 
cellular GSH pool, it is plausible that BCAT1 may indirectly influence p53 and caspase 
activity, explaining why U937-BCAT1(WT) cells are more resistant to Ara-C mediated 
killing than either U937-BCAT1(C338S) and U937-Control(EV). 
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Given that BCAT1 expression reduces cellular ROS and increases the GSH pool, 
the  possibility that BCAT1 low expressing AML cells may therefore be targeted by pro-
oxidant treatment using Rotenone was explored. Strikingly, the data show that  U937-
BCAT1(WT) overexpressing cells display an IC50 value that was double the concentration 
of U937-BCAT1(C338S) and U937-Control(EV) cells (Figure 6.5). Additionally, U937-
BCAT1(WT) retained significantly more viability compared with U937-BCAT1(C338S) 
cells across multiple Rotenone concentrations, where increased survival related to 
decreased intracellular ROS (Figure 6.4 and 6.5). This data indicates that the BCAT1 CXXC 
motif survival advantage is conferred through a reduction in the cellular redox 
environment i.e. an antioxidant effect.  
Rotenone is a ‘pro-oxidant’, that increases mitochondrial ROS generation 
through inhibition of complex I of the electron transport chain and has been shown to 
induce apoptosis in a wide range of cancer models including APL, neuroblastoma and 
liver cells (Deng, Huang and Lin, 2010; Sriskanthadevan et al., 2015). In the breast cancer 
cell line, MCF-7, Rotenone induced apoptosis is mediated through an increase in the pro-
apoptotic ‘p53 target’ Bax (Deng, Huang and Lin, 2010). Moreover, in the liver cell line, 
HepG2, Rotenone induced cytotoxicity resulted in the upregulation of - p53, Bax, and 
caspase-3, with down-regulation of Bcl-2 mRNA, indicating that Rotenone induced 
apoptosis is mediated through these previously described redox sensitive pathways 
(Deng, Huang and Lin, 2010; Siddiqui et al., 2013). Given that the data presented here 
demonstrate that BCAT1 overexpression results in a CXXC dependant reduction in 
intracellular ROS following Rotenone treatment, it is possible that increased cell survival 
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as seen in U937-BCAT1(WT) is mediated by modulating these pathways, however, 
further research is required, which is beyond the scope of this thesis. 
In Chapter 5, one of the most important observations was the demonstration 
that  BCAT1 overexpression was linked to an increased survival in response to serum 
starvation induced oxidative stress (Figure 5.7). This observation was attributed to both 
the CXXC motif and metabolic aspect of BCAT1, therefore the efficacy of metabolic 
inhibitor Gabapentin was next investigated in the U937 transgenic cells. Gabapentin is a 
competitive inhibitor of BCAT1, and has been proposed to act as a leucine analogue 
(Goto et al., 2005), however there are various hypotheses about the effects of 
Gabapentin treatment in leukaemia, which depend on the direction on the BCAT1 
metabolic reaction (i.e. leucine + α-KG → α-ketoisocaproate + Glutamate or α-
ketoisocaproate + Glutamate → Leucine + α-KG, see Section 1.3). For example, in a CML 
model it has been demonstrated that Gabapentin decreases cell density, where it is 
proposed that treatment results in a decreased leucine production blocking mTOR 
activation (Hattori et al., 2017).  Conversely, Gabapentin treatment has been 
demonstrated to reduce BCAT1 metabolite Glutamate in neuronal cells (Tönjes et al., 
2013).  Wang et al theorised that BCAT1 supplies Glutamate for GSH synthesis, thus 
protecting the BCAT1 overexpressing cell from ROS inducing Epidermal Growth Factor 
Receptor Tyrosine Kinase therapy (Wang et al., 2019). Contrary to these studies, 
Grankvist et al demonstrated that Gabapentin can supress cell density independent of 
BCAT1 mediated BCAA transamination, although they admit a convincing alternative 
mechanism remains unclear (Grankvist et al., 2018). Here treatment with Gabapentin 
shows a decreased density and viability for U937-BCAT1(WT) significantly more than 
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U937-Control(EV) (Figure 6.2), supporting the notion that Gabapentin treatment is 
targeting the BCAT1 metabolic activity. However, this treatment effect is nullified for 
U937-BCAT1(C338S) cells, indicating that there is a redox component, perhaps in this 
context the increased ROS levels found in BCAT1(C338S) cells, that is providing a 
proliferative advantage compared to U937-BCAT1(WT). Moreover, these results may 
indicate that pro-oxidant treatment works antagonistically with Gabapentin in patients 
with high BCAT1 expression and warrants further investigation. 
Finally, given that BCAT1 has been proposed to activate the growth and survival 
regulator mTOR, through leucine production (Hattori et al., 2017), the efficacy of the 
mTOR inhibitor ‘Rapamycin’ was examined here. For U937-BCAT1(WT) and U937-
BCAT1(EV) controls, no significant difference in density or viability was observed (Figure 
6.3). This may suggest that for the U937 cell line, BCAT1 favours the leucine catabolism, 
and therefore mTOR activation remains unaffected by blocking BCAT1 activity, although 
this cannot be confirmed from the data presented here. Exploration of BCAT1 
overexpression in multiple AML cell lines will be needed to elucidate this along with a 
metabolomics approach to evaluate BCAT1 metabolite changes, which is beyond the 
scope for this thesis. 
In summary here we have demonstrated for the first time that BCAT1 CXXC motif 
protects against standard chemotherapeutic treatment with Ara-C and Rotenone 
mediated pro-oxidant treatment. Ultimately both treatment effects are likely to be 
redox mediated, possibly through cysteine thiol oxidation/ S-glutathionylation of the 
Capase family and p53 resulting in differential expression of the BCL-2 pro and anti-
apoptotic effectors, although further work is needed to confirm this. Given this, it may 
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be possible to further increase the efficacy of Ara-C treatment in BCAT1 overexpressing 
cells by combining treatment pro-oxidant therapies opening up a new therapeutic 
avenue for clinicians. 
The work presented in this chapter was accepted for presentation at the Annual 
British Society of Haematology Meeting, Birmingham, UK (April, 2020) and the abstract 




Chapter 7. Final Discussion and Future Work 
_________________________________________________________________ 
7.1 Final Discussion 
BCAT1 is an aminotransferase that catalyses the breakdown of Branched Chain 
Amino Acids (BCAA) leucine, isoleucine and valine by transfer of NH3 from the BCAA to 
α-ketoglutarate (α-KG) forming the respective branched-chain alpha-keto acid (BCKA) 
and glutamate(J Davoodi et al., 1998). These metabolites play important roles in a 
variety of cellular processes, including in cellular energetics, epigenetics and glutathione 
synthesis which are all dysregulated in AML. It is perhaps not surprising then that whilst 
expression of BCAT1 in healthy individuals is restricted to Haematopoietic Stem Cells 
(HSC) and the central nervous system(Hutson, 2001), it is highly dysregulated in 
numerous cancers, including AML, where it is generally associated with unfavourable 
outcomes(Xu et al., 2016, 2018b). Recently, there has been increasing research interest 
in the metabolic effects of BCAT1, and several studies have examined the effect of 
BCAT1 silencing in myeloid leukaemia and various other cancer models(Tönjes et al., 
2013; Raffel et al., 2017b; Zhang and Han, 2017; Wang et al., 2019).  However, currently 
there have been no studies examining the effect of the BCAT1 CXXC motif, a redox 
sensitive sequence conserved in the cytosolic and mitochondrial BCAT isoforms and a 
feature of many antioxidant enzymes(Fomenko and Gladyshev, 2003). 
This project has examined the effect of overexpressing wild-type BCAT1 and 
CXXS motif mutant in U937 cells, in order to determine whether the CXXC motif is 
capable of modulating cellular oxidative stress and how this may affect processes 
important in the development of AML including proliferation and apoptosis. Mutating 
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the C338 cysteine residue to serine altered one atom from sulphur to oxygen (Figure 
3.1), preserving the metabolic activity of the enzyme whilst abolishing the antioxidant 
capacity, therefore comparison of U937-BCAT1(WT) and U937-BCAT1(C338S) 
overexpressing cells against an the U937-Control(EV) allowed the contribution of the 
CXXC motif to be elucidated. 
In vitro characterisation of the transgenic U937 cells revealed that U937-
BCAT(WT) and U937-BCAT1(C338S) overexpressing cells had a reduced doubling time as 
well as increased cell density and viability compared to U937-Control(EV), see Chapter 
5. The  reduction in doubling time during exponential growth was matched by an 
increased proportion of G2M phase cells, whilst increased cell density / viability related 
to lower levels of intracellular ROS / increased Glutathione (GSH) in BCAT1 
overexpressing cells. Although U937-BCAT1(WT) displayed a consistently lower doubling 
time, intracellular ROS and higher GSH content than U937-BCAT1(C338S) failed to reach 
significance indicating that in this context these effects were predominantly due to 
BCAT1 metabolic activity. 
Understanding the metabolic contribution of BCAT1 to the observations on cell 
growth and survival is not straightforward. Traditionally BCAT1 is seen as the first step 
in the catabolic breakdown of BCAAs leucine, isoleucine and valine (Figure 1.4), however 
in vitro enzyme kinetic data shows that BCAT1 favours BCAA anabolism i.e. the 
production of α-KG and Leucine (Conway et al., 2008), however metabolomic studies 
indicate that the BCAT1 enzymatic reaction is context dependant, where proliferating 
cells favour the canonical reverse reaction ( α-ketoisocaproate + Glutamate → Leucine 
+ α-KG) and quiescent cells favour the canonical forward reaction  i.e. Leucine + α-KG → 
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α-ketoisocaproate + Glutamate)(Raffel et al., 2017; Wang et al., 2019). The data 
presented in this thesis appears to agree with this interpretation, where an increased 
number of G2M phase cells during exponential growth indicates BCAT1 is stimulating 
growth through production of α-KG and leucine (Chapter 5). In this model of 
explanation, α-KG anaplerotically replenishes the TCA cycle, whilst leucine activates 
mTOR stimulating growth and survival (Pathways seen in Figure 1.7)(Zhang and Han, 
2017). 
 Following exponential growth in vitro cell cultures enter a stationary phase, 
where peak cell densities are reached, here U937-BCAT1(WT) and U937-BCAT1(C338S) 
reached significantly higher cell density than U937-Control(EV)(Figure 5.1). An 
explanation for this result may lie in the much studied observation that cancer cells 
display an increased dependency on glutamine metabolism, which is converted to 
glutamate by Glutaminase and subsequently to α-KG by Glutamate dehydrogenase 
(GDH), thus producing the toxic ammonium ion (NH4+)(Altman, Stine and Dang, 
2016).Aminotransferases, including BCAT1, allow conversion of Glutamate to α-KG 
without NH4+ production, which inhibits growth and survival in closed 
cultures(Schneider, Marison and Von Stockar, 1996).  
Furthermore, it was shown that as in vitro cell cultures entered the stationary 
phase GSH content increased and intracellular ROS decreased in BCAT1 overexpressing 
cells suggesting that the transamination reaction mediated by BCAT1 has reversed 
during stationery and death phases i.e. leucine + α-KG → α-ketoisocaproate + 
glutamate. Glutamate is a precursor for GSH synthesis which is the most abundant small 
molecule antioxidant, cellular antioxidant enzymes including Glutathione peroxidase 
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(GPx) and Peroxiredoxins (Prx) require GSH to act as an electron donor to in the 
reductive elimination of ROS and to regenerate antioxidant enzymes to their reduced 
active forms(Hanschmann et al., 2013). Therefore, an increase in glutamate production 
should permit increased GSH synthesis and decreased ROS levels in BCAT1 
overexpressing U937 transgenic cells, which the data presented in Chapter 5 support.  
Following on from the stationary phase, in vitro cell cultures enter death phase, 
here after 192 h in culture U937-BCAT(WT) cells were significantly more viable than 
U937-BCAT1(C338S) (Figure 5.3), indicating that the BCAT1 CXXC motif may, in part, be 
ameliorating ROS driven apoptosis. To investigate this further U937 transgenic cells 
were placed under serum starvation to induce mitochondrial derived ROS (Li, Chen and 
Gibson, 2013). Serum starvation induced a cell line dependant increase in cellular ROS 
and where U937-Control(EV)> U937-BCAT1(C338S)> U937-BCAT1(WT), a finding which 
was associated with proportional increase in apoptosis (Figures 5.5, 5.7 and 5.8). 
Moreover, the serum starvation phenotype was rescued by across all cell lines by 
addition of antioxidant N-acetyl-cysteine (NAC), demonstrating this effect was, ROS 
driven and therefore redox mediated. However, given that U937-BCAT1(C338S) 
displayed lower ROS and concurrent apoptosis compared to U937-BCAT1(EV) it must be 
reiterated that there is evidence to suggest that a part of the effect of BCAT1 
overexpression on U937 cell survival is likely due to the aminotransferase metabolic 
activity of BCAT1, presumably by production of glutamate as precursor to GSH, which is 




AML is partially defined as a block in cellular differentiation, a cellular process 
which is taken to be redox mediated. Previous work has demonstrated that PMA induces 
differentiation in U937 cells through the ROS second messenger, H202(Yamamoto et al., 
2009). Moreover, recent work has demonstrated metabolic inhibition of BCAT1 
suppresses production of Itaconate following lipopolysaccharide stimulation of 
macrophages(Papathanassiu et al., 2017; Ko et al., 2020). Given Itaconate is known to 
suppress Succinate Dehydrogenase(O’Neill and Artyomov, 2019), a known source of 
mitochondrial ROS, it was important to assess the impact of the CXXC motif on ROS 
following treatment with PMA. 
 In Chapter 5, treatment with PMA resulted in an increased ROS signal in a CXXC 
dependant manner i.e. ROS levels were greatest in U937-Control(EV) > U937-
BCAT1(C338S) > U937BCAT1(WT). This observation related to a proportional change in 
PMA induced CD36 expression, a cell surface marker of monocyte differentiation(Huh 
et al., 1996). Treatment with the BCAT1 inhibitor Gabapentin had a negligible effect on 
cellular ROS levels, however treatment with the antioxidant NAC effectively rescued the 
phenotype, reinforcing the notion PMA induced CD36 expression is ROS mediated, and 
that the BCAT1 CXXC modulates ROS levels in this process, thus causing a differentiation 
block.  
Interestingly, BCAT1 overexpressing U937 cells displayed decreased basal 
percentage of CD36+ cells compared to control(EV) cells, despite displaying no significant 
difference in basal ROS levels. It is possible modifying the CXXC motif by cysteine to 
serine substitution may have disrupted a redox sensitive signalling cascade. Work by 
Conway et al., 2008, demonstrated that under reducing conditions, BCAT1 binds to 
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several redox sensitive proteins that are associated with cytoskeletal remodelling. 
However, under oxidative stress, these proteins no longer bind to BCAT1. Moreover, 
through NEM alkylation studies, it was demonstrated that cysteine residues were 
essential to these redox interactions, where mutating the BCAT1 CXXC motif to SXXS, 
completely abolished these interactions (Conway at al., 2008). The data in Figure 5.12 
shows that U937-Control(EV) display the highest basal percentage of CD36+ cells 
followed by U937-BCAT1(C338S) and U937-BCAT1(WT) respectively. Given this, it may 
be that mutation of the C338 residue to serine has disrupted CXXC motif protein 
interactions that lie upstream of CD36, altering expression, however further proteomic 
studies are needed to elucidate this mechanism. 
Having previously established a protective role for the BCAT1 CXXC motif in 
oxidative stress induced apoptosis (Figures 5.7 and 5.8), chapter 6 looked to evaluate if 
the BCAT1 CXXC motif could protect against treatment with the pro-oxidant Rotenone, 
or against the standard chemotherapeutic Ara-C, which is known to induce apoptosis 
through redox regulated pathways(Irwin, Rivera-Del Valle and Chandra, 2013). Indeed, 
the results show that the BCAT1 CXXC motif protects against Rotenone induced 
apoptosis, which related to lower levels of intracellular ROS levels (Figures 6.4 and 6.5). 
Conversely, both BCAT1(WT) and BCAT1(C338S) overexpressing U937 cells were 
demonstrated to be more sensitive than U937-Control(EV) cells to Ara-C treatment, 
perhaps reflecting the observation BCAT1 overexpressing cells display an increased 
proportion of G2M phase cells (Figure 5.2). Ara-C interrupts cell division during the 
preceding S-phase(Momparler, 2013) therefore increased Ara-C sensitivity in these cells 
would be expected.  
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Comparison between U937-BCAT1(WT) and U937-BCAT(C338S) cellular viability 
shows that the CXXC motif provide a small but significant protective effect following Ara-
C treatment. This effect may be explained by the fact that Ara-C induced apoptosis has 
been demonstrated to be conducted through the ATR-Chk1-p53 pathway, resulting in 
activation mitochondrial mediated apoptosis, for which ROS is implicated(Liu, Chen and 
St. Clair, 2008). In summary, it appears that the mechanism of Ara-C mediated apoptosis 
in the context of BCAT1 overexpressing AML is complex. Whilst an increased S-phase 
may explain an increase in Ara-C sensitivity, reduced levels of ROS conferred by BCAT1 
CXXC motif may in part negate the Ara-C sensitivity. 
In conclusion, this thesis has demonstrated that the BCAT1 CXXC motif is able to 
modulate the intracellular redox environment in response to oxidative stress and that 
this impacts processes important to the development of AML, including cellular 
differentiation and apoptosis. Moreover, BCAT1 provides CXXC motif derived protection 
against pro-oxidant treatment whilst increasing sensitivity to treatment with standard 
chemotherapeutic Ara-C. This study therefore provides the first evidence to support the 
hypothesis set out in the introduction that the BCAT1 CXXC motif behaves as a novel 
antioxidant. 
7.2 Future Work 
Investigating BCAT1 CXXC motif derived CD36 expression 
The data presented here show that CD36+ expression is reduced in U937-
BCAT1(WT) cells compared to U937-BCAT1(C338S), however the mechanism for this 
difference remains unclear. CD36 has been identified to be under the control 
antioxidant transcription factor Nrf2 in macrophages (Ishii et al., 2004). Nrf2 is redox 
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regulated, where under low ROS conditions, cytoplasmic Nrf2 interacts with KEAP1. 
However, under oxidative stress, KEAP1 undergoes cysteine thiol oxidation, which 
mediates the dissociation from Nrf2, which then translocates to the nucleus, inducing 
expression of numerous genes, including CD36 (Ishii et al., 2004). It is possible that the 
BCAT1 CXXC motif is providing an antioxidant effect that is preventing disassociation of 
KEAP1 from Nrf2, explaining the decreased CD36 expression. Resolving the extent of 
Nrf2 expression in U937-BCAT1(WT) and U937-BCAT1(C388S) cells would be an 
important step to understanding the mechanism behind reduced CD36 expression seen 
in BCAT1 overexpressing cells. Moreover, the downregulation of CD36 in BCAT1 
expressing cells may have implications for AML treatment, given that CD36 ligand 
‘Thrombospondin-1’ has been shown to induce apoptosis and has been investigated as 
a possible therapeutic in CD36 positive cells (K. Li et al., 2003). If the BCAT1 CXXC motif 
is indeed linked to a wider redox sensing network that involves Nrf2, it may be possible 
to induce CD36 expression with pro-oxidants, thus allowing combinational 
Thrombospondin-1 treatment for BCAT1high AML patients.  
CD36 stimulation has also been associated with actin polymerisation in 
macrophages, which links CD36 signalling to cellular migration, adhesion, and 
phagocytosis (Stuart et al., 2007). Interestingly, as previously described in Chapter 5, 
work by Conway et al., 2008 demonstrated that under reducing conditions BCAT1 binds 
to several redox sensitive proteins that are associated with cytoskeletal remodelling 
including β-tubulin, Septin-4 and Myosin-6, all of which disassociate under oxidative 
stress (Conway et al.,2008). Mutation of the CXXC motif in this thesis may have altered 
a host of proteins that associate with BCAT1(WT) under ‘reduced’ and ‘oxidised’ 
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intracellular conditions. Therefore, a proteomic approach to compare proteins 
interactions with BCAT1(WT) and BCAT1(C338S) may uncover a previously unknown 
signalling components that links BCAT1 and cytoskeletal remodelling. The Conway et al., 
2008 study demonstrated that these redox interactions occur in neural cells, however 
the nature of these interaction in healthy myeloid blood and myeloid leukaemia cells 
remains unknown. Indeed, superficially, U937-BCAT1(C338S) cells appear to exhibit 
more extraneous pseudopodia than U937-BCAT(WT) cells upon visual examination. 
Therefore, future work that incorporates migration assays may reveal a significant 
difference between the two cell lines.  
 
Combinational Therapy investigations 
The data presented in Chapter 6 illustrate that BCAT1 confers sensitivity to 
treatment to with Ara-C, whilst the CXXC motif provides protection against pro-oxidant 
Rotenone treatment. However, it is not known if Rotenone can be delivered in 
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Appendix A. NCBI Blast vector sequence alignments  
 
Legend:  Start codon = ATG    
 Stop codon =  GAT 
 C335S codon = GCA  




Subject: serial cloner in silico pCMV6-BCAT1(WT) 
 
Query  137   ACCGAGGAGATCTGCCGCCGCGATCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTG  196 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1001  ACCGAGGAGATCTGCCGCCGCGATCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTG  1060 
 
Query  197   TACCGGAGAAGGAGGATCAAAAGAGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGT  256 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1061  TACCGGAGAAGGAGGATCAAAAGAGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGT  1120 
 
Query  257   CACACCAGCTACCATTTTAAAGGAAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGT  316 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1121  CACACCAGCTACCATTTTAAAGGAAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGT  1180 
 
Query  317   GTTCACGGATCATATGCTGACGGTGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCA  376 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1181  GTTCACGGATCATATGCTGACGGTGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCA  1240 
 
Query  377   TATCAAGCCTCTTCAGAACCTGTCATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGT  436 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1241  TATCAAGCCTCTTCAGAACCTGTCATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGT  1300 
 
Query  437   GGAATTATTTGAAGGATTGAAGGCATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCA  496 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1301  GGAATTATTTGAAGGATTGAAGGCATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCA  1360 
 
Query  497   GCCAAACCTCAACATGGATAGAATGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATT  556 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1361  GCCAAACCTCAACATGGATAGAATGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATT  1420 
 
Query  557   TGACAAAGAAGAGCTCTTAGAGTGTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGT  616 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1421  TGACAAAGAAGAGCTCTTAGAGTGTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGT  1480 
 
Query  617   CCCATATTCAACATCTGCTAGTCTGTATATTCGTCCTACATTCATTGGAACTGAGCCTTC  676 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1481  CCCATATTCAACATCTGCTAGTCTGTATATTCGTCCTACATTCATTGGAACTGAGCCTTC  1540 
 
Query  677   TCTTGGAGTCAAGAAGCCTACCAAAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACC  736 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1541  TCTTGGAGTCAAGAAGCCTACCAAAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACC  1600 
 
Query  737   TTATTTTTCAAGTGGAACCTTTAATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAG  796 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1601  TTATTTTTCAAGTGGAACCTTTAATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAG  1660 
 
Query  797   AGCCTGGAAAGGTGGAACTGGGGACTGCAAGATGGGAGGGAATTACGGCTCATCTCTTTT  856 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 






Subject: serial cloner in silico pCMV6-BCAT1(WT) 
 
 
Query  141   TTGCTGCCAGATCCTCTTCTGAGATGAGTTTCTGCTCGAGCGGCCGCGTACGCGTGGATA  200 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2238  TTGCTGCCAGATCCTCTTCTGAGATGAGTTTCTGCTCGAGCGGCCGCGTACGCGTGGATA  2179 
 
Query  201   GCACAATTGTCCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAATTTGCTCAAGA  260 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2178  GCACAATTGTCCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAATTTGCTCAAGA  2119 
 
Query  261   TGCGGCTTGCCAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTCTCGCCTTTGT  320 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2118  TGCGGCTTGCCAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTCTCGCCTTTGT  2059 
 
Query  321   ACAGTATATCAGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAACATCTCTCTCA  380 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2058  ACAGTATATCAGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAACATCTCTCTCA  1999 
 
Query  381   CTCTGTTCCCCTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTCTCTGACACCT  440 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1998  CTCTGTTCCCCTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTCTCTGACACCT  1939 
 
Query  441   TAAATTCACCCCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACTCCTGGAAGAA  500 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1938  TAAATTCACCCCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACTCCTGGAAGAA  1879 
 
Query  501   TGATGCCATCTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTTATCCAGTAAA  560 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1878  TGATGCCATCTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTTATCCAGTAAA  1819 
 
Query  561   GAAAAAGATTCATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAGAGCCACAGGA  620 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1818  GAAAAAGATTCATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAGAGCCACAGGA  1759 
 
Query  621   CCTGCTGACACCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAGCCGTAATTCC  680 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1758  CCTGCTGACACCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAGCCGTAATTCC  1699 
 
Query  681   CTCCCATCTTGCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTGGGATTGGCCC  740 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1698  CTCCCATCTTGCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTGGGATTGGCCC  1639 
 
Query  741   ACAGGGACACTGGATTAAAGGTTCCACTTGAAAAATAA   
             ||||||||||||||||||||||||||||||||||||||  























Subject: serial cloner in silico pCMV6-BCAT1(WT) 
 
 
Query  135   ACCGAGGAGATCTGCCGCCGCGATCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTG  194 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1001  ACCGAGGAGATCTGCCGCCGCGATCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTG  1060 
 
Query  195   TACCGGAGAAGGAGGATCAAAAGAGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGT  254 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1061  TACCGGAGAAGGAGGATCAAAAGAGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGT  1120 
 
Query  255   CACACCAGCTACCATTTTAAAGGAAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGT  314 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1121  CACACCAGCTACCATTTTAAAGGAAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGT  1180 
 
Query  315   GTTCACGGATCATATGCTGACGGTGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCA  374 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1181  GTTCACGGATCATATGCTGACGGTGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCA  1240 
 
Query  375   TATCAAGCCTCTTCAGAACCTGTCATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGT  434 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1241  TATCAAGCCTCTTCAGAACCTGTCATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGT  1300 
 
Query  435   GGAATTATTTGAAGGATTGAAGGCATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCA  494 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1301  GGAATTATTTGAAGGATTGAAGGCATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCA  1360 
 
Query  495   GCCAAACCTCAACATGGATAGAATGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATT  554 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1361  GCCAAACCTCAACATGGATAGAATGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATT  1420 
 
Query  555   TGACAAAGAAGAGCTCTTAGAGTGTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGT  614 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1421  TGACAAAGAAGAGCTCTTAGAGTGTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGT  1480 
 
Query  615   CCCATATTCAACATCTGCTAGTCTGTATATTCGTCCTACATTCATTGGAACTGAGCCTTC  674 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1481  CCCATATTCAACATCTGCTAGTCTGTATATTCGTCCTACATTCATTGGAACTGAGCCTTC  1540 
 
Query  675   TCTTGGAGTCAAGAAGCCTACCAAAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACC  734 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1541  TCTTGGAGTCAAGAAGCCTACCAAAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACC  1600 
 
Query  735   TTATTTTTCAAGTGGAACCTTTAATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAG  794 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1601  TTATTTTTCAAGTGGAACCTTTAATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAG  1660 
 
Query  795   AGCCTGGAAAGGTGGAACTGGGGACTGCAAGATGGGAGGGAATTACGGCTCATCTCTTTT  854 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1661  AGCCTGGAAAGGTGGAACTGGGGACTGCAAGATGGGAGGGAATTACGGCTCATCTCTTTT  1720 
 
Query  855   TGCCCAATGTGAAGCAGTAGATAAT 879  
             |||||||||||||||||||||||||  















Subject: serial cloner in silico pCMV6-BCAT1(WT) 
 
 
Query  12    GATCCTCTTCTGAGATGAGTTTCTGCTCGAGCGGCCGCGTACGCGTGGATAGCACAATTG  71 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2229  GATCCTCTTCTGAGATGAGTTTCTGCTCGAGCGGCCGCGTACGCGTGGATAGCACAATTG  2170 
 
Query  72    TCCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAATTTGCTCAAGATGCGGCTTG  131 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2169  TCCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAATTTGCTCAAGATGCGGCTTG  2110 
 
Query  132   CCAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTCTCGCCTTTGTACAGTATAT  191 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2109  CCAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTCTCGCCTTTGTACAGTATAT  2050 
 
Query  192   CAGAAACTGGGCAAACAACAGAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCC  251 
             |||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct  2049  CAGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCC  1990 
 
Query  252   CCTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTCTCTGACACCTTAAATTCAC  311 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1989  CCTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTCTCTGACACCTTAAATTCAC  1930 
 
Query  312   CCCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACTCCTGGAAGAATGATGCCAT  371 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1929  CCCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACTCCTGGAAGAATGATGCCAT  1870 
 
Query  372   CTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTTATCCAGTAAAGAAAAAGAT  431 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1869  CTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTTATCCAGTAAAGAAAAAGAT  1810 
 
Query  432   TCATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAGAGCCACAGGACCTGCTGAC  491 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1809  TCATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAGAGCCACAGGACCTGCTGAC  1750 
 
Query  492   ACCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAGCCGTAATTCCCTCCCATCT  551 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1749  ACCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAGCCGTAATTCCCTCCCATCT  1690 
 
Query  552   TGCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTGGGATTGGCCCACAGGGACA  611 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1689  TGCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTGGGATTGGCCCACAGGGACA  1630 
 
Query  612   CTGGATTAAAGGTTCCACTTGAAAAATAAGGTCCCACTGGGCTCAAGAGTACAAAGAGCA  671 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 

















Subject: serial cloner in silico pCMV6-BCAT1(WT) 
 
 
Query  138   ACCGAGGAGATCTGCCGCCGCGATCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTG  197 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1001  ACCGAGGAGATCTGCCGCCGCGATCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTG  1060 
 
Query  198   TACCGGAGAAGGAGGATCAAAAGAGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGT  257 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1061  TACCGGAGAAGGAGGATCAAAAGAGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGT  1120 
 
Query  258   CACACCAGCTACCATTTTAAAGGAAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGT  317 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1121  CACACCAGCTACCATTTTAAAGGAAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGT  1180 
 
Query  318   GTTCACGGATCATATGCTGACGGTGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCA  377 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1181  GTTCACGGATCATATGCTGACGGTGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCA  1240 
 
Query  378   TATCAAGCCTCTTCAGAACCTGTCATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGT  437 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1241  TATCAAGCCTCTTCAGAACCTGTCATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGT  1300 
 
Query  438   GGAATTATTTGAAGGATTGAAGGCATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCA  497 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1301  GGAATTATTTGAAGGATTGAAGGCATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCA  1360 
 
Query  498   GCCAAACCTCAACATGGATAGAATGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATT  557 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1361  GCCAAACCTCAACATGGATAGAATGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATT  1420 
 
Query  558   TGACAAAGAAGAGCTCTTAGAGTGTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGT  617 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1421  TGACAAAGAAGAGCTCTTAGAGTGTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGT  1480 
 
Query  618   CCCATATTCAACATCTGCTAGTCTGTATATTCGTCCTACATTCATTGGAACTGAGCCTTC  677 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1481  CCCATATTCAACATCTGCTAGTCTGTATATTCGTCCTACATTCATTGGAACTGAGCCTTC  1540 
 
Query  678   TCTTGGAGTCAAGAAGCCTACCAAAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACC  737 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1541  TCTTGGAGTCAAGAAGCCTACCAAAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACC  1600 
 
Query  738   TTATTTTTCAAGTGGAACCTTTAATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAG  797 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1601  TTATTTTTCAAGTGGAACCTTTAATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAG  1660 
 
Query  798   AGCCTGGAAAGGTGGAACTGGGGACTGCAAGATGGGAGGGAATTACGGCTCATCTCTTTT  857 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 



















Subject: serial cloner in silico pCMV6-BCAT1(WT) 
 
 
Query  16    GATCCTCCTTCTGGRGATGAGTTTCTGCTCGAGCGGCCGCGTACGCGTGGATAGCACAAT  75 
             |||||| ||||| | ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2229  GATCCT-CTTCT-GAGATGAGTTTCTGCTCGAGCGGCCGCGTACGCGTGGATAGCACAAT  2172 
 
Query  76    TGTCCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAATTTGCTCAAGATGCGGCT  135 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2171  TGTCCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAATTTGCTCAAGATGCGGCT  2112 
 
Query  136   TGCCAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTCTCGCCTTTGTACAGTAT  195 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2111  TGCCAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTCTCGCCTTTGTACAGTAT  2052 
 
Query  196   ATCAGAAACTGGGCTAACAACACAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTT  255 
             |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2051  ATCAGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTT  1992 
 
Query  256   CCCCTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTCTCTGACACCTTAAATTC  315 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1991  CCCCTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTCTCTGACACCTTAAATTC  1932 
 
Query  316   ACCCCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACTCCTGGAAGAATGATGCC  375 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1931  ACCCCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACTCCTGGAAGAATGATGCC  1872 
 
Query  376   ATCTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTTATCCAGTAAAGAAAAAG  435 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1871  ATCTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTTATCCAGTAAAGAAAAAG  1812 
 
Query  436   ATTCATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAGAGCCACAGGACCTGCTG  495 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1811  ATTCATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAGAGCCACAGGACCTGCTG  1752 
 
Query  496   ACACCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAGCCGTAATTCCCTCCCAT  555 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1751  ACACCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAGCCGTAATTCCCTCCCAT  1692 
 
Query  556   CTTGCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTGGGATTGGCCCACAGGGA  615 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1691  CTTGCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTGGGATTGGCCCACAGGGA  1632 
 
Query  616   CACTGGATTAAAGGTTCCACTTGAAAAATAAGGTCCCACTGGGCTCAAGAGTACAAAGAG  675 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1631  CACTGGATTAAAGGTTCCACTTGAAAAATAAGGTCCCACTGGGCTCAAGAGTACAAAGAG  1572 
 
Query  676   CAGGGCTTTGGTAGGCTTCTTGACTCCAAGAGAAGGCTCAGTTCCAATGAATGTAGGACG  735 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1571  CAGGGCTTTGGTAGGCTTCTTGACTCCAAGAGAAGGCTCAGTTCCAATGAATGTAGGACG  1512 
 
Query  736   AATATACAGACTAGCAGATGTTGAATATGGGACCCATTCTTGATCCAATTTCACAAGCTG  795 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1511  AATATACAGACTAGCAGATGTTGAATATGGGACCCATTCTTGATCCAATTTCACAAGCTG  1452 
 
Query  796   TTGAATACACTCTAAGAGCTCTTCTTTGTCAAATACCGGCAGAGTTGCCCTCACAGCAGA  855 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 











Subject: serial cloner in silico pCMV6-BCAT1(WT) 
 
 
Query  137   ACCGAGGAGATCTGCCGCCGCGATCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTG  196 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1001  ACCGAGGAGATCTGCCGCCGCGATCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTG  1060 
 
Query  197   TACCGGAGAAGGAGGATCAAAAGAGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGT  256 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1061  TACCGGAGAAGGAGGATCAAAAGAGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGT  1120 
 
Query  257   CACACCAGCTACCATTTTAAAGGAAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGT  316 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1121  CACACCAGCTACCATTTTAAAGGAAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGT  1180 
 
Query  317   GTTCACGGATCATATGCTGACGGTGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCA  376 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1181  GTTCACGGATCATATGCTGACGGTGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCA  1240 
 
Query  377   TATCAAGCCTCTTCAGAACCTGTCATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGT  436 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1241  TATCAAGCCTCTTCAGAACCTGTCATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGT  1300 
 
Query  437   GGAATTATTTGAAGGATTGAAGGCATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCA  496 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1301  GGAATTATTTGAAGGATTGAAGGCATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCA  1360 
 
Query  497   GCCAAACCTCAACATGGATAGAATGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATT  556 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1361  GCCAAACCTCAACATGGATAGAATGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATT  1420 
 
Query  557   TGACAAAGAAGAGCTCTTAGAGTGTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGT  616 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1421  TGACAAAGAAGAGCTCTTAGAGTGTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGT  1480 
 
Query  617   CCCATATTCAACATCTGCTAGTCTGTATATTCGTCCTACATTCATTGGAACTGAGCCTTC  676 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1481  CCCATATTCAACATCTGCTAGTCTGTATATTCGTCCTACATTCATTGGAACTGAGCCTTC  1540 
 
Query  677   TCTTGGAGTCAAGAAGCCTACCAAAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACC  736 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1541  TCTTGGAGTCAAGAAGCCTACCAAAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACC  1600 
 
Query  737   TTATTTTTCAAGTGGAACCTTTAATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAG  796 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1601  TTATTTTTCAAGTGGAACCTTTAATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAG  1660 
 
Query  797   AGCCTGGAAAGGTGGAACTGGGGACTGCAAGATGGGAGGGAATTACGGCTCATCTCTTTT  856 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1661  AGCCTGGAAAGGTGGAACTGGGGACTGCAAGATGGGAGGGAATTACGGCTCATCTCTTTT  1720 
 
Query  857   TGCCCAATGTGAAGCAGTAGATAATGGGTGTCAGCAGGTCCTGTGGCTCTATGGAGAGGA  916 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 















Subject: serial cloner in silico pCMV6-BCAT1(WT) 
 
 
Query  12    ATCCTCTTCTGAGATGAGTTTCTGCTCGAGCGGCCGCGTACGCGTGGATAGCACAATTGT  71 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2228  ATCCTCTTCTGAGATGAGTTTCTGCTCGAGCGGCCGCGTACGCGTGGATAGCACAATTGT  2169 
 
Query  72    CCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAATTTGCTCAAGATGCGGCTTGC  131 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2168  CCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAATTTGCTCAAGATGCGGCTTGC  2109 
 
Query  132   CAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTCTCGCCTTTGTACAGTATATC  191 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2108  CAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTCTCGCCTTTGTACAGTATATC  2049 
 
Query  192   AGAAACTGGGCTAACAACAGAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCCC  251 
             ||||||||||| ||||||| |||||||||||||||||||||||||||||||||||||||| 
Sbjct  2048  AGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCCC  1989 
 
Query  252   CTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTCTCTGACACCTTAAATTCACC  311 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1988  CTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTCTCTGACACCTTAAATTCACC  1929 
 
Query  312   CCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACTCCTGGAAGAATGATGCCATC  371 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1928  CCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACTCCTGGAAGAATGATGCCATC  1869 
 
Query  372   TAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTTATCCAGTAAAGAAAAAGATT  431 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1868  TAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTTATCCAGTAAAGAAAAAGATT  1809 
 
Query  432   CATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAGAGCCACAGGACCTGCTGACA  491 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1808  CATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAGAGCCACAGGACCTGCTGACA  1749 
 
Query  492   CCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAGCCGTAATTCCCTCCCATCTT  551 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1748  CCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAGCCGTAATTCCCTCCCATCTT  1689 
 
Query  552   GCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTGGGATTGGCCCACAGGGACAC  611 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1688  GCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTGGGATTGGCCCACAGGGACAC  1629 
 
Query  612   TGGATTAAAGGTTCCACTTGAAAAATAAGGTCCCACTGGGCTCAAGAGTACAAAGAGCAG  671 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1628  TGGATTAAAGGTTCCACTTGAAAAATAAGGTCCCACTGGGCTCAAGAGTACAAAGAGCAG  1569 
 
Query  672   GGCTTTGGTAGGCTTCTTGACTCCAAGAGAAGGCTCAGTTCCAATGAATGTAGGACGAAT  731 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1568  GGCTTTGGTAGGCTTCTTGACTCCAAGAGAAGGCTCAGTTCCAATGAATGTAGGACGAAT  1509 
 
Query  732   ATACAGACTAGCAGATGTTGAATATGGGACCCATTCTTGATCCAATTTCACAAGCTGTTG  791 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1508  ATACAGACTAGCAGATGTTGAATATGGGACCCATTCTTGATCCAATTTCACAAGCTGTTG  1449 
 
Query  792   AATACACTCTAAGAGCTCTTCTTTGTCAAATACCGGCAGAGTTGCCCTCACAGCAGAGCG  851 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1448  AATACACTCTAAGAGCTCTTCTTTGTCAAATACCGGCAGAGTTGCCCTCACAGCAGAGCG  1389 
 
Query  852   ATACATTCTATCCATGTTGAGGTTTGGCTGAAACAGTCGAATTT-ATTATCTACTCCTCG  910 
             |||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||| 







Subject: serial cloner in silico pET28-BCAT1(WT) 
 
 
Query  134   ATGGATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAGGTG  193 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1345  ATGGATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAGGTG  1286 
 
Query  194   GTGGGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAAAAA  253 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1285  GTGGGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAAAAA  1226 
 
Query  254   CCAGACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGGTGGAG  313 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1225  CCAGACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGGTGGAG  1166 
 
Query  314   TGGTCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCATTG  373 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1165  TGGTCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCATTG  1106 
 
Query  374   CACCCTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGGCATTT  433 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1105  CACCCTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGGCATTT  1046 
 
Query  434   CGAGGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATGTAT  493 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1045  CGAGGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATGTAT  986 
 
Query  494   CGCTCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGTATT  553 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  985   CGCTCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGTATT  926 
 
Query  554   CAACAGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTCTGTAT  613 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  925   CAACAGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTCTGTAT  866 
 
Query  614   ATTCGTCCTACATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCAAAGCC  673 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  865   ATTCGTCCTACATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCAAAGCC  806 
 
Query  674   CTGCTCTTTGTACTCTTGAGCCCAGTGGGACCTTATTTTTCAAGTGGAACCTTTAATCCA  733 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 



























Subject: serial cloner in silico pET28-BCAT1(WT) 
 
 
Query  70    GCGGCCGCAAGCTTGTCGACTGATCAGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTT  129 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  165   GCGGCCGCAAGCTTGTCGACTGATCAGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTT  224 
 
Query  130   CCATACTGGATATCAGTTAATTTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCC  189 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  225   CCATACTGGATATCAGTTAATTTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCC  284 
 
Query  190   ATAGTTGGAATGTGTATTGTCTCGCCTTTGTACAGTATATCAGAAACTGGGCAAACAACA  249 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  285   ATAGTTGGAATGTGTATTGTCTCGCCTTTGTACAGTATATCAGAAACTGGGCAAACAACA  344 
 
Query  250   CAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAG  309 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  345   CAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAG  404 
 
Query  310   TCATCCATGGTGAGGTATCTCTCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCC  369 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  405   TCATCCATGGTGAGGTATCTCTCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCC  464 
 
Query  370   AGAATGCACCGCCTTGTCACTCCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGT  429 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  465   AGAATGCACCGCCTTGTCACTCCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGT  524 
 
Query  430   TCTTCTTCTCCATCTTCATTTATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTG  489 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  525   TCTTCTTCTCCATCTTCATTTATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTG  584 
 
Query  490   ATCTGATGGTCCTCTCCATAGAGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCA  549 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  585   ATCTGATGGTCCTCTCCATAGAGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCA  644 
 
Query  550   CATTGGGCAAAAAGAGATGAGCCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCT  609 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  645   CATTGGGCAAAAAGAGATGAGCCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCT  704 
 
Query  610   TTCCAGGCTCTTACATACTTGGGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTT  669 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  705   TTCCAGGCTCTTACATACTTGGGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTT  764 
 
Query  670   GAAAAATAAGGTCCCACTGGGCTCAAGAGTACAAAGAGCAGGGCTTTGGTAGGCTTCTTG  729 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  765   GAAAAATAAGGTCCCACTGGGCTCAAGAGTACAAAGAGCAGGGCTTTGGTAGGCTTCTTG  824 
 
Query  730   ACTCCAAGAGAAGGCTCAGTTCCAATGAATGTAGGACGAATATACAGACTAGCAGATGTT  789 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 

















Primer : T7 F 
Query: pET28-BCAT1(C335S) 
Subject: serial cloner in silico pET28-BCAT1(WT) 
 
 
Query  92    TCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGCTAGCATGGATTGCAGTAA  151 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1391  TCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGCTAGCATGGATTGCAGTAA  1332 
 
Query  152   CGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAGGTGGTGGGGACTTTTAA  211 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1331  CGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAGGTGGTGGGGACTTTTAA  1272 
 
Query  212   GGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAAAAACCAGACCCCAATAA  271 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1271  GGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAAAAACCAGACCCCAATAA  1212 
 
Query  272   TCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGGTGGAGTGGTCCTCAGAGTT  331 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1211  TCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGGTGGAGTGGTCCTCAGAGTT  1152 
 
Query  332   TGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCATTGCACCCTGGCTCATC  391 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1151  TGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCATTGCACCCTGGCTCATC  1092 
 
Query  392   AGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGGCATTTCGAGGAGTAGATAA  451 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1091  AGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGGCATTTCGAGGAGTAGATAA  1032 
 
Query  452   TAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATGTATCGCTCTGCTGTGAG  511 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1031  TAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATGTATCGCTCTGCTGTGAG  972 
 
Query  512   GGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGTATTCAACAGCTTGTGAA  571 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  971   GGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGTATTCAACAGCTTGTGAA  912 
 
Query  572   ATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTCTGTATATTCGTCCTACATT  631 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  911   ATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTCTGTATATTCGTCCTACATT  852 
 
Query  632   CATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCAAAGCCCTGCTCTTTGTACT  691 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 

























Primer : T7 R 
Query: pET28-BCAT1(C335S) 
Subject: serial cloner in silico pET28-BCAT1(WT) 
 
 
Query  92    TTGTCGACTGATCAGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTTCCATACTGGATA  151 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  177   TTGTCGACTGATCAGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTTCCATACTGGATA  236 
 
Query  152   TCAGTTAATTTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCCATAGTTGGAATG  211 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  237   TCAGTTAATTTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCCATAGTTGGAATG  296 
 
Query  212   TGTATTGTCTCGCCTTTGTACAGTATATCAGAAACTGGGCAAACAACAGAGGCTGTACCA  271 
             |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||| 
Sbjct  297   TGTATTGTCTCGCCTTTGTACAGTATATCAGAAACTGGGCAAACAACACAGGCTGTACCA  356 
 
Query  272   GAGCCAAACATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAGTCATCCATGGTG  331 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  357   GAGCCAAACATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAGTCATCCATGGTG  416 
 
Query  332   AGGTATCTCTCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCCAGAATGCACCGC  391 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  417   AGGTATCTCTCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCCAGAATGCACCGC  476 
 
Query  392   CTTGTCACTCCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCA  451 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  477   CTTGTCACTCCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCA  536 
 
Query  452   TCTTCATTTATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTGATCTGATGGTCC  511 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  537   TCTTCATTTATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTGATCTGATGGTCC  596 
 
Query  512   TCTCCATAGAGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCACATTGGGCAAAA  571 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  597   TCTCCATAGAGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCACATTGGGCAAAA  656 
 
Query  572   AGAGATGAGCCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCTTTCCAGGCTCTT  631 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  657   AGAGATGAGCCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCTTTCCAGGCTCTT  716 
 
Query  632   ACATACTTGGGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTTGAAAAATAAGGT  691 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  717   ACATACTTGGGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTTGAAAAATAAGGT  776 
 
Query  692   CCCACTGGGCTCAAGAGTACAAAGAGCAGGGCTTTGGTAGGCTTCTTGACTCCAAGAGAA  751 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 













Primer : T7 F 
Query: pET28-BCAT1(C338S) 
Subject: serial cloner in silico pET28-BCAT1(WT) 
 
 
Query  79    atcatcmtcatcatcaCAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGCTAGCATGG  138 
             |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1401  ATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGCTAGCATGG  1342 
 
Query  139   ATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAGGTGGTGG  198 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1341  ATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAGGTGGTGG  1282 
 
Query  199   GGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAAAAACCAG  258 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1281  GGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAAAAACCAG  1222 
 
Query  259   ACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGGTGGAGTGGT  318 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1221  ACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGGTGGAGTGGT  1162 
 
Query  319   CCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCATTGCACC  378 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1161  CCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCATTGCACC  1102 
 
Query  379   CTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGGCATTTCGAG  438 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1101  CTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGGCATTTCGAG  1042 
 
Query  439   GAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATGTATCGCT  498 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1041  GAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATGTATCGCT  982 
 
Query  499   CTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGTATTCAAC  558 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  981   CTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGTATTCAAC  922 
 
Query  559   AGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTCTGTATATTC  618 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  921   AGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTCTGTATATTC  862 
 
Query  619   GTCCTACATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCAAAGCCCTGC  678 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  861   GTCCTACATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCAAAGCCCTGC  802 
 
Query  679   TCTTTGTACTCTTGAGCCCAGTGGGACCTTATTTTTCAAGTGGAACCTTTAATCCAGTGT  738 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 





















Primer : T7 R 
Query: pET28-BCAT1(C338S) 
Subject: serial cloner in silico pET28-BCAT1(WT) 
 
 
Query  72    GCGGCCSCAAGCTTGTCGACTGATCAGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTT  131 
             |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  165   GCGGCCGCAAGCTTGTCGACTGATCAGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTT  224 
 
Query  132   CCATACTGGATATCAGTTAATTTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCC  191 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  225   CCATACTGGATATCAGTTAATTTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCC  284 
 
Query  192   ATAGTTGGAATGTGTATTGTCTCGCCTTTGTACAGTATATCAGAAACTGGGCTAACAACA  251 
             |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||| 
Sbjct  285   ATAGTTGGAATGTGTATTGTCTCGCCTTTGTACAGTATATCAGAAACTGGGCAAACAACA  344 
 
Query  252   CAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAG  311 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  345   CAGGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAG  404 
 
Query  312   TCATCCATGGTGAGGTATCTCTCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCC  371 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  405   TCATCCATGGTGAGGTATCTCTCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCC  464 
 
Query  372   AGAATGCACCGCCTTGTCACTCCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGT  431 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  465   AGAATGCACCGCCTTGTCACTCCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGT  524 
 
Query  432   TCTTCTTCTCCATCTTCATTTATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTG  491 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  525   TCTTCTTCTCCATCTTCATTTATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTG  584 
 
Query  492   ATCTGATGGTCCTCTCCATAGAGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCA  551 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  585   ATCTGATGGTCCTCTCCATAGAGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCA  644 
 
Query  552   CATTGGGCAAAAAGAGATGAGCCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCT  611 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  645   CATTGGGCAAAAAGAGATGAGCCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCT  704 
 
Query  612   TTCCAGGCTCTTACATACTTGGGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTT  671 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  705   TTCCAGGCTCTTACATACTTGGGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTT  764 
 
Query  672   GAAAAATAAGGTCCCACTGGGCTCAAGAGTACAAAGAGCAGGGCTTTGGTAGGCTTCTTG  731 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  765   GAAAAATAAGGTCCCACTGGGCTCAAGAGTACAAAGAGCAGGGCTTTGGTAGGCTTCTTG  824 
 
Query  732   ACTCCAAGAGAAGGCTCAGTTCCAATGAATGTAGGACGAATATACAGACTAGCAGATGTT  791 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  825   ACTCCAAGAGAAGGCTCAGTTCCAATGAATGTAGGACGAATATACAGACTAGCAGATGTT  884 
 
Query  792   GAATATGGGACCCATTCTTGATCCAATTTCACAAGCTGTTGAATACACTCTAAGAGCTCT  851 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 








Primer : T7 F 
Query: pET28-BCAT1(C335/8S) 
Subject: serial cloner in silico pET28-BCAT1(WT) 
 
 
Query  78    ATCATCATCATMATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGCTAGCATGG  137 
             ||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1401  ATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGCTAGCATGG 1342 
 
Query  138   ATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAGGTGGTGG  197 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1341  ATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAGGTGGTGG 1282 
 
Query  198   GGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAAAAACCAG  257 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1281  GGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAAAAACCAG 1222 
 
Query  258   ACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGGTGGAGTGGT  317 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1221  ACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGGTGGAGTGGT 1162 
 
Query  318   CCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCATTGCACC  377 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1161  CCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCATTGCACC 1102 
 
Query  378   CTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGGCATTTCGAG  437 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1101  CTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGGCATTTCGAG 1042 
 
Query  438   GAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATGTATCGCT  497 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1041  GAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATGTATCGCT  982 
 
Query  498   CTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGTATTCAAC  557 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  981   CTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGTATTCAAC  922 
 
Query  558   AGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTCTGTATATTC  617 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  921   AGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTCTGTATATTC  862 
 
Query  618   GTCCTACATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCAAAGCCCTGC  677 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  861   GTCCTACATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCAAAGCCCTGC  802 
 
Query  678   TCTTTGTACTCTTGAGCCCAGTGGGACCTTATTTTTCAAGTGGAACCTTTAATCCAGTGT  737 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 




















Primer : T7 R 
Query: pET28-BCAT1(C335/8S) 
Subject: serial cloner in silico pET28-BCAT1(WT) 
 
 
Query  75    GGCCSCAAGCTTGTCGACTGATCAGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTTCC  134 
             |||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  167   GGCCGCAAGCTTGTCGACTGATCAGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTTCC  226 
 
Query  135   ATACTGGATATCAGTTAATTTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCCAT  194 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  227   ATACTGGATATCAGTTAATTTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCCAT  286 
 
Query  195   AGTTGGAATGTGTATTGTCTCGCCTTTGTACAGTATATCAGAAACTGGGCTAACAACAGA  254 
             |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||| | 
Sbjct  287   AGTTGGAATGTGTATTGTCTCGCCTTTGTACAGTATATCAGAAACTGGGCAAACAACACA  346 
 
Query  255   GGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAGTC  314 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  347   GGCTGTACCAGAGCCAAACATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAGTC  406 
 
Query  315   ATCCATGGTGAGGTATCTCTCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCCAR  374 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct  407   ATCCATGGTGAGGTATCTCTCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCCAG  466 
 
Query  375   AATGCACCGCCTTGTCACTCCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGTTC  434 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  467   AATGCACCGCCTTGTCACTCCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGTTC  526 
 
Query  435   TTCTTCTCCATCTTCATTTATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTGAT  494 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  527   TTCTTCTCCATCTTCATTTATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTGAT  586 
 
Query  495   CTGATGGTCCTCTCCATAGAGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCACA  554 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  587   CTGATGGTCCTCTCCATAGAGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCACA  646 
 
Query  555   TTGGGCAAAAAGAGATGAGCCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCTTT  614 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  647   TTGGGCAAAAAGAGATGAGCCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCTTT  706 
 
Query  615   CCAGGCTCTTACATACTTGGGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTTGA  674 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  707   CCAGGCTCTTACATACTTGGGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTTGA  766 
 
Query  675   AAAATAAGGTCCCACTGGGCTCAAGAGTACAAAGAGCAGGGCTTTGGTAGGCTTCTTGAC  734 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  767   AAAATAAGGTCCCACTGGGCTCAAGAGTACAAAGAGCAGGGCTTTGGTAGGCTTCTTGAC  826 
 
Query  735   TCCAAGAGAAGGCTCAGTTCCAATGAATGTAGGACGAATATACAGACTAGCAGATGTTGA  794 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  827   TCCAAGAGAAGGCTCAGTTCCAATGAATGTAGGACGAATATACAGACTAGCAGATGTTGA  886 
 
Query  795   ATATGGGACCCATTCTTGATCCAATTTCACAAGCTGTTGAATACACTCTAAGAGCTCTTC  854 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  887   ATATGGGACCCATTCTTGATCCAATTTCACAAGCTGTTGAATACACTCTAAGAGCTCTTC  946 
 
Query  855   TTTGTCAAATACCGGCAGAGTTGCCCTCACAGCAGAGCGATACATTCTATCCATGTTGAG  914 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 











Subject: serial cloner in silico pLenti-BCAT1(WT) 
 
 
Query  77    TCSCCATGGATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAG  136 
             || || |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7552  TCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAG 7611 
 
Query  137   AGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGG  196 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7612  AGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGG 7671 
 
Query  197   AAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGG  256 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7672  AAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGG 7731 
 
Query  257   TGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGT  316 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7732  TGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGT 7791 
 
Query  317   CATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGG  376 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7792  CATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGG 7851 
 
Query  377   CATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAA  436 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7852  CATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAA 7911 
 
Query  437   TGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGT  496 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7912  TGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGT 7971 
 
Query  497   GTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTC  556 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7972  GTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTC 8031 
 
Query  557   TGTATATTCGTCCTACATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCA  616 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8032  TGTATATTCGTCCTACATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCA 8091 
 
Query  617   AAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACCTTATTTTTCAAGTGGAACCTTTA  676 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8092  AAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACCTTATTTTTCAAGTGGAACCTTTA 8151 
 
Query  677   ATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAGAGCCTGGAAAGGTGGAACTGGGG  736 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8152  ATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAGAGCCTGGAAAGGTGGAACTGGGG 8211 
 
Query  737   ACTGCAAGATGGGAGGGAATTACGGCTCATCTCTTTTTGCCCAATGTGAAGCAGTAGATA  796 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8212  ACTGCAAGATGGGAGGGAATTACGGCTCATCTCTTTTTGCCCAATGTGAAGCAGTAGATA 8271 
 
Query  797   ATGGGTGTCAGCAGGTCCTGTGGCTCTATGGAGAGGACCATCAGATCACTGAAGTGGGAA  856 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 















Subject: serial cloner in silico pLenti-BCAT1(WT) 
 
 
Query  53    CGCGTGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAAT  112 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8716  CGCGTGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAAT 8657 
 
Query  113   TTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTC  172 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8656  TTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTC 8597 
 
Query  173   TCGCCTTTGTACAGTATATCAGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAAC  232 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8596  TCGCCTTTGTACAGTATATCAGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAAC 8537 
 
Query  233   ATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTC  292 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8536  ATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTC 8477 
 
Query  293   TCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACT  352 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8476  TCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACT 8417 
 
Query  353   CCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTT  412 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8416  CCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTT 8357 
 
Query  413   ATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAG  472 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8356  ATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAG 8297 
 
Query  473   AGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAG  532 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8296  AGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAG 8237 
 
Query  533   CCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTG  592 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8236  CCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTG 8177 
 
Query  593   GGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTTGAAAAATAAGGTCCCACTGGG  652 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8176  GGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTTGAAAAATAAGGTCCCACTGGG 8117 
 
Query  653   CTCAAGAGTACAAAGAGCAGGGCTTTGGTAGGCTTCTTGACTCCAAGAGAAGGCTCAGTT  712 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8116  CTCAAGAGTACAAAGAGCAGGGCTTTGGTAGGCTTCTTGACTCCAAGAGAAGGCTCAGTT 8057 
 
Query  713   CCAATGAATGTAGGACGAATATACAGACTAGCAGATGTTGAATATGGGACCCATTCTTGA  772 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8056  CCAATGAATGTAGGACGAATATACAGACTAGCAGATGTTGAATATGGGACCCATTCTTGA 7997 
 
Query  773   TCCAATTTCACAAGCTGTTGAATACACTCTAAGAGCTCTTCTTTGTCAAATACCGGCAGA  832 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 













Primer V2  
Query: pLenti-BCAT1(C338S) 
Subject: serial cloner in silico pLenti-BCAT1(WT) 
 
 
Query  80    ATCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAA  139 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7551  ATCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAA 7610 
 
Query  140   GAGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAG  199 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7611  GAGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAG 7670 
 
Query  200   GAAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACG  259 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7671  GAAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACG 7730 
 
Query  260   GTGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTG  319 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7731  GTGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTG 7790 
 
Query  320   TCATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAG  379 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7791  TCATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAG 7850 
 
Query  380   GCATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGA  439 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7851  GCATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGA 7910 
 
Query  440   ATGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAG  499 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7911  ATGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAG 7970 
 
Query  500   TGTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGT  559 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7971  TGTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGT 8030 
 
Query  560   CTGTATATTCGTCCTACATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACC  619 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8031  CTGTATATTCGTCCTACATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACC 8090 
 
Query  620   AAAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACCTTATTTTTCAAGTGGAACCTTT  679 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8091  AAAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACCTTATTTTTCAAGTGGAACCTTT 8150 
 
Query  680   AATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAGAGCCTGGAAAGGTGGAACTGGG  739 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8151  AATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAGAGCCTGGAAAGGTGGAACTGGG 8210 
 
Query  740   GACTGCAAGATGGGAGGGAATTACGGCTCATCTCTTTTTGCCCAATGTGAAGCAGTAGAT  799 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8211  GACTGCAAGATGGGAGGGAATTACGGCTCATCTCTTTTTGCCCAATGTGAAGCAGTAGAT 8270 
 
Query  800   AATGGGTGTCAGCAGGTCCTGTGGCTCTATGGAGAGGACCATCAGATCACTGAAGTGGGA  859 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8271  AATGGGTGTCAGCAGGTCCTGTGGCTCTATGGAGAGGACCATCAGATCACTGAAGTGGGA 8330 
 
Query  860   ACTATGAATCTTTTTCTTTACTGGATAAATGAAGATGGAGAAGAAGAACTGGCAACTCCT  919 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8331  ACTATGAATCTTTTTCTTTACTGGATAAATGAAGATGGAGAAGAAGAACTGGCAACTCCT 8390 
 
Query  920   CCACTAGATGGCATCATTCTTCCAGGAGTGACAAGGCGGTGCATTCTGGACCTGGCACAT  979 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 







Subject: serial cloner in silico pLenti-BCAT1(WT)Match 
 
Query  58    CGCGTGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAAT  117 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8716  CGCGTGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAAT 8657 
 
Query  118   TTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTC  177 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8656  TTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTC 8597 
 
Query  178   TCGCCTTTGTACAGTATATCAGAAACTGGGCTAACAACACAGGCTGTACCAGAGCCAAAC  237 
             ||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||| 
Sbjct  8596  TCGCCTTTGTACAGTATATCAGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAAC 8537 
 
Query  238   ATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTC  297 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8536  ATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTC 8477 
 
Query  298   TCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACT  357 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8476  TCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACT 8417 
 
Query  358   CCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTT  417 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8416  CCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTT 8357 
 
Query  418   ATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAG  477 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8356  ATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAG 8297 
 
Query  478   AGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAG  537 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8296  AGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAG 8237 
 
Query  538   CCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTG  597 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8236  CCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTG 8177 
 
Query  598   GGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTTGAAAAATAAGGTCCCACTGGG  657 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8176  GGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTTGAAAAATAAGGTCCCACTGGG 8117 
 
Query  658   CTCAAGAGTACAAAGAGCAGGGCTTTGGTAGGCTTCTTGACTCCAAGAGAAGGCTCAGTT  717 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
























Subject: serial cloner in silico pLenti-BCAT1(WT) 
 
 
Query  79    TCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAG  138 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7552  TCGCCATGGATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAG 7611 
 
Query  139   AGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGG  198 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7612  AGGTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGG 7671 
 
Query  199   AAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGG  258 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7672  AAAAACCAGACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGG 7731 
 
Query  259   TGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGT  318 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7732  TGGAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGT 7791 
 
Query  319   CATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGG  378 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7792  CATTGCACCCTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGG 7851 
 
Query  379   CATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAA  438 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7852  CATTTCGAGGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAA 7911 
 
Query  439   TGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGT  498 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7912  TGTATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGT 7971 
 
Query  499   GTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTC  558 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7972  GTATTCAACAGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTC 8031 
 
Query  559   TGTATATTCGTCCTACATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCA  618 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8032  TGTATATTCGTCCTACATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCA 8091 
 
Query  619   AAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACCTTATTTTTCAAGTGGAACCTTTA  678 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8092  AAGCCCTGCTCTTTGTACTCTTGAGCCCAGTGGGACCTTATTTTTCAAGTGGAACCTTTA 8151 
 
Query  679   ATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAGAGCCTGGAAAGGTGGAACTGGGG  738 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8152  ATCCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAGAGCCTGGAAAGGTGGAACTGGGG 8211 
 
Query  739   ACTGCAAGATGGGAGGGAATTACGGCTCATCTCTTTTTGCCCAATGTGAAGCAGTAGATA  798 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8212  ACTGCAAGATGGGAGGGAATTACGGCTCATCTCTTTTTGCCCAATGTGAAGCAGTAGATA 8271 
 
Query  799   ATGGGTGTCAGCAGGTCCTGTGGCTCTATGGAGAGGACCATCAGATCACTGAAGTGGGAA  858 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8272  ATGGGTGTCAGCAGGTCCTGTGGCTCTATGGAGAGGACCATCAGATCACTGAAGTGGGAA 8331 
 
Query  859   CTATGAATCTTTTTCTTTACTGGATAAATGAAGATGGAGAAGAAGAACTGGCAACTCCTC  918 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8332  CTATGAATCTTTTTCTTTACTGGATAAATGAAGATGGAGAAGAAGAACTGGCAACTCCTC 8391 
 
Query  919   CACTAGATGGCATCATTCTTCCAGGAGTGACAAGGCGGTGCATTCTGGACCTGGCACATC  978 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 







Subject: serial cloner in silico pLenti-BCAT1(WT) 
 
Query  55    CGCGTGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAAT  114 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8716  CGCGTGGATAGCACAATTGTCCAGTCGCTCTCTTCTCTTCCATACTGGATATCAGTTAAT 8657 
 
Query  115   TTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTC  174 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8656  TTGCTCAAGATGCGGCTTGCCAGCTTAGGACCATTCTCCATAGTTGGAATGTGTATTGTC 8597 
 
Query  175   TCGCCTTTGTACAGTATATCAGAAACTGGGCTAACAACAGAGGCTGTACCAGAGCCAAAC  234 
             ||||||||||||||||||||||||||||||| ||||||| |||||||||||||||||||| 
Sbjct  8596  TCGCCTTTGTACAGTATATCAGAAACTGGGCAAACAACACAGGCTGTACCAGAGCCAAAC 8537 
 
Query  235   ATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTC  294 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8536  ATCTCTCTCACTCTGTTCCCCTCCAGGGCTGTTGTCAAGTCATCCATGGTGAGGTATCTC 8477 
 
Query  295   TCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACT  354 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8476  TCTGACACCTTAAATTCACCCCACTGATGTGCCAGGTCCAGAATGCACCGCCTTGTCACT 8417 
 
Query  355   CCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTT  414 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8416  CCTGGAAGAATGATGCCATCTAGTGGAGGAGTTGCCAGTTCTTCTTCTCCATCTTCATTT 8357 
 
Query  415   ATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAG  474 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8356  ATCCAGTAAAGAAAAAGATTCATAGTTCCCACTTCAGTGATCTGATGGTCCTCTCCATAG 8297 
 
Query  475   AGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAG  534 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8296  AGCCACAGGACCTGCTGACACCCATTATCTACTGCTTCACATTGGGCAAAAAGAGATGAG 8237 
 
Query  535   CCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTG  594 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8236  CCGTAATTCCCTCCCATCTTGCAGTCCCCAGTTCCACCTTTCCAGGCTCTTACATACTTG 8177 
 
Query  595   GGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTTGAAAAATAAGGTCCCACTGGG  654 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8176  GGATTGGCCCACAGGGACACTGGATTAAAGGTTCCACTTGAAAAATAAGGTCCCACTGGG 8117 
 
Query  655   CTCAAGAGTACAAAGAGCAGGGCTTTGGTAGGCTTCTTGACTCCAAGAGAAGGCTCAGTT  714 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8116  CTCAAGAGTACAAAGAGCAGGGCTTTGGTAGGCTTCTTGACTCCAAGAGAAGGCTCAGTT 8057 
 
Query  715   CCAATGAATGTAGGACGAATATACAGACTAGCAGATGTTGAATATGGGACCCATTCTTGA  774 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  8056  CCAATGAATGTAGGACGAATATACAGACTAGCAGATGTTGAATATGGGACCCATTCTTGA 7997 
 
Query  775   TCCAATTTCACAAGCTGTTGAATACACTCTAAGAGCTCTTCTTTGTCAAATACCGGCAGA  834 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7996  TCCAATTTCACAAGCTGTTGAATACACTCTAAGAGCTCTTCTTTGTCAAATACCGGCAGA 7937 
 
Query  835   GTTGCCCTCACAGCAGAGCGATACATTCTATCCATGTTGAGGTTTGGCTGAAACAGTCGA  894 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7936  GTTGCCCTCACAGCAGAGCGATACATTCTATCCATGTTGAGGTTTGGCTGAAACAGTCGA 7877 
 
Query  895   ATTTTATTATCTACTCCTCGAAATGCCTTCAATCCTTCAAATAATTCCACTGCATAGTGC  954 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 







Query  955   AAAGCTGATGAGCCAGGGTGCAATGACAGGTTCTGAAGAGGCTTGATATGAGGTTTCTCC 1014 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7816  AAAGCTGATGAGCCAGGGTGCAATGACAGGTTCTGAAGAGGCTTGATATGAGGTTTCTCC 7757 
285 
 
Appendix B. Densitometric analysis of RNA agarose gels. 28S:18S rRNA ratio ≥2 


































Appendix C. Melt-curve analysis of qPCR calibration curves. Profile of A) BCAT1 product 
amplified from pCMV6-BCAT1 template and B)BCAT1 product amplified from U937-
Control(EV), non-specific amplification of primer dimer seen after x1000 dilution of 
template. C) β2M product amplified from U937-Control(EV) template. multiple curves 















Appendix D Differential aggregation of U937 transgenic cells following addition of 
PMA. Light microscope images displaying U937 cells following incubation with ±10 
ng/mL PMA 48h. A) Giemsa stained U937-Control(EV) cells display aggregation and  
monocyte to macrophage differentiation (indicated by arrows) following addition of 
PMA. B) U937-BCAT1(WT) cells display visibly reduced aggregation (dark patches 
indicated by arrows) compared to U937-Control(EV).  
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